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“You will become suddenly, and possibly irrevocably, incredibly boring.
People ask, "So, what are you up to these days?" and you say, "Thesis." That's about 
all you can handle because inexplieably, your facility for the spoken English language 
has deteriorated. You have stopped seeing people, going places, and doing things. You 
live entirely in your own head and in the computer lab, if you're as lucky as me. Your 
life is not your own. You struggle with monumental questions of rhetoric and logic, 
about minutia. No one likes you anymore. You are paranoid.”
'Deconstructing A Nervous Breakdown’ The Declaration, 29^ April, 1999
“The chessboard is the world; the pieces are the phenomena of the universe; the rules 
of the game are what we call the Laws of Nature, The player on the other side is 
hidden from us. We know that his play is always fair, and patient. But also we know, 
to our cost, that he never overlooks a mistake, or makes the smallest allowance for 
ignorance.”
Thomas Henry Huxley (1825-95)
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Abstract
Three sets of molecular markes were used to investigate the population genetics of 
three populations of Plasmodium falciparum  from Kenya; Mwea (low transm ission), 
Tiwi (moderate transm ission) and Bondo (high transm ission). One set of markers codes 
for polymorphic antigens while the other two are microsatellite markers; one set located 
in non coding regions of the genome while the other set is located in the regions 
flanking two genes whose products aie targets of the antimalarial drug 
sulphadoxine/pyrimetham ine (SP).
A comparison of the effectiveness of antigen-coding and the unlinked 
microsatellite loci in differentiating recrudescence from reinfection revealed that both 
sets of markers are equally effective. The microsatellite loci however, revealed more 
alleles per population than the antigen-coding loci possibly due to their different 
mutation rates.
An analysis of the three populations using the neutral m icrosatellite loci revealed 
high levels of diversity, lack of linkage disequilibrium and virtually no population 
substructuring (F^r<0.008) in the Kenyan P, falciparum  populations even with the 
geographical areas being as much as 800 km apart. This indicates a lot of gene flow 
among these populations a factor that can only be explained by movement of people 
between the areas studied.
An analysis of the same samples from the three areas at the dihydrofolate 
reductase {dhfr) and dihydropteroate synthase {dhps) gene loci that code for targets of 
the antimalarial drug SP revealed high prevalence of the multiply substituted alleles 
associated with SP resistance in the three regions.
An analysis of -17  kb regions flanking both sides c/A/r reveal a strong selective 
sweep of the 108N/51I/59R triple mutation alleles associated with pyrimetham ine
1
resistance. The work presented also demonstrates that alleles of the dhfr gene, especially 
the triple mutant allele, isolated from the three different areas are closely related to one 
another and probably share a common and very recent ancestor. Most notable is the 
finding that dhfr triple mutants seeem to be imported into the country through 
immigration from elsewhere. An equivalent region flanking the dhps gene also revealed 
a strong selective sweep of the 437G/540E double mutation allele associated with 
sulphadoxine resistance in two of the three sites. However, double mutation dhps alleles 
from Mwea revealed no selection at all. While the three populations reveal no 
geographic substructuring using the results of the unlinked microsatellite loci, they 
seem to be highly structured in their drug resistance patterns. While it would be 
expected that these populations would have the same prevalence of drug resistance 
mutations (due to the apparent panm ixia), the Mwea population appears quite different 
in regard to selection for drug resistance-associted alleles. This is possibly due to the 
diet, other drug interactions or the hosts’ genetics in this area.
A simplistic model on the rate of spread of drug resistance in the three 
populations reveals that the selection for drug resistance alleles is faster in the lower 
transm ission area of Mwea (selection coefficient, s = 0.26) and slowest in Bondo (5  = 
0.10) indicating selection for drug resistant alleles is favoured by low transm ission. 
These observations have implications for malaria drug resistance surveillance programs 
due to the fact that if treatment failure spreads faster in low transm ission areas where 
almost all the population has low immunity, malaria epidemics are bound to occur 
resulting in huge morbidity and mortality.
1.0... Introduction and literature review
1.1 Introduction
Malaria is one of the most prevalent parasitic diseases of man affecting over 100 
countries with a combined population of 2.4 billion people (Breman 2001). Plasmodium  
falciparum, P. ovale, P. malariae and P. vivax are the four species of the parasite that 
cause malaria in man with the first accounting for most of the lethal infections.
The annual number of clinical cases is estimated at between 300-500 m illion per 
year, more than 90% of which occur in sub-Saharan Africa. Malaria mortality is 
estimated to be over 2 million persons per year with the principal victims being African 
children below 5 years of age (Phillips 2001; Snow et al., 2005; World Health 
Organization 2003a). The other high-risk groups for malaria include pregnant women, 
non-immune travellers, refugees and displaced persons.
The malaria parasite is transm itted by an insect vector of the genus Anopheles, 
the most important of which is Anopheles gambiae. The distribution of the disease 
mirrors that of the vector.
Within the past few decades there has been rapid emergence of P. falciparum  
malaria resistant to almost all of the available antimalarial drugs. This has added a 
further blow to the war against the disease, making the provision of malaria treatment 
and control increasingly difficult and costly. This has generally been attributed to the 
great genetic diversity of the parasite especially in countries with a wide range of 
transm ission intensities (Babiker & Walliker 1997). Infection with genotypically 
different parasites of the same species, often refen'ed to as multi-clonal infection, is also 
relatively frequent, and a positive relationship has been reported in three African 
countries between entomological inoculation rates (EIR) and number of genotypes in 
infected people (Babiker & Walliker 1997; Walliker, Babiker, & Ranford-Cartwright 
1998).
1.2 The Lifecycle of the Malaria parasite, Plasmodium falciparum
Plasmodium  spp. belong to the phylum Apicomplexa, members of which 
alternate in one or more vertebrate or invertebrate hosts. Plasmodium falciparum  
undergoes a haploid asexual replication in the human host and a brief diploid sexual 
phase in the mosquito vector (Good et al., 1988; Walliker et al., 1987; Walliker et al., 
1975).
The feeding mosquito injects sporozoites into the skin of the human host, from 
where they migrate to the liver, invade hepatocytes, and undergo asexual differentiation 
to form a hepatic schizont. Merozoites burst from the cell and invade erythrocytes. 
Multiple rounds of asexual replication, schizogony, erythrocyte lysis and merozoite 
reinvasion then take place, with blood parasite density rising exponentially with each 
round of replication. The duration of the erythrocytic cycle determines the periodicity of 
fever and gave rise to the old-fashioned names of tertian and quartian malaria. For P. 
falciparum  the cycle takes approximately 48 hours, with fever appearing every third day 
(reviewed in Good et al. 1988).
Gamétocytes of Plasmodium  spp. are formed from a subset of asexual parasites 
after one or more rounds of intraerythrocytic proliferation. It appears that a combination 
of innate genetic factors and environmental cues in the blood stream of the host triggers 
the switch from erythrocytic schizogony to gametocytogenesis (Bruce et al., 1990; 
Smith et al., 2002). All merozoites within a single schizont of P. falciparum  are 
destined either to produce further asexual stages or to develop into gametocytes (Bruce 
et al., 1990), and all of the merozoites released from one sexually comm itted schizont 
become gametocytes of the same sex (Silvestrini F et al., 2000; Smith et al., 2000).
Male and female gametocytes are taken up in the blood meal by the mosquito as 
it feeds from an infected person. Male and female gametocytes emerge from their red
blood cell hosts; undergo a process of gametogenesis, and the resultant gametes fuse to 
form the zygote (ookinete). The ookinete migrates through the midgut wall of the 
mosquito and develops into an oocyst. The first stage of meiosis is known to take place 
within the ookinete (the second stage is not clear), followed by multiple rounds of 
mitosis, to produce between 2,000-10,000 (Pringle 1965; Rosenberg & Rungsiwongse 
1991) haploid sporozoites per oocyst, which migrate to the salivary glands ready for 
reinfection into the human host during the next blood meal.
1.3 Ploidy and the Genome of P. falciparum
The paiasite in the vertebrate host is entirely haploid. Studies on inheritance of 
isoenzymes and other characters in P. chabaudi (Walliker et al., 1975) and in P. 
falciparum  (Walliker et al., 1987) have supported haploidy for the erythrocytic stages. 
Exo-erythrocytic stage haploidy was demonstrated by studies on the inheritance of 
antigens of these forms (Szarfman et aL, 1988).
Studies on DNA content have demonstrated that sporozoites, ring forms, young 
trophozoites and mature microgametes possess a similar quantity of DNA, assumed to 
be the haploid amount (Janse et al., 1986). Mature macrogametes were found to have 
approximately 50% more DNA than the haploid quantity, possibly because of 
amplification of gametocyte-specific genes.
The only diploid phase in the Plasmodium  lifecycle is the zygote (ookinete) in 
the mosquito gut. Approximately 4 times the haploid DNA quantity is synthesised 
during meiosis that takes place at this time (Janse et al., 1986). This is consistent with 
the duplication of the diploid chromosome set at the first stage of meiosis.
The nuclear genome of P. falciparum  is composed of 22.8 megabases (Mb) of 
DNA distributed among 14 chromosomes. These chromosomes range in size from 0.643 
Mb to 3.29 Mb (reviewed in (Gardner et al., 2002)). Overall the genome of P.
falciparum  is very (A+T)-rich varying from 80.6% in genes to approximately 90% in 
introns and intergenic regions (Gardner et a l ,  2002).
Approximately 5,300 protein-encoding genes have been predicted which 
suggests an average gene density in P. falciparum  of 1 gene per 4,300bp (Gardner et a l ,  
2002). Introns have been predicted in 54% of P. falciparum  genes. Excluding introns, 
the mean length of these genes is 2.3 kilobases (kb), substantially larger than in other 
organisms in which gene lengths range from 1.3kb to 1.6kb (Louis et a l,  1994).
The parasite also has two other genomes: the mitochondrial and the apicoplast 
genomes (Vaidya et a l ,  1993; Vaidya et al., 1989). The mitochondrial genome of P. 
falciparum  is a 6.0 kb tandemly repeated linear element which is uniparentally inherited 
(Creasey et a l ,  1993; Feagin 1992; Joseph et a l,  1989). There is 90% conservation of 
sequence identity among the mitochondrial genomes of P. falciparum, P. vivax, P. 
yoelii, and P. gallinaceum  (McIntosh et a l ,  1998). Detailed processes of replication and 
expression have been well characterized in the mitochondrial genes of the asexual stage 
parasite (Feagin & Drew 1995; Preiser et a l ,  1996).
Based on the malaria genome databases, about 380 proteins are predicted to 
target the mitochondrion post-translationally. These include the pyruvate dehydrogenase 
complex, the complete tricarboxylic acid cycle enzymes, many electron transport 
complexes and ATP synthase (Bender et a l ,  2003; Gardner et a l ,  2002). However, 
functional analyses of the mitochondrion and its products still remain to be elucidated 
e.g. what controls processes like gene deletion, RNA interference, transcriptomics and 
proteomics. The mitochondrion is a potential chemotherapeutic target for antimalarial 
drug development, for instance, the enzyme dihydroorotate dehydrogenase which is 
essential to parasite function (Baldwin et a l,  2002; Krungkrai 1993; Ridley 2002).
There is also evidence that the malaria parasites produce oxidative stress via the 
mitochondrial superoxide radical generation, a phenomenon that exists in mammalian 
m itochondria (Dileepan & Kennedy 1985), and is finely balanced against the parasite’s 
antioxidant enzyme activities (Kiungkiai 1991). This intracellular redox environment 
minimizes the generation of reactive oxygen species that damage nucleic acids, 
proteins, lipids and membranes and still allows essential metabolic functions.
M alaiia parasites also harbour a relict plastid, homologous to the chloroplasts of 
plants and algae, called the apicoplast. This organelle seems to be essential to parasite 
growth but its exact role is unclear. The apicoplast in malaria parasites has a 35kb 
genome that encodes only 30 proteins. Among the apicoplast’s genes include those that 
code for a set of tRNAs, rRNAs, rpoB, rpoC, tufA, and ribosomal protein (rp) genes. 
The apicoplast genome contains genes typical for plastids (ycf24 and clpC) but also 
several open reading frames of unknown function (Kohler et al., 1997; McFadden & 
Roos 1999). Translation with prokaryotic features may be present in the apicoplast; 
however, most of its proteins appear to be nucleus-encoded and imported into the 
organelle, using an import secretory pathway (Waller et al., 2000).
1.4 Generation of genetic diversity in Plasmodium falciparum
The chromosomes of P. falciparum  vary considerably in size, with most 
variation occurring in the subtelomeric regions. Chromosomal size vaiiation is also 
observed in cultures of erythrocytic parasites, but is probably due to chromosome 
breakage and healing events and not due to recombination (Scheif & Mattei 1992). The 
subtelomeric regions of the chromosomes show a striking display of conservation 
within the genome that is probably due to promiscuous inter-chromosome exchange of 
subtelomeric regions (Scherf & Mattei 1992). Subtelomeric exchanges are known to 
occur in other eukaryotes (Louis et al., 1994; Rudenko et al., 1996; van Deutekom et
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aL, 1996), but the regions involved are much smaller. Various mechanisms may 
produce these size polymorphisms in P. falciparum. Chromosome breakage and healing 
during mitotic expansion of parasite populations is one mechanism for loss of 
subtelomeric sequences and genes from P. falciparum  chromosomes (Cappai et al., 
1989; Pologe & Ravetch 1988; Scherf et a l ,  1992). Expansion of large tandemly 
repeated units within individual chromosomes has been shown to be another means of 
generating large chromosome size polymoiphisms (Triglia et a l ,  1991). Homologous 
recombination among subtelomeric repetitive elements has been postulated as a third 
mechanism of polymoiphic variation (Corcoran et a l ,  1988). Homologous 
chromosomes of different sizes readily undergo meiotic recombination after zygote 
formation to produce new size variants (Hinterberg K et a l ,  1994; Sinnis & Wellems 
1988; Walliker et a l ,  1987).
The recognition of parasite polymorphisms and their association with distinct 
properties has made considerable progress in the last few years. This is largely due to 
the advent of polymerase chain reaction (PCR)-based assays. Single nucleotide 
polymoiphisms (SNPS) and other types of polymorphisms have been analysed using 
specific digestion assays with restriction enzymes, DNA hybridisation techniques using 
specific oligonucleotides, allele specific amplification, or by sequencing of PCR 
products.
Single nucleotide polymorphisms (SNPs) contribute to most of the 
polymorphism of the parasite’s genes. Some researchers have argued that synonymous 
mutations are scarce in most of the parasite’s genes thus supporting a clonal population 
structure and a recent bottleneck (Rich et a l ,  1998; Rich et a l ,  1997), while others have 
for the existence of long-lasting polymorphisms and high levels of intraspecific 
synonymous polymorphism in P.falciparum  (Hughes & Verra, 1998). Rich and
colleagues’ arguments were based on alignment of some sequences from isolates 
obtained from multiple geographical locations (Rich et al., 2000). However, this work 
only exam ined a small proportion of genes such as M spl, which are antigen-coding and 
infact are vaccine candidates, where there are multiple sequences. Most of the loci 
exam ined by these authors (Rich et al., 1998; Rich & Ayala 1998) are housekeeping 
genes encoding metabolic enzymes, chaperone proteins and surface proteins. The 
existence of balancing selection at such loci is not expected and most are probably 
evolving neutrally. It is not expected that the pattern of coalescence at a neutral locus 
would be the same as that at a locus under balancing selection; rather, polymorphism at 
the former will be much less long-lasting than at the latter (Takahata & Nei 1990). A 
closer reexam ination of the work by Rich and colleagues (Rich et al., 1998) also reveals 
that their analysis excluded repeat sequences and the authors ened  in calculating the 
ratios of synonymous to nonsynonymous substitutions which could have led to their 
conclusions. It is also known that P. falciparum  has a strong codon bias due to the 
extraordinary AT-richness of the genome. This nucleotide content bias affects codon 
usage (Nakamura et al., 1998). The rate of synonymous substitutions in organisms with 
highly biased genomes such as P.falciparum  is less than in organisms such as humans, 
whose codon usage is less biased (Hughes & Veixa 1998). The fact that long-lasting 
polymorphisms have been maintained at certain loci of P.falciparum  but not at others is 
also strong evidence that interlocus recombination has been an important factor in the 
evolution of this species (Hughes & Verra 1998).
Non-synonymous SNPs are found at high frequencies in genes that aie under 
strong selective pressure and an excess of non-synonymous mutations is thought to 
indicate an area of the genome under diversifying selection (McDonald 1994). 
Compaiison of the frequency of the putatively neutral synonymous and the more
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frequent non-synonymous substitutions suggests that natural selection may account for 
most polymorphisms observed at functional gene loci (Escalante et at., 1998).
SNPs affecting drug resistance in P. falciparum  have been found in the 
dihydrofolate reductase-thymidylate synthase (dhfr-ts) and the dihydropteroate synthase 
(dhps) genes. Mutations in these genes are associated with resistance to pyrimetham ine 
and sulphadoxine, respectively (Cowman et al., 1988; Peterson et al., 1990; Peterson et 
al., 1988a; Wang et al., 1997a). SNPs in the chloroquine resistance transporter gene 
fPfcrt) with a modifying effect from the multidrug resistance gene 1 {Pfmdr 1) have 
been shown to be responsible for chloroquine resistance (Fidock et al., 2000a). Genes 
where polymorphism has most likely arisen through intragenic recombination and other 
mechanisms in repetitive segments are characterised by repeat motifs with length 
variability differing between strains (Jongwutiwes et al., 1993).
1.5 Genetic Analysis of P. falciparum: Complexity of infections
Both clinical and asymptomatic infections are often composed of a mixture of 
parasite strains, which were assumed to be the result of many superimposed 
independent infections, hence reflecting transmission intensity (reviewed in (Konate et 
a l,  1999; Smith et al., 1999a). Many studies have been conducted to analyse the genetic 
diversity, dynamics and population structure of P. falciparum  using different molecular 
tools, which are discussed, in later sections.
1.5.1 Multiclonality in malaria infections
P. falciparum  infections have been shown to be genetically diverse in all except 
unusual situations (such as epidemics on islands or in isolated populations), and most 
infected individuals in moderate to highly endemic transmission areas harbour more 
than one parasite clone, a condition known as multiclonality (Amot 1998). PCR-based 
techniques have shown a high prevalence of multiclonal infections (Sherman 1998).
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Diverse multiclonal infections have been found to be almost as common in regions of 
low endemicity such as eastern Sudan (Babiker et ah, 1991a; Babiker et al., 1991b; 
Bayoum i et al., 1993) as they are in areas of higher transm ission such as The Gambia 
and Tanzania (Babiker et al., 1997; Conway & McBride 1991). In other areas such as 
South America, where transmission is low, low diversity and population substructuring 
of parasites are observed (Anderson et al., 2000a).
In humans living in regions endemic for malaria, partial immunity to 
Plasmodium falciparum  is acquired as a result of natural exposure to these multiple 
infections over many years. One study in Senegal demonstrated that while most 
symptomatic and asymptomatic subjects were infected by multiple P. falciparum  
genotypes, the number of clones present in asymptomatic infections decreased at the 
age where a more efficient immune response is in place, as indicated by lower parasite 
densities and reduced clinical attack rates (Ntoumi et al., 1995). This study was 
conducted in Dielmo, an area with intense transmission and where partial immunity 
develops with age. Another study in Ndiop, a Senegalese area with low transmission 
observed different results. This study used the three polymorphic markers M spl, Msp2 
and Glurp and showed that the average number of fragments (multiplicity of infection, 
MCI) per clinical malaria sample was higher than for samples taken from asymptomatic 
infections: 1.75 for M spl, 2.15 fov Msp2 and 1.4 for Glurp compared to 1.5, 1.5, and 1.2 
for the asymptomatics, for M spl block 2, Msp2, and Glurp typing reactions, 
respectively. They also showed that in both groups, most multiple infections contained 
2-3 alleles (Zwetyenga et al., 1998).The later study was conducted in an area of low 
endemicity where clinical malaria is seen in adults as well as children, and the main 
finding was that age had no influence on either the complexity of infection or on the 
distribution of alleles (Zwetyenga et al., 1998). This observation is consistent with other
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studies that have shown a reduction w ith increasing age in the number of genotypes 
present in infected individuals from high transm ission aieas (Ntoumi et aL, 1995; Smith 
et al., 1999b) suggesting that this is a reflection of acquired immunity.
Multiple clone infections are important because they provide the possiblility of 
cross-fertilisation, which itself allows recombination. The extent of recombination 
between parasites defines population structure.
L5.2 Population structure, mating and recombination
A clonal structure of P. falciparum, where all parasites are related due to 
inbreeding, was first proposed in 1990 (Tibayrenc et al., 1990). However other authors 
(Babiker & Walliker 1997) have argued that in highly endemic areas outcrossing 
(mating between/among different parasite genotypes) occurs frequently enough to 
generate a great diversity of molecular genotypes.
In the mosquito midgut, fertilisation can occur between a male and a female 
gamete of the same genotype (self-fertilisation) or between gametes of different 
genotype (cross-fertilisation). Mating occurs in a random fashion between gametes 
present in the bloodmeal, in accordance with Hardy-Weinberg equilibrium (Ranford- 
Cartwright et al., 1993). In naturally infected mosquitoes, both crossing and selfing 
have been shown to occur (Babiker et al., 1994; Paul et al., 1995), although the ratio 
varies according to the genetic structure of the population. The population structure of 
this parasite is very diverse, showing variation in outcrossing rates from 10% in Papua 
New Guinea (Paul et al., 1995) to 60 % in Tanzania (Babiker et al., 1994).
Strong linkage disequilibrium (LD), low genetic diversity and high levels of 
geographical variation have been observed in areas of low malaria transmission while 
random association (linkage equilibrium (LE)), high genetic diversity and minimal 
geographical differentiation were observed in regions with high transmission especially
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in Africa and Papua New Guinea (Anderson et al., 2000a). The observed association 
between transm ission intensity and LD can be explained by the fact that P. falciparum  
has a m ixed mating system in which inbreeding predominates in low transm ission areas, 
while higher levels of outbreeding occur in regions with higher transmission. People are 
rarely superinfected with more than one parasite clone in low transm ission areas, and 
thus unrelated parasites rarely co-occur in the same mosquito blood meal. Mating can 
only occur between parasites in the same mosquito bloodmeal. While it is theoretically 
possible that a mosquito could take a partial bloodmeal on two or more people 
(Soremekun et al., 2004), the second bloodmeal would have to be taken very rapidly 
after the first one, as gametogenesis and fertilisation occur within 10 m inutes of the 
bloodmeal. Therefore self-fertilisation (and inbreeding) will be much more common in 
low transm ission areas. Conversely, multiple clone infections are frequent in high 
transmission areas and mosquitoes therefore often ingest unrelated parasites, leading to 
higher levels of outbreeding (and recombination) (Babiker et al., 1994; Paul et al., 
1995). The extent of parasite diversity may vary with transmission intensity, being at 
least in part generated by recombination during meiosis in the mosquito. Since every 
inoculation is preceded by sexual reproduction of parasites in the mosquito, the 
inoculation rate is predicted to reflect the rate of parasite recombination. Sexual 
reproduction, which generates new genotypes (Babiker et al., 1994; Paul et al., 1995; 
Rosenberg & Rungsiwongse 1991; Walliker et al., 1987) and novel alleles by intragenic 
recombination, (Kerr et al., 1994) is likely to play a significant role in the generation of 
parasite diversity. Recombination during meiosis however, is only able to increase 
diversity in heterozygotes, formed by crossfertilisation between different gametes. This 
is mainly found in areas of high transmission where probabilities of multiple clone 
infections and, hence mating between unlike gametes, will be more frequent. Levels of
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LD have important influences on the population biology of P. falciparum  particularly 
the rate at which recombination breaks down association between genes, which may in 
turn influence the persistence of clonal genotypes (Hastings & Wedgewood-Oppenheim 
1997; Paul et al., 1995). LD also influences the maintenance of antigenically distinct 
“strains” (Gupta et al., 1996; Hastings & Wedge wood-Oppenheim 1997), and the 
spread of drug resistance (Dye & Godfray 1993; Hastings 1997; Hastings & Mackinnon 
1998), and may also influence sex ratio (Dye & Godfray 1993; Read et al., 1992).
These studies, though few, demonstrate the high diversity of P. falciparum  
populations especially in Africa where transm ission is intense. The strong geographical 
sub-structuring in South America may be explained by multiple colonization events; 
malaria is thought to have been introduced into South America = 500 yeai's ago with the 
arrival of Europeans and that subsequent réintroduction from Africa occurred with the 
slave trade (Anderson et al., 2000a).
Regardless of the causes, the differences in genetic diversity, population 
differentiation, and LD in different locations have important consequences for our 
understanding of P. falciparum  biology (Anderson et a l, 2000b). In parasite 
populations with low microsatellite diversity, we would expect to see reduced diversity 
in antigen-encoding loci (Eeneira et a l ,  1998) and a smaller repertoire of variant 
surface antigens. Hence, under a model of genotype-specific immunity, we might expect 
effective immunity to malaria to be generated following a relatively small number of 
infective mosquito bites in low transm ission regions (Gupta & Day 1994). In areas with 
low recombination, multilocus genotypes will be maintained through multiple 
generations making it possible to track the spread of multilocus genotypes within 
communities (Anderson et a l ,  2000a). Compaiison of infection characteristics of 
multiply represented haplotypes can be used to investigate which aspects of P.
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falciparum  traits are a product of paiasite genetics rather than host factors (Anderson et 
al., 2000a; Walliker et al., 2005).
1.5.3 Choice of molecular markers
Genetic markers are powerful tools for investigating the population structure and 
epidemiology of parasites. For both these purposes the most effective markers would be 
those that are neutral, highly polymorphic and stable during the course of infection. 
However, such markers do not exist. Each genetic marker has a range over which it can 
detect genetic variation (Sunnucks 2000). For instance, if the marker is too 
polymorphic, either the required sample size to describe diversity will be too high, or 
the samples will be too different resulting in homoplasy. If the marker has little 
polymorphism, then samples will appear the same when infact they are genetically 
different. Genetic markers should also be chosen based on the question being asked and 
also their applicability for the particulai’ situation. For example, microsatellite markers 
might be good for population studies but they are not ideal for situations like 
differentiating recmdescences from reinfections (Mwangi et al., 2006).
Multiple loci are used since measures of population structure characteristically 
show high levels of variance among loci (Mcdonald 1994; Nei 1973). Selectively 
‘neutral’ loci are preferred, since the aim is to use these markers to make inferences 
about population history or transm ission of parasites between hosts. These markers are 
most likely to be found in the non-coding sequences of the DNA.
The molecular markers so far used in population genetic analyses can be 
classified as antigen-encoding genes (Abderrazak et al., 1999; Babiker et al., 1995; 
Maitland et al., 2000; Zwetyenga et ah, 1998), enzymes with electrophoretic variants 
(Abderrazak et al., 1999), and microsatellite loci (Anderson et al., 1999). G iven that 
some of the antigen genes encode proteins that are recognised by the host’s immune
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mechanism, the observed high levels of diversity have been attributed to positive or 
diversifying natural selection, an outcome of accumulation and frequent switch of 
suitable mutations, by means of which the parasite escapes the host’s immune defences 
(Anders & Saul 2000; Hughes 1991; Hughes 1992; Hughes & Hughes 1995). Evidence 
for selection comes from comparison of the ratio of synonymous to non-synonymous 
mutation rates (Escalante et al., 1998).(Felger et al., 1997; Hughes 1991; Hughes & 
Hughes 1995; Rich et al., 1997) In most organisms, synonymous nucleotide 
substitutions are usually less common than non-synonymous substitutions (Lockyer et 
al., 1989; Shi et al., 1992; Thomas et al., 1990a; Thomas et al., 1990b). Synonymous 
substitutions are likely to be neutral whereas non-synonymous substitutions may be 
functionally constrained and thus, subject to purifying natural selection (Kimura 1977; 
Ohta 1996). However, selection can also act to favour temporal diversity, and therefore 
non-synonymous mutation. For allozyme markers, natural selection may account for the 
rapid spread of a favoured genotype throughout populations, paiticularly when the 
population is large and/or the selection is strong (Rich et al., 1998). However, this 
would overtime reach saturation of the favoured genotype and the diversity would be 
lost.
Some of the markers that have been employed in epidemiological studies of P. 
falciparum  are discussed in the following sections.
1.5.3.1 Allozyme typing
Allozymes, in particular variants of parasite enzymes such as glucose phosphate 
isomerase (GPI) and lactate dehydrogenase (LDH) (Carter & M cGregor 1973) were the 
first plasmodial variant proteins to be analysed. Electrophoretic variants of these 
enzymes were observed in individual malaria patients, and were used to demonstrate the
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existence of mixed infections with differing P. falciparum  clones in individuals (Carter 
& McGregor 1973).
Allozymes however, have various disadvantages over other loci; for instance, it 
is possible that differential selection could be acting to maintain different combinations 
of Allozyme alleles in a population. This impacts on the neutrality of these markers 
(Jordan et a l ,  1997). The number of electrophoretic variants in a given population and 
therefore the resolution of these markers are quite low. The other disadvantage of 
Allozymes over other markers is that the likelihood of an amino acid change translating 
into a mobility shift is very low and this increases the frequency of different alleles 
being typed as similar.
1.5.3.2 Polymerase chain reaction and DNA polymorphism
The use of polymerase chain reaction (PCR) amplification of deoxyribonucleic acid for 
the detection of genetic polymorphism in malaria parasites has broadened our 
knowledge of the parasites’ natural genetic diversity. The main polymorphic 
Plasmodium  genes studied are those encoding merozoite surface proteins 1 and 2 
(M SPl and MSP2) and the glutamate rich protein (GLURP). The genes have been used 
to make community-based comparisons between parasites infecting different human 
populations exposed to malaria, and have also been used to determine clonal 
multiplicity in individuals.
In an analysis of the genetic characteristics of parasite populations, the PCR 
typing methodology provides the advantage of a great sensitivity and specificity, 
without the need to culture parasites, as was necessary for allozyme typing. The single 
copy genes M spl, Msp2, and Glurp show high allelic polymorphism, allowing easy 
detection of parasite diversity; alleles with similar or identical serologic properties can 
be distinguished by size polymorphism of the PCR product.
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1.5.3.2.1 Merozoite surface protein-1 (MSP-1)
The merozoite surface protein-1 (MSP-1), also known as merozoite surface 
antigen-1 (MSA-1), glycoprotein 195 (gpl95), and P190, is one of the most studied 
plasmodial antigens. It is synthesised by liver- and blood-stage schizonts (Holder & 
Freeman 1982; Szaifman et a l ,  1988) and varies in size between different parasite lines 
from 180-220kDa (McBride et a l ,  1985). The antigen is encoded by a single gene 
located on chromosome 9 (Kemp et a l ,  1987). Each haploid parasite therefore produces 
one allelic variant of this protein (Howard et a l ,  1986; McBride & Heidrich 1987). The 
extensive polymorphism of MSP-1 was originally characterized using a panel of 
monoclonal antibodies, some to polymorphic epitopes of the molecule (Holder 1988; 
Holder et a l ,  1988b; Holder et a l,  1988a; McBride et a l ,  1985). Sequencing of the 
gene from different P. falciparum  isolates has revealed the extent of the allelic 
polymorphism (Holder et a l ,  1985; Kemp et a l ,  1986; Miller et a l ,  1993; Ranford- 
Cartwright et a l ,  1991; Tanabe et a l,  1987; Holder et a l ,  1985; Kemp et a l ,  1986; 
Holder ern/., 1985).
By comparing nucleotide sequences, Tanabe and colleagues (Tanabe et a l ,  
1987) identified polymorphic domains, conserved domains, and intermediate or ‘semi­
conserved domains’ based on the percentage identity of conserved nucleotide 
sequences. On this basis the gene was divided into 17 domains or blocks; 7 of which are 
variable, interspersed with five conserved and five semi-conserved blocks (Figure 1). 
Sequences are dimorphic, i.e., substitutions at given positions are either one or the other 
of any 2 residues, in most parts of the gene with the exception of a polymorphic 
tripeptide-encoding region in block 2. Sequences from the MAD20 and K1 strains serve 
as representative types for the two dimorphs (Peterson et a l ,  1988b; Tanabe et a l ,  
1987).
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«The block 2 domain contains tripeptide repeats and exhibits considerable 
polymorphism. This block differs by sequence and/or by numbers of repeats in almost 
every allele investigated so far. Three basic families of block 2 have been defined 
largely on the basis of non-repetitive sequences at the ends of the repeat regions and are 
named after the isolates from which they were originally described; the MAD20“type, 
the K l-type and the R033-type (Tanabe et al., 1987). The R 033-type block 2 lacks the 
typical N-terminal repeat structure found in the other two alleles (Ceita 1990) and is 
non-polymorphic between alleles of this family.
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Figure 1: Schematic diagram of the 17 domains of the mspl gene of P.falciparum,
The open, hatched and completely Oiled regions are the conserved semi-conserved 
and variable domains respectively.
M spl alleles may be defined as unique combinations of: (a) one of three
versions of block 2 (MAD20, K1 or R 033), (b) one of four possible versions of block 4,
because recombination within this region generates MAD20/K1 and K1/MAD20
hybrids in addition to the ‘pure’ allelic types MAD20 and K1 (Conway et al., 1991;
Kaneko et al., 1996), and (c) one of two versions (MAD20 or K l) of the segment
between the variable blocks 6 and 16, that comprises about 60% of the gene.
Recombinant-type alleles have not been described in this 3’ portion of the gene
covering blocks 6 to 16 (Conway et al., 1991; Jongwutiwes et al., 1993; Kaneko et al.,
1996; Tanabe et al., 1989; Tanabe et al., 1987). Minor differences also exist between
homologous versions of the same variable block, and nucleotide substitutions (most of
I
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which are dimorphic) occur in semi-conserved and conserved blocks (Tanabe et a l ,  
1987).
Excluding the polymoiphism seen in block 2, most allelic diversity is thought to 
be generated by intragenic recombination, at the diploid stage in the mosquito host, 
within blocks 3, 4 and 5. Direct evidence of recombination in block 3 has been 
demonstrated following a genetic cross (Ken* et ah, 1994).
1.5.3.2.2 Merozoite surface protein-2 (MSP-2)
This antigen, also known as merozoite surface antigen-2 (MSA-2), is 
synthesised in the blood-stage schizonts and, like MSP-1, is incorporated on the 
schizont surface, and on the surface of free merozoites (Miettinen-Bauman et ah, 1988; 
Stanley et ah, 1985). MSP-2 was first defined by monoclonal antibodies (Fenton et ah, 
1989), and the size of the protein (Stanley et ah, 1985) was found to vary greatly in size 
from 35-36kDa on Western blots with protein extracted from different parasite isolates 
(Ramasamy 1987). MSP-2 is known to be one of the antigens present in immune 
complexes that form at the surface of merozoites when antibodies in immune serum 
inhibit merozoite dispersal (Thomas et ah, 1990c). The Msp2 locus has been mapped to 
a region of approximately 800 bp on chromosome 2 (Kemp et ah, 1987),
The MSP2 protein consists of conserved amino- and carboxy-terminal regions 
flanking a central variable region that is in turn composed of non-repetitive sequences 
suiTOunding a repetitive sequence (Figure 2). Compaiisons of Msp2 sequences from 
different parasite isolates revealed a similar block structure to that seen with M spl, but 
with four distinct blocks by virtue of local differences in the degree of homology 
between sequences from different strains (Thomas et a l, 1990; Smythe et a l ,  1988; 
Smythe et a l,  1990).
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Figure 2: Schematic diagrams of the two main MSP2 allelic families.
Dark regions at the left and right indicate signal and anchor sequences. Open 
regions internal to these represent conserved regions, whereas grey and striped 
regions represent variable nonrepetitive and repetitive sequences, respectively.
The repetitive part of the gene exhibits marked polymoiphism (Fenton et al., 
1991; Smythe et al., 1988; Smythe et al., 1990; Thomas et al., 1990c). All of the alleles 
of Msp2 so far exam ined can be grouped into two families, defined by the non-repetitive 
region 3 (Thomas et al., 1990c). These ai'e denoted the Indochina 1-like (IC I-like) and 
FC27-like families (Figure 2).
The 5' conserved region, with 100% conservation of nucleotide sequence (region 
1), encompasses the first 129 bp from the initiation codon. The translation of this region 
includes the predicted signal peptide, which is presumably absent from the mature 
parasite protein (Smythe et al., 1990).
Region 2 is strain variable, and is characterized by the presence of tandemly 
arranged repeat sequences. It begins with a short stretch of amino acids, some of which 
are conservatively substituted within the ICI-type allele. This stretch lies immediately
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N-terminal to a glycine, serine and alanine-rich block that is present in all IC I-type 
strains, but absent from the FC27-type strains. The MSP2 sequence from parasite FC27 
contains two identical copies of a 96-bp repeat unit commencing at base 178. In 
contrast, the alleles from parasites 3D7 and ICI contain multiple copies (5 and 12, 
respectively) of a 12-bp repeat unit commencing in both genes at base 169. The repeat 
in alleles of IC I-family encodes the amino acid sequence Gly Gly Ser Ala and bears no 
apparent relationship at either the nucleotide or amino acid level to the 32-amino-acid 
repeat in FC27-type alleles (Thomas et al., 1990b).
Sequencing of a large number of Msp2 alleles from isolates drawn from various 
geographical regions has revealed hybrid alleles that do not fall into either the IC I-type 
or FC27-type families (Marshall et al. 1991). An allele (NIG60) was sequenced with an 
N-terminal region of the ICI allelic family and a C-terminal region of the FC27 allelic 
family. As the Msp2 gene is found in a single copy in the haploid genome, this allele 
was suggested to have been formed by intragenic recombination, presumably occuning 
during meiosis. The apparent crossover event occuiTed within the repetitive variable 
regions (Mai’shall et al. 1991).
1.5.3.2.3 Glutamate-Rich Protein (GLURP)
The glutamate-rich protein {glurp) gene has been used as a marker in many 
malaria studies (Borre et al., 1991). The single copy glurp gene is located on 
chromosome 10, and encodes a polypeptide of 1271 residues with a predicted molecular 
mass of 145 kDa. Rabbit anti serum against a fusion protein expressing the C-terminal 
end of the molecule detects a protein with a molecular mass of 220 kDa (Hogh et al., 
1993). The 220-kDa GLURP protein is located in the parasitophorous vacuole of liver- 
stage parasites, in erythrocytic schizonts, and on the surface of newly released 
merozoites and may facilitate merozoite invasion (Bone et al., 1991). The gene encodes
23
an antigen with an am ino-terminal nonrepeat region, denoted RO (GLURP94_489). as well 
as a central repeat region (GLURP489-705) and a carboxy-terminal (GLURPvos-ins) 
repeat region (denoted R1 and R2, respectively). All 3 regions are quite polymorphic 
among isolates (Bone et al., 1991) . GLURP has not been as widely studied as the 
merozoite surface proteins but its variability, exhibited by length polymorphisms of the 
repeat regions, has been described and determined in studies on multiclonal P. 
falciparum  infections (Boudin et al., 1993; Dodoo et al., 2000; Hogh et al., 1992; 
Theisen et al., 1998).
1.5.2.3 Polymorphism of Noncoding Sequences
Intergenic and intronic DNA regions often contain simple sequence repeats of 
variable lengths known as satellites. These are further classified into satellites, mini- 
and micro-satellites based on the length of the repeat unit.
Satellite DNA was the first of the tandemly repeating DNA sequences to be 
discovered, and was so named by its appearance as m inor or “satellite” bands that 
separated from the “bulk” DNA upon buoyant density gradient centrifugation (Britten & 
Kohne 1968). Human satellite DNA is not transcribed, and is found in heterochromatin 
(condensed areas of chromatin consistently lacking actively expressed genes), especially 
centromeric heterochromatin (Bennett 2000). However, there is no evidence to suggest 
that these restrictions upon chromosomal localization are associated with any functional 
importance. Furthermore, because of its enormous size and restricted localization, 
satellite DNA is of no real use for either individual DNA profiling or genetic linkage 
studies (Bennett 2000).
Minisatellites are blocks of repeated core elements longer than 10 to 15 bp in 
tandem arrays. It can be subdivided into two types, the first of which is known as 
telomeric. Telomeric DNA consists of 10-15 kb of hexanucleotide repeats (mainly
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TTAGGG), added to the telomeres of all chromosomes by the enzyme telomerase. Such 
DNA is most definitely functional in that it protects the ends of chromosomes from 
degradation and provides a means for the complete replication of telomeric sequences 
(Bennett 2000). It is also thought to play a role in the pairing and orientation of 
chromosomes during cell division (Bennett 2000), The second type of minisatellite 
sequences is hypervariable minisatellite DNA, and includes those first discovered in 
1985 by Jeffreys and colleagues (Jeffreys et a l ,  1985). The basic repeat unit may vary 
in length from six to > 50 nucleotides, with the overall number of repeats at any one 
locus usually being highly polymorphic between individuals (Bennett 2000).
The molecular processes that generate vail ability at minisatellites remain 
obscure. A subset of mini satellites share a common “core” sequence, which, based on 
sequence similarity to the Chi sequence of E. coli, has led to speculation that the core 
sequence may serve as a recombination signal to promote unequal crossing over, at least 
in human minisatellites (Jeffreys et al., 1988a; Jeffreys et a t,  1985). Direct estimation 
of minisatellite mutation rates to new length alleles in human pedigrees has shown that 
paternal and maternal mutations arise with similar frequency, consistent with length 
change events being restricted to one stage of gametogenesis and possibly meiosis 
(Jeffreys et a t ,  1988b). However, new mutants have been detected in clonal tumor cell 
populations (Armour et al., 1989) and eai'ly in mouse development, indicating that 
mutation events are not restricted to the germline but can also arise in the soma (Jeffreys 
et al., 1990). It is still not clear the extent to which interallelic unequal exchange 
through meiotic or mitotic recombination is involved in generating minisatellite 
variability, or whether other processes, such as unequal exchange between sister 
chromatids and replication slippage, are the primary source of minisatellite variation 
(Jeffreys eta l., 1990).
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Minisatellite-type repeats appear to be ubiquitous in many antigen-encoding 
genes in P. falciparum, such as merozoite surface proteins (MSP-1 and MSP-2), S- 
antigen and circumsporozoite protein, and may be important in generating an immune 
response to malaria parasites (Hughes & Hughes 1995). This immune response 
generated to the repetitive regions, however, is thought to be a diversion by the parasite 
and is generally thought to be very poor at affecting the parasite. This is refened to as 
the ‘smokescreen’ hypothesis (Anders et ah, 1986). A few of these mini satellites have 
also been found in housekeeping genes, sequenced during the P. falciparum  genome 
project (Gardner et al., 1998).
Using data from 12 laboratory parasite lines together with field isolates from 
Papua New Guinea and the Democratic Republic of the Congo to analyse patterns of 
repeat structure, Anderson and colleagues observed numerous 
minisatellite/microsatellite combinations suggesting that minisatellites might be just as 
common as microsatellites in the Plasmodium  genome (Anderson et al., 2000b).
Microsatellites are defined as simple tandemly repeated DNA sequence elements 
of 2-6nucIeotides as repeat units. They were first isolated by chance by Wyman and 
White (Wyman & White 1980) from a library of random segments of human DNA. 
Microsatellites are found in greater or less abundance in the genomes of just about every 
known organism and organelle (Bennett, 2000), and are sometimes referred to as short 
tandem repeats (STR) or simple sequence repeats. To denote the type of motif being 
iterated, terms such as mono-, di-, tri- and tetranucleotide repeats are used. 
Polymorphism of microsatellites is mainly due to allelic length variation, caused by a 
difference in the number of repeat units between alleles. Microsatellites therefore 
belong to a class of sequences termed variable number of tandem repeats (VNTR), 
which refer to any tandemly repetitive DNA that can show length polymorphism
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(reviewed by Ellegren (Ellegren 2000)). PCR amplification and subsequent gel 
electrophoresis can determine the length of a distinct allele.
At present the function of microsatellite sequences is not clear. It is likely that a 
large proportion of microsatellites evolves neutrally, but in some cases, microsatellite 
variation can be associated with an altered phenotype (Chambers & MacAvoy 2000). 
The most direct evidence for the involvement of microsatellites in gene function comes 
from studies of human genetic disorders that result from trinucleotide-repeat expansion, 
in particular from the observed strong conelation between repeat length, age of onset 
and severity of disease (Rubinsztein et a l ,  1999). This is exemplified by the 
trinucleotide repeat associated diseases such as Huntington’s disease, myotonic 
dystrophy, and certain types of spinocerebellar ataxia (Brook et a l ,  1992; McDonald 
1994; OiT et a l ,  1993; Schols et a l ,  1995). The primary genetic cause seems to be the 
expansion of a trinucleotide repeat far outside of its “normal” polymorphic range 
(Debrauwere et al., 1997). Such repeats are usually inside the disease gene, wherein 
most encode runs of glutamine residues; others, which are outside, are close enough to 
disrupt its correct functioning.
Microsatellites offer several advantages as genetic markers. These include the 
fact that they are relatively easy to isolate in many species (Armour et a l,  1994; 
Schlotterer et a l ,  1991; Su & Wellems 1996), different loci can be used according to 
the level of variation, which range from very low to very high (Beaumont 1999), they 
can easily be amplified by PCR and thus can be used on a wide range of sample 
material for example blood, hair, saliva, skin and faeces, and their genetic systems are 
easily automated enabling the analysis of a large number of samples (Heyen et a l,  
1997; Luikart & England 1999). Their applications range from estimation of the spatial
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relationships between chromosome segments to the elucidation of temporal 
relationships between origins of species and genera (Chambers & MacAvoy 2000).
However microsatellites have several disadvantages. These include reports that 
for certain groups of organisms they are difficult to isolate (Beaumont & Bruford 1999), 
the tendency of Taq polymerase to add an additional dATP to PCR products, Taq 
polymerase-generated slippage products in some mono- and di-nucleotide microsatellite 
loci causing base shifts and sizing problems (Gill et ah, 1985; Ginot et ah, 1996; 
Schlotterer & Tautz 1992), the considerable technical challenges of microsatellite 
analysis of some types of samples e.g. saliva, hair or faecal material (Taberlet et al., 
1997; Taberlet & Fumagalli 1996) and the reports that data generated in different 
laboratories using different chemistries have proved difficult to amalgamate (Beaumont 
& Bruford 1999).
However the popularity of microsatellites as markers remains undiminished, 
probably because researchers are of the opinion that the advantages offered by the 
microsatellites, for example their resolving power, outweighs their disadvantages.
1.6 The Evolution of microsateiiites
Microsatellites have been estimated to mutate at rates in the order of 10'^ to 10’"^ 
changes per locus per generation, which is relatively high compared to the rate of point 
mutations (Hancock 1999). The high rates of change mean that the microsatellites differ 
from most other types of DNA sequences in their unusual degree of polymorphism, 
making them attractive as genetic markers (Goldstein et a l ,  1999; Goldstein & 
Schlotterer 1999). The mechanisms by which microsatellites mutate are poorly 
understood but two main mechanisms have been proposed, which may act in concert.
Levinson and Gutman formulated the first model for microsatellite mutation 
about 15 years ago (Levinson & Gutman 1987). This model is based on the replication
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slippage or slipped-strand mispairing. It refers to the out-of-register alignment of the
1993;M onal e ta l ,  1991). 
o The rate and pattern of m icrosatellite mutation does not seem to differ between 
hemizygote chromosomes (e.g. the Y chromosome) and chromosome pairs 
(autosomes of diploids) (Kayser et a l ,  2000), suggesting that mutation events
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two strands following dissociation at the time when the DNA polymerase traverses the 
repetitive region. If the 3 ’ repeat unit of the nascent strand rehybridises with a
complementary repeat unit downstream along the template strand, a loop will be formed 
in the nascent strand and the new sequence will become correspondingly longer than the 
template sequence upon elongation. Conversely, if the incorrect alignment occurs 
upstream along the template strand, the new strand will become shorter than the 
template strand (Ellegren 2000).
The other mechanism for microsatellite evolution is interchromosomal exchange
: ■
(Ellegren 2000). In theory, new-length variants at repetitive DNA sequences can form 
through interchromosomal exchange, for example, in conjunction with recombination 
(unequal crossing-over) or gene conversion. However, the accumulated evidence is in 
favour of replication slippage, and includes:
o Mutant alleles are generally non-recombinant for flanking markers, which would l |  
indicate intrahelical mutation rather than recombination (Mahtani & Willard
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do not require contact between homologous chromosomes (Heyer et a l ,  1997). 
o It has been demonstrated from experiments done in vitro, that microsatellite 
sequences have the intrinsic ability to undergo DNA slippage (Schlotterer &
Tautz 1992).
The mutation rates of microsatellites differ not only between species but also within 
species; that is, between loci. For most species studied, the average repeat number at
loci is directly proportional to the degree of length polymorphism indicating that long 
loci mutate more often than short loci (Weber 1990).
It has also been speculated that the flanking sequence content might affect the 
mutation rate e.g. through a simple GC content effect. Brock and colleagues showed 
that the %GC in the 100 bp region flanking the repeat sequence was positively 
associated with relative expandability of the microsatellite (Brock et al., 1999). Another 
factor proposed to affect microsatellite mutation rate is the size difference between the 
two alleles present within an individual, denoted the ‘allele span’. Amos and colleagues 
(Amos et al., 1996) suggested that microsatellite mutations were more likely to occur in 
heterozygous individuals with a larger difference between the sizes of their two alleles. 
However, this idea is not supported by the evidence for mutations representing 
intrahelical events (Ellegren 2000).
The mutation patterns of microsatellites are assumed to evolve via two models; 
stepwise mutation model (SMM) or the infinite allele model (IAM). The SMM assumes 
that length changes result from either losses or gains of one or a few repeat units 
(Valdes et al., 1993; Zhivotovsky & Feldman 1995). The SMM can be easily modelled 
and the length of repeat sequences contains infonnation on the relationships between 
alleles. Evidence in support of this model comes from direct observation of mutations in 
human pedigrees (Weber & Wong 1993), experimental yeast systems (Weirdl et al., 
1997) and in tetranucleotide repeats of swallows (Primmer et al., 1998). However, the 
problem with SMM is that it has little power to detect rare mutation events resulting in 
large changes in allele length. For instance SMM has failed to detect indels in flanking 
regions, which also play a significant role in generating length variation (Angers & 
Bernatchez 1997; Grimaldi & Crouau Roy 1997; Weber & Wong 1993).
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The lAM  model was developed to study loci that violate the SMM model (Kimura & 
Crow 1964). Under this model, a mutation involves any number of tandem repeats and 
always results in an allelic state not previously encountered in the population.
1.7 Microsatellites in malaria genetic studies
Microsatellites have been shown to be extremely widespread in P. falciparum, 
occuiTing every 2-3 kb throughout the genome (Su et al., 1999; Su & Wellems 1996). A 
total of 901 markers have now been isolated and mapped to the genome of clone 
3D7(Su et al., 1999). The most common repeat motifs seen in microsatellites have been 
those with an AT bias, which is not surprising given the extreme AT- richness of the 
parasite genome (Gardner et al., 2002). Typical repetitive sequences are (TA)n, (CA)n, 
(A or T)n, (AAT)n and (CAA)n motifs (Su & Wellems 1996).
Microsatellite maikers were first used to map a genetic cross. Su and Wellems 
(Su & Wellems 1996) described 224 microsatellite markers for P. falciparum, and used 
188 polymorphic microsatellites to map the segregation patterns in the progeny from a 
genetic cross. They also investigated the variations in allele size present in 12 laboratory 
lines, from diverse geographical locations, at all 224 loci. From the prevalence of 
nonparental alleles in 35 progeny of this genetic cross, Anderson and colleagues 
(Anderson et al., 2000a) estimated the microsatellite mutation rate for P. falciparum  to 
be 1.59 X 10" .^ Anderson and colleagues (Anderson et al., 2000b) used data from the 
same 12 laboratory parasite lines together with field isolates from Papua New Guinea 
and the Democratic Republic of the Congo to analyse patterns of repeat structure and 
expected heterozygosity at 114 of the same microsatellite loci. They also examined the 
sequence variation at 12 tri-nucleotide repeat loci. They found that there were complex 
mutation patterns in at least five of the twelve loci in the sequencing study. While 
alleles for some loci differed in size by one or two repeats, others were found to contain
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compound repeats each of which showed length variation. Still others were found to 
have multiple sources of length variation including sequences of indels. Another finding 
from this study was the differences in allele sizes between the two populations studied. 
While alleles from Papua New Guinea were extremely conserved in size, parasite alleles 
from the Democratic Republic of Congo showed large size variations (Anderson et al., 
2000b). This was found to be as a result of various insertions, including minisatellites, 
in the microsatellite repeats of the pai'asites from Congo. In fact, some of the sequences 
observed in some loci could be best described as minisatellites containing microsatellite 
repeats. However, despite the complex repeat structures in these sequences, point 
mutations were found to be virtually absent from the flanking regions (Anderson et al., 
2000b).
These studies also suggested that the mutation rate of dinucleotide-bearing loci 
is 1.6-2.1 times faster than trinucleotides. The mean He (calculated as the proability of 
drawing two alleles of different length (for the same locus) from a population sample) 
over all loci was found to be 0.72 but was higher in di- than trinucleotide repeats. He 
was also found to be lower in seven loci that contained monomers or repeats >4 bp 
(Anderson et al., 2000b). A positive relationship was also found between the repeat 
number and He, with He reaching a plateau around 13 repeats. This suggests that loci 
with large arrays of repeats have a higher mutation rate than loci containing small an'ays 
(Anderson et a l ,  2000b) until the maximum allele length is attained.
In perhaps the most comprehensive study on P. falciparum  population genetics 
to date, Anderson and colleagues analysed the population structure in 465 infections 
from 9 locations worldwide using 12 microsatellites (Anderson et al., 2000a). This 
study revealed an array of parasite population structures in different locations.
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A study done in Senegal (Leclerc et al., 2002) also revealed high mean 
heterozygosities for both microsatellites (0.745) and antigenic (0.702) loci but the 
values were lower than those obtained by Anderson and colleagues (Anderson et a l,  
2000a) for the Africa region. This can perhaps be explained by different transm ission 
intensities between the areas from which the samples were collected. Higher 
transm ission rates would lead to higher recombination rates which would be expected to 
result in more parasites with different alleles (read higher He).
Some of the microsatellites used in the two studies that investigated parasite 
variation in field isolates (Anderson et a l ,  2000a; Leclerc et a l ,  2002) are situated in 
introns within protein coding sequences (loci denoted 2490, PfPK2, Polya, G377 and 
ARAII (Anderson et a l ,  2000b). These markers may therefore not be entirely neutral, 
since they are situated within protein-encoding genes subject to selection. Therefore, the 
values of He obtained may be lower than the true values as a result of the removal of 
genetic variation in these markers through “hitchhiking”.
Hitchhiking refers to the process by which polymorphism of sites within the 
vicinity of a positive selection (selective sweep) is reduced (Hedrick 1980). This 
phenomenon has been observed on m icrosatellite loci around some genes of P. 
falciparum, Pfcrt, (Cortese et a l ,  2002; Wootton et a l,  2002) dhfr and dhps (Nair et a l ,  
2003; Nash et a l,  2005; Roper et a l ,  2003). In one of the studies with Southeast Asian 
isolates He of the microsatellite loci around dhfr was observed to reduce from 0.80 at 
markers situated 58 kb to 0.10 in markers situated 1.2 kb from the gene (Nair et a l ,  
2003). Two studies; one with parasites isolated from worldwide locations (Wootton et 
a l,  2002) and the other on Thai and Laos isolates (Nash et a l ,  2005) made the same 
observation with markers around the Pfcrt gene. Though it is still quite difficult to 
unequivocally prove neutrality of a marker (Kreitman 1996; Rand et a l,  1994), it is
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imperative to use markers that are as neutral as possible for any conclusive arguments 
on the population structure of P. falciparum  to be made.
1,8 Drug resistance in malaria
The malaria parasite P. falciparum  has developed clinically significant 
resistance to all classes of antimalarial drugs, with the possible exception of the 
artemisinin derivatives. Drug resistance is defined as the ability of a parasite strain to 
multiply or to survive in the presence of concentrations of a drug that normally destroy 
parasites of the same species or prevent their multiplication (World Health Organization 
1973). Such resistance may be relative, yielding to increased doses of the drug that can 
be tolerated by the host (also referred to as drug tolerance); or complete, when the 
parasite withstands maximum doses tolerated by the host (outright resistance). It is 
usually demonstrated as a shift to the right of the dose-response curve, thus requiring 
higher drug concentrations to achieve the same parasite clearance (White 2004). 
Resistance emerges de novo through spontaneous mutations or gene duplications, which 
are thought to be independent of drug selection pressure. The mutated parasites have a 
selective advantage in the presence of the drug, and their frequency in the population 
will increase at a rate proportional to dmg use (Mackinnon & Hastings 1998).
A number of different mechanisms are known to give rise to drug resistance 
including alterations of drug transport and permeability, conversion of the drug to an 
altered form with lower activity, increased expression of the drug target, and alterations 
to the drug target that decrease the affinity of binding of the inhibitor (White 1992). 
Different levels of drug resistance are encountered in malaria chemotherapy. Studies 
monitoring the spread of drug resistant malaria have tended to use various tools ranging 
from the standard in vivo method involving the exam ination of a blood film for parasites 
during the study period (WHO, 1996), to the more recent, parasite genotyping.
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1.8,1 Therapeutic response and levels of drug resistance
The in vivo drug efficacy test is normally carried out following protocols 
published by the WHO (World Health Organization 2003b) and the therapeutic 
response is classified as outlined below. The first day of treatment corresponds to day 0; 
the days of follow-up are then counted from this date.
Early treatment failure (ETF):
- development of danger signs or severe malaria (see below for definition) on
day 1, day 2 or day 3.
- axillary temperature > 37.500 on day 2 with parasitaemia > that of day 0; 
axillary temperature > 37.500 on day 3 in the presence of parasitaemia;
- Parasitaemia on day 3 > 25% of the count on day 0.
Late treatment failure (LTF);
- danger signs or severe malaria in the presence of parasitaemia on any day from
day 4 to day 14, [or 21, 28 or 42 depending on the study period] without 
previously meeting any of the criteria of early treatment failure;
- axillary temperature > 37.500 in the presence of parasitaemia on any day from 
day 4 to any day within the follow-up period without previously meeting any of 
the criteria of early treatment failure.
Adequate clinical response (ACR):
- absence of parasitaemia on day 7, 14, 21, 28 or 42 irrespective of axillary 
temperature, without previously meeting any of the criteria of early or late 
treatment failure;
axillary temperature < 37.500 irrespective of the presence of parasitaemia, 
without previously meeting any of the criteria for early or late treatment failure.
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Adequate clinical and parasitological response
absence of any malaria clinical signs and parasitaemia on any day within the 
follow-up period after treatment.
Treatment response is also classified according to the level of parasitaemia during the 
follow-up period using as a reference, the parasitaemia on day 0 (World Health 
Organization 1996).
RIII resistance: this is defined as day-3 parasite density > 75% of the day 0 
parasitaemia (Figure 3),
RII resistance: this is defined as day-3 parasitaemia equal to 25% of the day 0 density 
with the patient continuing to be parasitaemic on days 4-7 (Figure 3).
RI resistance: this is defined as day-7 parasite densities < 25% of day-0 density 
following either an initial parasite clearance on day 3 or presence of parasite density on 
day-3 at < 25% of day 0 (Figure 3).
Sensitive response: this defined as day 3 parasitaemia < 25% of that on day 0 [or 
absence of parasitaemia], a negative blood smear on day 7 and negative smears for the 
remainder of the follow-up period (Figure 3).
 RI
RII
 RIII
 detection threshold
Day post treatment
Figure 3: Graph showing parasite resistance after treatment over a 28-day period
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One explanation for the different types of resistant parasite observed is that RI 
parasites may be the result of a low proportion of resistant parasites in a m ixed 
infection. Drug treatment would kill the sensitive parasites, thereby reducing the 
resistant parasite population to a parasitaemia below that detectable by microscopy and 
possibly below the threshold for symptomatic malaria. These resistant parasites would 
continue to grow in the presence of the drug and eventually reach m icroscopically 
detectable parasitaemias (RI) or the threshold for symptomatic malaria to return (LTF) 
(Figure 3). An alternative explanation is that resistance is not an 'all-or-nothing' 
response. Some parasites could be highly resistant and their growth would be unaffected 
by the treatment; these would be classified as RIII resistant. Other parasites could show 
slightly lower resistance, such that their growth would be initially inhibited by the drug, 
but as concentrations fall they would be able to grow again; these would be RII. Finally, 
RI parasites could be resistant to the drug at a lower level still, such that growth is 
inhibited until the drug concentration drops further, although this level would still be 
able to prevent growth of parasites sensitive to the drug.
There is some correlation between clinical and parasitological response, but 
generally the rate of resistance/treatment failure is higher when measured by 
parasitaemia than by clinical response.
1.8.3 History of antimalarial drug resistance
The emergence of dmg resistance became particularly evident during the Global 
Malaria Eradication campaign launched in 1955 by WHO (Bruce-Chwatt 1956). At the 
beginning, the campaign's strategy was mainly based on DDT indoor spraying; the 
insecticidal properties of DDT would inteiTupt malaria transmission by decreasing the 
survival of potentially infected mosquitoes. However, the first reports of insecticide 
resistance (to dieldrin) in Anopheles gambiae in Nigeria prompted the Second African
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Malaria Conference held in Lagos in 1955 to stress the importance of obtaining the 
complete interruption of local transmission as quickly as possible (Bruce-Chwatt 1956). 
Therefore, the use of chemotherapeutic methods in association with residual insecticides 
was recommended whenever the rapid elimination of malaria was thought to be 
possible.
The introduction of cooking salt medicated with an antimalarial drug (mass drug 
administration (MDA)) was adopted for coverage of larger populations with 
antimalarials (Pinotti, 1953; World Health Organization 1961). It soon became clear 
that these interventions, besides the operational difficulties, could easily select for 
resistant parasites. In a few Kenyan villages, MDA with monthly pyrimethamine 
initially decreased the parasite prevalence but was followed by the emergence of 
parasites showing increased tolerance to the drug: sensitive parasites were rapidly 
replaced by resistant ones that disappeared when the administration of monthly 
pyrimethamine was stopped (Avery Jones 1958; Clyde & Shute 1954). A similar 
observation was reported from Ghana, although in this case it was explained by the 
irregular ingestion of tablets (Charles 1961; Charles et a l ,  1962).
Interventions based on the introduction of pyrimethamine-medicated salt were 
implemented, among others, in The Netherlands, New Guinea, Brazil and Cambodia 
(Eyles et a l,  1963). Usually, despite an initial decrease, parasite rates returned to pre- 
operational levels within a period of 6 months. In New Guinea, the emergence of 
pyrimethamine resistance, unsatisfactory distribution of medicated salt and 
underestimation of the salt ration were identified as major causes for the campaign 
failure (World Health Organization 1961). Better results were reported with chloroquine 
(CQ)-medicated salt from Guyana (Giglioli et a l ,  1967) and Uganda (Hall & Wilks 
1967), where parasite rates decreased. In general, the widespread use of medicated salt
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produced a wide variation of drug levels in the population because of the great variation 
in salt intake. This resulted in a very high selection pressure that induced an almost 
instantaneous P. falciparum  resistance to pyrimetham ine. CQ seemed to induce 
resistance less easily. However, the first cases of CQ-resistant strains originated from or 
near areas where CQ-medicated salt had been distributed (Payne 1988).
The first reports of confirmed P. falciparum  resistance (RI) to CQ came, almost 
simultaneously, from South America (Colombia, Brazil, Venezuela) in 1960 (Moore & 
Lanier 1961; Wemsdorfer & Payne 1991) and from South-east Asia (Thailand, 
Kampuchea) in 1961 (Hartinuta, Migasen& Boonag, 1962). By 1973, CQ resistance had 
been reported in several countries in South America (Brazil, Colombia, Guyana and 
Venezuela) and in Asia (Burma, Cambodia, Malaysia, Philippines, Thailand and 
Vietnam) but not in sub-Saharan Africa (World Health Organization 1973). In Africa, 
P. falciparum  CQ resistance was firstly reported from the eastern region, in Kenya 
(Fogh et ah, 1979) and Tanzania (Campbell et ah, 1979), in the late 1970s and it spread 
from east to west. By 1989, the distribution of CQ resistance was almost identical to 
that of P. falciparum  (Wemsdorfer & Payne 1991).
Levels of resistance have been shown to vary widely between and within countries. In 
Kenya, for example, there were major differences in CQ resistance between the North, 
where malaria transmission is low, and the West and Southeast, where transmission is 
intense. In the early 1990s, CQ resistance (positive slide on day 14 after treatment) was 
about 18% around Lake Turkana (Clarke et ah, 1996) while in Kisumu, on the shores of 
Lake Victoria, it was around 70% (R ll and R ill) (Bloland et al., 1993).
This kind of situation within one country presents a real dilemma for health 
managers needing to decide whether and with which drug to change the country's 
antimalarial drug policy. Such a change constitutes a major undertaking that can take
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several year's before being fully operational. In optimal conditions the "reaction time' 
has been estimated to be at least 2 years (Baudon 1995), Once the decision of changing 
the first-line drug is taken, there is no way back. However, it has always been difficult 
to give detailed guidelines or to establish a threshold at which a change should be 
implemented because this depends on several factors such as the cost of the drug and 
compliance.
1.8.4 Chloroquine resistance
Chloroquine (CQ) has been the mainstay of malaria treatment for well over half 
a century, but its exact mechanism of action remains controversial. Much evidence has 
pointed to the formation of a chloroquine-haem complex in the acid food vacuole of the 
parasite as being responsible for the antimalarial activity of chloroquine (Bray et al., 
1998; Chou et al., 1980). The concentration of the drug at the site of action, the acid 
food vacuole of the parasite, is thought to be essential for its activity.
It has been known for some time that there is a reduced accumulation of 
chloroquine in chloroquine-resistant parasites (Geary et al., 1986; Saliba et al., 1998). 
Most studies have indicated a reduced rate of chloroquine uptake in resistant (CQR) 
compared to sensitive (CQS) strains. Several studies have suggested that this could be 
due to an elevated vacuolar pH, leading to reduced accumulation of chloroquine (Bray 
et al., 1992a; Bray et al., 1992b). Others have suggested that this is a consequence of 
CQ being actively transported out of the digestive vacuole (DV) away from its 
presumed site of accumulation in resistant parasites (Krogstad & Schlesinger 1987). 
The efforts to understand the molecular basis of CQ resistance with the goal of 
circumventing or suppressing it have identified two genes that have been shown to play 
a role in chloroquine resistance. These have been identified as Pfcrt, coding for the
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chloroquine resistant transporter (PfCRT) (Fidock et ah, 2000a) and pfindrl, (Foote et 
a l,  1989) coding for the multidrug resistance 1 genes.
Resistance to chloroquine resembles that of multidrug resistance (mdr) seen in 
mammalian cells: there is a reduced accumulation of the drug, and resistance can be 
reversed by the presence of verapamil (Geary et a l ,  1986) (Krogstad et a l ,  1987; 
Martin et aL, 1987). Multi dmg resistance occurs when cells are exposed to one 
chemotherapeutic agent, but become resistant to a broad range of structurally unrelated 
drugs (Juliano & Ling 1976). The major protein mediating this phenotype in many 
mammalian cell-lines is the multidrug-resistance (mdr) transporter or P-glycoprotein 
(Pgh) (Gerlach et al., 1986). Gene amplification, increased noRNA expression and 
mutation of the mdr genes have all been shown to confer resistance to various drugs 
across different cell lines (Roepe et al., 1996). In many tumour cells the mdr phenotype 
has been shown to be dependent on the hydrolysis of ATP molecules, suggesting that 
Pgh may act as an energy-dependent drug efflux pump. Alternatively, it has been 
suggested that Pgh indirectly mediates substrate accumulation by regulating the plasma 
pH gradient and/or membrane potential (Roepe et al,, 1996).
Chloroquine-resistance in malaria parasites and multidrug resistance in cancer 
cell-lines share the features of reduced accumulation of the drug, and the ability to 
reverse this resistance with verapamil (Krogstad et al., 1987). Therefore P. falciparum  
sequences conesponding to homologs of the mdr transporters that mediate multidrug 
resistance in mammalian cell-lines were identified and investigated for their possible 
role in chloroquine resistance (Foote et al., 1989; Wilson et al., 1989). Two homologues 
of mdr were found in the P. falciparum  genome, and these were denoted Pfm drl and 
Pfm drl (Wilson et al., 1989).
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The pfmdr2 gene, located on chromosome 14 and present as a single-copy gene, 
encodes a 110-kDa protein with structural similarity to the heavy-metal tolerance gene, 
hm tl, of the yeast Schizosaccharomyces pombe (Riffkin et al., 1996). Pfmdr2 contains 
only 10 transmembrane domains, demonstrating 26% am ino acid homology with 
mammalian m drl, and a single nucleotide-binding site (Rubio & Cowman 1994; Zalis 
et al., 1993); a profile that is somewhat atypical for ABC transporters. Although some 
studies have reported increased transcription of pjmdr2 in chloroquine-resistant 
parasites (Ekong et a l ,  1993), other studies have demonstrated neither amplification, 
nor overexpression of pfmdr2 (Rubio & Cowman 1994; Zalis et al., 1993). To date, 
there appears to be no evidence to suggest that pjmdr2 is involved in mediating drug 
resistance in P. falciparum.
1.8.4.1 Pfmdrl and chloroquine resistance
Pfm drl is a typical member of the ABC transporter superfamily, with a 
conserved structure of two domains consisting of six predicted transmembrane 
segments, coupled to a nucleotide-binding fold. The two domains are joined together by 
a linker region. The -162  kD protein was termed Pghl (P-glycoprotein homolog 1) 
(Cowman et a l,  1991; Cowman & Karcz 1991; Higgins 1992). Pghl was subsequently 
localized to the parasite vacuole throughout the asexual cycle of the parasite, where it 
was postulated to regulate intracellular drug concentrations (Cowman et a l ,  1991). 
Sequence polymorphisms in pfm dr 1 have been identified which are associated with 
chloroquine-resistant phenotypes in vitro. One polymorphism, exemplified by the K1 
allele at codon 86, involves a single amino-acid change, N86Y, (Foote et a l ,  1990a) 
while the other, exemplified by the 7G8 allele, involves four amino acid changes, 
Y184F, S1034C, N1042D, and D1246Y, the latter three being contained in 
transmembrane domain 11 (Foote et a l ,  1990a). Moleculai' epidemiological analysis of
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these polymorphisms in a double-blind study correctly predicted the chloroquine 
resistance profile of 34 of 36 isolates (Foote et al., 1990a). Molecular epidemiological 
analysis of field isolates using rapid polymerase chain reaction and endonuclease 
restriction digestion techniques have demonstrated association of some of these 
polymorphisms with chloroquine resistance in studies from sub-Saharan Africa (Basco 
et a t ,  1995), Nigeria (Adagu et a t ,  1995a), Malaysia (Cox-Singh et a t ,  1995), Guinea- 
Bissau (Adagu et a t ,  1995b), and Thailand (Duraisingh et a t ,  2000). Studies from the 
Sudan, (Awad-el-Kariem et a t ,  1992) South America (Povoa et a t,  1998), and 
Southeast Asia (Basco et a t ,  1996; Mungthin et a t ,  1999), however, have failed to 
identify an association with these intra-allelic variations. In an attempt to establish 
linkage of chloroquine resistance to pfindr 1, a genetic cross between a chloroquine- 
sensitive central American clone (HB3), and a multidrug-resistant Southeast Asian 
clone (Dd2) was performed (Wellems et a t ,  1990). Chloroquine resistance was mapped 
as a Mendelian trait to a 36-kb locus on chromosome 7 (Wellems et a t ,  1990), which 
segregated independently of the pfindr 1 locus found on chromosome 5 (Foote et a t ,  
1989; Foote et a t,  1990a; Foote & Kemp 1989). Amplification of Pfindrl has also been 
suggested as a mechanism of resistance (Triglia et a t ,  1991). When field isolates 
are analysed, both mutation and amplification are found to be widespread in numerous 
geographical areas (Basco et a t ,  1995; Price et a t ,  1999). Together these data suggest 
that mutations in pfindrl can affect P. falciparum  parasite response to CQ, but how big 
a role it plays in clinical resistance remains uncertain.
1,8.4.2 Pfcrt and chloroquine resistance
Analysis of the progeny aiising from the HB3 x Dd2 cross mapped a single 
genetic locus, localized to a 36 kb segment on chromosome 7, that segregated with the 
inheritance of verapamil-reversible CQ resistance (CQR) (Su et a t ,  1997; Wellems et
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a l,  1991). Subsequent studies of this segment identified nine open reading frames, with 
that denoted cg2 having the closest linkage to the phenotype (Su et a l ,  1997). 
Polymorphism in cg2 was characterised by a complex series of repeat unit length 
differences and point mutations. Later studies used DNA transfection and allelic 
exchange to replace cg2 polymorphisms in CQR parasites with those sequences from 
chloroquine sensitive parasites (Fidock et a l ,  2000b) . Drug assays of the allelic all y 
modified lines showed no change in the degree of CQR. Similarly, a parasite (106/1), 
which contains the exact sequence of cg2 from CQR parasites, was found to be CQS, 
and cg2 haplotypes were found to be present within CQS parasites (Fidock et a l ,  
2000b).
Cg2 was mled out as the candidate Chloroquine resistance gene. Re-examination 
of the 36kb segment on chromosome 7 revealed a highly interrupted gene, with 13 
exons, some of which were very short. The gene now known as Plasmodium falciparum  
chloroquine resistance transporter (Pfcrt) spans 3.1 kb and encodes a 424 amino acid 
(48.6 kDa) protein (PfCRT) with 10 predicted transmembrane domains (Fidock et a l ,  
2000a). The protein was localized by immunofluorescence to the digestive vacuole 
(DV) membrane (Cooper, et a l  2002; Fidock, et a l  2000).
Transfection studies provided direct evidence of a role for PfCRT in CQ 
resistance. Coexpression of mutant forms of Pfcrt in the presence of a wild-type 
background confened a modest degree of Verapamil-reversible CQ resistance to CQ 
sensitive (CQS) parasites (Fidock et a l ,  2000a). More recently, a system was developed 
to replace the entire Pfcrt allele in a CQS parasite with Pfcrt alleles representative of 
mutant sequences prevalent in CQR parasites from Asia, Africa, South America and 
Papua New Guinea (Sidhu et a l,  2002). The resulting recombinant clones displayed 
reduced PfCRT expression as a result of the genetic modifications, but nevertheless
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demonstrated all the hallmarks of a bona fide  CQ resistance phenotype, i.e. increased 
CQ IC50 values (exceeding 100 nM), acquisition of VP-reversibility, and decreased CQ 
accumulation.
Mutations in the Pfcrt gene have been very closely associated with in vitro CQ 
resistance in culture-adapted isolates from around the world (Fidock et al., 2000a; 
Wootton et a l ,  2002). The critical mutation in CQR isolates results in a change of 
Lysine to Threonine at codon 76 (K76T). Other amino acid changes exist in flanking 
regions (72-75) with the allele present dependent on the geographical origin of the 
isolate. For CQR African and most South-east Asian strains, the resistance-linked allele 
encodes CVIET (amino acids 72-76), whereas CQS parasites have Pfcrt encoding 
CVMNK (Mehlotra et ah, 2001; Wellems & Plowe 2001). By contrast, most South 
American (and Papua New Guinea and Philippines) CQR strains encode SVMNT, 
while CQS strains have a CVMNK or related haplotype (Chen et ah, 2003; Durand et 
ah, 2001; Duirand et ah, 2004; Mehlotra et al., 2001; Nagesha et al., 2003; Wellems & 
Plowe 2001). A number of additional mutations are predicted to lie within the 
transmembrane segments. The recent discovery of additional Pfcrt mutations in 
Cambodian isolates (Lim et ah, 2003) brings the total number of variant residues to 15, 
making this quite a polymorphic gene for a non-surface molecule. It is presumed that 
many of these mutations serve to compensate for a loss of the endogenous function 
associated with the K76T variation, although some may serve to confer resistance to 
related antimalarial agents (Bray et ah, 2005).
Mutations in Pfcrt are believed to confer CQ resistance by reducing the amount 
of CQ accumulated by the parasite. The bulk of the intraparasitic CQ is believed to be 
concentrated within the digestive vacuole (DV). This, combined with the DV membrane 
location of PfCRT is consistent with the view that mutations in Pfcrt cause CQ
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resistance by reducing the drug concentration in the DV (Saliba et al., 1998). There are 
three main hypotheses on how PfCRT might exert this effect on DV CQ concentration. 
The first is that the reduced partitioning of chloroquine into the vacuole of CQR 
parasites is a consequence of alterations in the pH of the digestive vacuole (Bennett et 
ah, 2004). The second is that it is a consequence of the transport of CQ out of the DV 
(Saliba et al., 1998) while the third is a consequence of conformational changes in the 
PfCRT as a result of mutations in the Pfcrt gene (Sanchez et al., 2003). These 
hypotheses are discussed in the following sections.
1.8.4.2.1 Chloroquine resistance and pH of the digestive vacuole
One of the early hypothesis proposed that CQR parasites maintained an elevated 
pH in the digestive vacuole or DV, leading to reduced accumulation of CQ at steady 
state (Ginsburg & Stein 1991; Yayon 1985). Each molecule of CQ can associate with 
two protons, thus in theory leading to a concentration gradient across the DV membrane 
(de Duve et al., 1974; Yayon et al., 1984), it was thought that relatively small changes 
in pH should have a dramatic effect on the concentration of CQ in this organelle (Geary 
et a l,  1986).
The first reports of a comparison of pH in digestive vacuoles of CQS and CQR 
parasites suggested that CQR parasites have a more acidic DV than CQS parasites 
(Dzekunov et al., 2000; Ursos et al., 2000). However, these results were thought to be 
erroneous as they relied on measurements of fluorescence arising from acridine orange 
monomer, which was later shown to be undetectable in the DV and is, in fact, localized 
to the parasite cytoplasm (Bray et al., 2002; Wissing et al., 2002).
Roepe and colleagues (Bennett et ah, 2004) repeated their studies using the 
ratiometric dextran-tagged pH probe 5-(and 6-) carboxy-2', 7 '-dimethyl-3'-hydroxy-6 
V-ethylaminospiro [isobenzofuran-1 (3H), 9'-{9H) xanthen]-3-one (DM-NERF), which
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again showed that CQR parasite lines exhibited a more acidic pH in the DV than CQS 
parasites. CQS parasites were reported to have a DV pH of around 5.7 and this was 
found to be decreased to around 5.2 in CQR lines, including lines in which the 
endogenous wild Pfcrt allele had been replaced by alleles from CQR lines (Bennett et 
al., 2004). This study provided the first evidence of a direct link between CQ resistance- 
associated Pfcrt alleles and altered DV physiology. However, the reported differences in 
pH aie difficult to reconcile with the CQ accumulation data. According to weak base 
theory, an increase of 0.5 in the pH gradient across the DV membrane in CQR parasites 
has the potential to produce up to a 10-fold increase in the uptake of CQ into the DV of 
CQR parasites compared to CQS lines. However, what is observed when the uptake is 
measured directly is a six fold decrease in the uptake of CQ into CQR isolates, relative 
to that in CQS isolates (Bray et al., 1998; Sanchez et al., 2003; Sanchez et al., 1997).
1.8.4.2.2 Chloroquine resistance and efflux from the digestive vacuole
An alternative hypothesis for the reduced uptake of chloroquine by CQR 
parasites is that the drug is transported out of the DV, away from its presumed site of 
accumulation (Krogstad et al., 1987). Krogstad and colleagues showed that addition of 
glucose to the medium reduced the steady-state accumulation of CQ by CQR pai'asites. 
By contrast, adding glucose to suspensions of CQS parasites markedly stimulated CQ 
accumulation (Krogstad et al., 1992). These data suggest that CQS parasites have an 
energy-dependent CQ uptake mechanism (with energy being required both to maintain 
the DV proton gradient and to traffic and digest haemoglobin) and that CQR parasites 
have an energy-dependent CQ efflux mechanism.
However, these compelling data are inconsistent with some of the available 
literature. It has been shown previously that replacing glucose with its non- 
metabolizable analogue 2- deoxy-D-glucose, a procedure known to deplete the paiasite
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of ATP (Kirk et a l ,  1996), has no effect on the steady-state accumulation of CQ by 
CQR parasites (Bray et a l ,  1996), In the absence of ATP the DV HC-ATPase fails and 
the H+ gradient across the DV membrane decreases markedly (Saliba et al., 2003). 
Under these conditions there is very little possibility of active CQ efflux out of the DV. 
If CQR parasites were reliant on an active efflux process to reduce the CQ within the 
DV, then replacement of glucose with 2-deoxy-D-glucose would have been expected to 
result in a substantial increase in CQ accumulation. Other studies have shown that 
lowering the incubation temperature reduces the CQ accumulation of CQR 
parasites(Sanchez et a l,  1997). This is in contrast to the increased drug accumulation 
that might be expected at low temperature if an active efflux process were operating in 
the resistant parasites (Gottesman & Pastan 1993). These data suggest that the reduced 
CQ uptake in CQR lines that is observed upon addition of glucose (Sanchez et al.,
2003) might be unrelated to the concentration of ATP and, by implication, might not be 
caused by the active efflux of CQ from the DV.
1.8.4.2.3 The ‘Charged drug leak’ hypothesis
The mutations in Pfcrt that cause CQ resistance are associated with a loss of 
basic and hydrophobic residues (Warhurst et al., 2002). These mutations (including the 
one for K76T) are predicted to be in the barrel of the transporter on the DV side of the 
membrane, in a region of PfCRT implicated in substrate selectivity (Martin & Kirk
2004). The presence of the positively charged lysine residue at position 76 in wild- type 
PfCRT is predicted to repulse the doubly protonated form of CQ (CQ^^), and prevent its 
interaction with the transporter. The CQ resistance-conferring mutation at codon 76 
resulting in threonine (or isoleucine or asparagine; (Cooper, et a l, 2002; Fidock, et a l,
2000) removes the positive charge, possibly allowing CQ^^ to interact with PfCRT and 
exit the vacuole down the steep outward CQ^^ concentration gradient. This would result
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in a decrease in the overall CQ concentration at its site of action within the DV, and 
hence a decreased CQ sensitivity of the parasite. This ‘chai'ged drug leak’ hypothesis 
provides a plausible mechanism by which PfCRT could directly mediate CQ resistance.
This hypothesis is supported by some data obtained from earlier studies on CQ 
resistance. It was shown that CQR culture-adapted field isolates are often hypersensitive 
to the anti-influenza drug amantadine (Evans & Havlik 1993) and to the phenanthrene 
methanol, halofantrine (Nateghpour et ah, 1993). Using a stepwise selection protocol, 
CQR lines were selected for increasing levels of resistance to amantadine or 
halofantrine. Surprisingly, as the parasites became resistant to these drugs, they became 
sensitive to CQ (Nateghpour et a i ,  1993; Ritchie et aL, 1996; Ward 2002). Detailed 
examination of these parasite lines revealed that CQ accumulation and access to 
haematin were restored and the resistance-reversing effect of verapamil was lost 
(Johnson et a l ,  2004). Both the amantadine-resistant line and the halofantrine-resistant 
line exhibited novel mutations of Pfcrt including one mutation (coding for S163R) that 
was common to both drug-selected lines. Surprisingly, both lines retained the Pfcrt 
K76T-coding mutation, making these the first fully characterised examples of CQS 
parasite lines with this mutation. The novel mutation common to both lines (resulting in 
S163R) is proposed to replace a positive charge in the transporter baiTel, thereby 
compensating for the loss of positive charge associated with the K76T variation. This 
single amino acid change in PfCRT is proposed to block the leak of diprotonated CQ 
and thereby return the parasites to full CQS status, restoring access of CQ to 
ferriprotopophyrin IX and ablating verapamil synergism (Johnson et al., 2004).
The debate on the mechanism of chloroquine and how its resistance arises is still 
ongoing. Nevertheless, a combination of Pfcrt and pfm dr 1 polymorphisms together 
have been shown to result in higher levels of chloroquine resistance (Babiker et al.,
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2001). This observation is also supported by a whole genome survey which, using 
m icrosatellite markers to detect linkage disequilibrium in a range of parasites, has 
shown that Pfcrt is the major locus (Djimde et a l ,  2001; Fidock et a l ,  2000a), but the 
pfm dr 1 locus on chromosome 5 is also an important secondary mutation (Wootton et 
a l,  2002) for chloroquine resistance.
1.8.5 Antifolates
Antifolates are generally classified as type I (sulfonamides and sulfones) and 
type II (pyrimetham ine. Trimethoprim and cycloguanil, the active metabolite of 
proguanil). They mimic the essential metabolites of the malaria parasite in the folate 
pathway, and are active against all the growing stages in the liver (liver schizonts), 
erythrocytic stages in the blood (blood schizonts) and growing stages in the mosquito 
(sporogonie stages) (Sherman 1979). In Plasmodium falciparum, two genes involved in 
the pyrimidine biosynthetic pathway, dhfr and ts are contiguous and are expressed as a 
bifunctional enzyme DHFR-TS (Bzik et a l ,  1987). DHFR is the biochemical target of 
pyrimetham ine, and also of cycloguanil, the biologically active metabolite of proguanil. 
Pyrimetham ine binds to the parasite DHFR with a high affinity, inhibiting enzyme 
activity, resulting in the eventual depletion of deoxythymidine monophosphate (dTMP) 
and the disruption of DNA synthesis (Hyde 1990). The DHFR inhibition results in a 
reduction in the intracellular* pool of tetrahydrofolate cofactors, which are used in most 
cells for the de novo synthesis of pyrimidines, methionine and thymidylate and for the 
interconversion of glycine with serine. Serine is the only identified source of methyl 
groups of methionine and thymidylate. Serine hydroxymethyltransferase converts serine 
to glycine with the formation of N5-N 10-methylene tetrahydrofolate, which is then 
reduced to N-5-methyl tetrahydrofolate, the cofactor used to provide the methyl group 
that converts deoxyuridine monophosphate to the deoxythymidine monophosphate
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required for DNA synthesis. This activity is catalyzed by the enzyme thymidylate 
synthase (TS) and results in the regeneration of dihydrofolate (DHF) (Figure 4).
Differences in folate metabolism between malaria parasites and their 
mammalian and avian hosts permit the use of antifolates as antimalarial agents. The 
selective activity of pyrimetham ine has usually been attributed to higher affinity of the 
drug for Plasmodium  DHFR-TS than for human DHFR (Foote et al., 1990b; Hitchings 
1969; Peterson et al., 1990). Recent work has shed light on the differential specificity of 
the drug for parasite and human DHFR. Pyrimetham ine treatment removes the 
translational repression of the human enzyme, and more DHFR is produced to partially 
overcome the drug banier. However, in Plasmodium  DHFR-TS, mRNA binding is not 
coupled to enzyme active sites. Therefore, antifolate treatment does not relieve 
translational inhibition and the parasites do not have the ability to make fresh enzyme 
(Zhang & Rathod 2002). Other authors (Ninnalan et a l,  2004) have however, reported 
lack of discernible effect of antifolate drugs on the level of mRNA expression from the 
dhfr-ts gene. Nirmalan and colleagues (2004) showed that expression levels of DHFR- 
TS are elevated three-fold by pyrimetham ine, and up to seven-fold upon challenge by 
TS inhibitors, but not by a drug whose mechanism of action is unrelated to the folate 
pathway. They therefore concluded that the increases reflect enhanced synthesis of the 
DHFR-TS enzyme in the parasite as compared to human cells (Nirmalan et al., 2004).
Studies on the sulfonam ides and 4-aminobenzoic acid (PABA) in malaria date 
back to when the azo dye sulfachrysoidine and sulfanilamide were first used to treat 
human malarial infections and PABA was found to reverse sulfonam ide inhibition in 
Plasmodium gallinaceum  (Maier & Riley 1942).
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Figure 4: Simplified diagram of the Folate pathway indicating some the enzymes.
The numbered boxes indicate the relevant enzymes 1. Dihydropteroate synthase, 
Dihydrofolate synthase, 3. Dihydrofolate reductase, 4. Serine 
hydroxymethyltransferase, 5. Thymidylate synthase. Dashed arrows indicate 
multiple steps
The success of proguanil as an antimalarial agent in humans (Curd et aL, 1945) 
stimulated further study of pyrimidine derivatives, which resulted in the development of 
pyrimethamine (Falco et a l ,  1951). The enzyme DHPS (dihydropteroate synthase) 
(Figure 4), which is not found in mammals, is the primary target of type I antifolates. 
DHPS has been shown to be a bifunctional enzyme with 6-hydroxymethyl-7, 8-
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dihydropterin pyrophosphate (PPPK) at the N-terminus of the protein (Brooks et aL, 
1994; Triglia & Cowman 1994). Expression and purification of the enzyme from P. 
falciparum  in E. colt have shown that the activity purifies as an 83-kDa protein (Triglia 
et al., 1997). DHPS is responsible for the synthesis of 7,8-dihydropteroate from 2- 
anainO“4“hydroxy-6-hydroxymethyl-7,8- dihydropteridine pyrophosphate and (Para 
aminobenzoic acid) PABA (Figure 4). The drugs of the sulfa group are analogues of 
PABA and have been shown to be competitive inhibitors of the DHPS enzyme from the 
murine malarias P. berghei (Ferone 1973; Ferone 1977; McCullough & Maren 1974) 
and P. chabaudi (Ferone 1977; Walter & Konigk 1980), as well as in P. falciparum  
(Ferone et ah, 1970; Sirawarapom et al., 1990; Sirawaraporn et al,, 1997; Sirawaiaporn 
& Yuthavong 1984; Triglia et al., 1997; Zhang & Meshnick 1991; Zolg et al., 1989) 
Sulfones and sulfonamides (sulfa drugs) were also used as antimalarials during 
World War II, but their use declined with the advent of more effective drugs such as 
chloroquine and pyrimethamine. The ability of sulfa drugs to show potentiating effect 
with proguanil or pyrimethamine (Chulay et ah, 1984; Greenberg et ah, 1948; Rollo 
1955; Sirawaraporn & Yuthavong 1986) suggested that combinations of these two 
groups of dmgs would not only be more effective antimalarial agents but would also 
delay, if not avoid, the development of resistance. The first combination used was the 
sulfone, dapsone, which was combined with pyrimethamine (Maloprim), but clinical 
trials were not encouraging and parasite resistance developed rapidly (Peters 1985). The 
most commonly used combination is that of a sulfonamide, sulfadoxine, and 
pyrimethamine (Fansidar), which has been particularly effective in areas such as Africa 
where chloroquine resistance is now widespread (Landgraf et a l ,  1994; Peters 1985; 
W emsdorfer & Kouznetsov 1980).
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1.8.5.2 Mechanisms of resistance to DHFR inhibitors
Eaiiy studies done with P. berghei showed that it was possible to select 
resistance rapidly to pyrimetham ine, suggesting that a single point mutation was 
involved (Bishop 1963; Diggens 1970; Diggens et al., 1970). Genetic crossing 
experiments in both P. chabaudi and P. yoelii using pyrimetham ine-sensitive and 
pyrimetham ine-resistant strains showed that the resistance phenotype segregated as a 
single gene in both cases (Knowles et al., 1981; Walliker et al., 1976; Walliker et al., 
1975). This gene was confirmed to be dhfr, when it was shown that in P. berghei strains 
increased expression of the DHFR protein (Ferone 1970) and decreased binding affinity 
of the drug to the enzyme had occumed (Diggens 1970). In the case of P. chabaudi, no 
large differences in the enzyme amounts or turnover numbers were observed between 
resistant and sensitive clones. However, a large decrease in affinity for binding of 
pyrimetham ine with the enzyme from the resistant clone, together with changes in 
kinetic and other properties, indicated that the resistance is due to genetic change 
leading to a structurally different enzyme (Sirawarapom & Yuthavong 1984).
The major mechanism of resistance to pyrimetham ine appears to be altered dmg 
binding to DHFR. Studies of the enzyme kinetics of DHFR in the rodent malaria 
parasites, P. berghei, P. vinckei, and P. chabaudi, as well as studies in P. falciparum  
demonstrated that the inhibition constant {Ki) for pyrimetham ine of the DHFR enzyme 
had increased in pyrimetham ine-resistant strains and isolates (Chen et al., 1987; Ferone 
1970; Sirawarapom & Yuthavong 1984; Walter 1986; Zolg et al., 1989). One exception 
of this work was the observation that the DHFR activity from a pyrimethamine-resistant 
P. falciparum  isolate had the same Ki as the DHFR enzyme from a sensitive isolate; 
however it was suggested that the enzyme was increased in the level of expression 30 -  
80-fold (Kan & Siddiqui 1979). Other analysis of equivalent isolates has not shown any
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altered levels of enzyme, and suggested that the DHFR enzyme was structurally altered 
(Cowman et ah, 1988; Peterson et ah, 1988a). However, these studies used crude 
extracts, making it hard to justify the assumptions of the Michaelis-Menten (MM) 
kinetics. The kinetic properties of DHFR enzymes purified from highly resistant, 
moderately -resistant and pyrimethamine-sensitive isolates of P. falciparum  have been 
compared (Zolg et ah, 1989). DHFR enzymes extracted from the moderately resistant 
and highly resistant parasites were found to bind to pyrimethamine with 15 X and 500 X 
lower affinity respectively, when compared to the enzyme of the sensitive isolate.
The cloning of the gene encoding the DHFR enzyme from P. falciparum  (Bzik 
et ah, 1987; Cowman et ah, 1988; Cowman & Lew 1989) and P. chabaudi (Cowman & 
Lew 1989) allowed a detailed analysis of alterations in this enzyme and their role in the 
mechanism of resistance. The DHFR enzyme had earlier been shown to co-purify with 
thymidylate synthase (TS) in Crithidia fasciculata (Ferone & Roland 1980) and the 
association of the DHFR and TS activities was confirmed in P. falciparum  when it was 
shown that a single open reading frame encoded both activities (Bzik et ah, 1987; 
Cowman et ah, 1988; Sirawarapom et ah, 1990), a property that is shared by most 
apicomplexan organisms (Ganett et ah, 1984; Gmmont et ah, 1986).
Analysis of the alterations in the dhfr gene of experimentally-induced 
pyrimethamine-resistant P. chabaudi and P. falciparum  strains has shown that both 
amplification and mutation of the gene can occur (Cowman & Lew 1989; Inselburg et 
ah, 1987; Tanaka et ah, 1990a; Thaithong et ah, 2001; Watanabe & Inselburg 1994; 
Cowman & Lew 1989; Inselburg et ah, 1987; Cowman & Lew 1989). Pyrimethamine 
resistance was selected for in both P. chabaudi (Cowman & Lew 1989; Cowman & 
Lew 1990) and in two independent experiments with P. falciparum  (Inselburg et ah, 
1987; Tanaka et ah, 1990b; Tanaka et ah, 1990a; Thaithong et ah, 2001) by slowly
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increasing the level of drug. In one selected line of pyrimetham ine-resistant P. 
falciparum, parasites exhibited increased expression of DHFR-TS, which correlated 
with a duplication of part of the chromosome containing the gene, which resulted in an 
increase in karyotype from 14 chromosomes to 15 chromosomes (Inselburg et ah, 1987; 
Tanaka et a l,  1990b). The selected lines of Plasmodium chabaudi, resistant to high 
levels of the pyrimetham ine, showed rearrangement and duplication of a portion of 
chromosome 7 (Cowman & Lew 1989). This chromosomal duplication resulted in an 
increase in the chromosome number from 14 to 15; two derived chromosomes (450 
kilobases and 1.1 megabases) were smaller than the original chromosome 7 (1.3 
megabases), so that essentially only a 200-kilobase region was duplicated. This region 
contained the dhfr-ts gene and the closely linked Hsp70 gene. The duplication of the 
DHFR-TS gene presumably conferred the observed drug resistance (Cowman & Lew 
1989). Cowman and Lew extended this analysis by selecting a highly pyrimethamine 
resistant line of P. chabaudi from the line that had duplicated and rearranged 
chromosome 7. This resulted in reversion back to the original parental type 
chromosome 7 but a point mutation was found to have occuiTed in the dhfr gene 
(Cowman & Lew 1990). Increased selection for high levels of pyrimethamine resistance 
resulted in the selection of parasites can’ying a mutated dhfr gene, encoding a protein 
where the amino acid at position 108 was replaced with asparagine (Cowman & Lew 
1989). The second P, falciparum  selected line was found to have amplification of the 
DHFR gene up to a copy number of 44, correlating with a lOOOX increase in minimum 
inhibitory concentration (MIC) of pyrimethamine (Thaithong et al., 2001). The 
resistance was unstable, and following withdrawal of pyrimethamine, MIC levels 
dropped over 16 months almost to that of the unselected parental line, accompanied by a 
decrease in DHFR copy number to 4. No mutations in the dhfr gene were observed.
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The mutation at codon 108 was subsequently also found in naturally occum ng 
pyrimetham ine-resistant P. falciparum  parasites collected from the naturally infected 
individuals. Peterson and colleagues exam ined the molecular basis of pyrimetham ine 
resistance in isolates and clones of Plasmodium falciparum  from geographically distant 
sources (Peterson et ah, 1988a). A genetic cross between pyrimetham ine-resistant clone 
HB3 and and pyrimetham ine-sensitive clone 3D7 showed absolute linkage of resistance 
to the point mutation (Asn-108) in dhfr (Peterson et ah, 1988a).
Peterson and colleagues exam ined the in vitro pyrimetham ine susceptibilities 
and DHFR sequences of eight additional isolates and clones from geographically distant 
locations (Peterson et aL, 1988a). All of the pyrimetham ine sensitive parasites had Thr- 
108 (ACC) or Ser-108 (AGC), whereas all of the resistant parasites exhibited the point 
mutation to Asn-108. An additional mutation to Ile-51 (AAT to ATT) was associated 
with a 4- to 8-fold increase in resistance in some lines, and a third mutation from Cys- 
59 to Arg-59 (TGT to CGT) in one clone was associated with even higher levels of 
resistance (Peterson et aL, 1988a).
Polymorphic sequences of P. falciparum dhfr were first described in the late 
1980s (Cowman et aL, 1988; Peterson et aL, 1988a; Snewin et aL, 1989), and it is now 
well established that high-level Pyrimethamine resistance results from the accumulation 
of mutations in the dhfr gene, principally at codons 108, 59 and 51, where allelic 
polymorphism gives rise to S108N, N51I and C59R (Table 1). Evidence also exists that 
parasites with additional mutations of 164 to Leu (I164L) have increased levels of 
resistance to Pyrimethamine and Cycloguanil (Cowman et aL, 1988; Peterson et aL, 
1988a). Variation at residue 16 (Ala-16 to Yal A16V) confers resistance only to 
cycloguanil and the variation is always found to be associated with S108T variation 
(Foote et aL, 1990b; Peterson et aL, 1990). Analysis of the single A16V and S108T
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variations revealed that the former is highly resistant to cycloguanil without cross 
resistance to pyrimetham ine, while the latter is susceptible to both Pyrimetham ine and 
cycloguanil, indicating that the cycloguanil resistance in the A16+SI08T must be 
attributed almost completely to the A16V mutation (Sirawaraporn et aL, 1997). 
Therefore, it is conceivable that the A16V+SI08T mutant would not have survived 
pyrimetham ine pressure, but instead must have arisen in response to cycloguanil 
selection.
Kinetic studies of the different alleic variants of DHFR have revealed that the 
A16V protein has a severely-impaired enzyme kinetic (Vmax), which could have 
significant effects on the enzyme catalytic efficiency to support DNA synthesis, 
rendering the mutant unable to survive in nature under selective drug pressure 
(Sirawaraporn et aL, 1997). The S108T enzyme shows almost unperturbed Vmax kinetics 
(Sirawaraporn et aL, 1997). The enzyme is as inhibited by both pyrimetham ine and 
cycloguanil as the wild-type enzyme, so it is very likely that the A16V+S108T mutant 
must have derived from the S108T, a variant which is rare (Reeder et aL, 1996), 
reviewed in (Hyde 2002; Hyde 2005).
The two double mutants found in nature (N51FS108N and C59R/S108N) could 
have arisen from point mutation of the S108N as they both provide a small increase in 
resistance toward pyrimethamine, which would have led to their selection (Siriwaraporn 
et aL, 1997). The N51I/S108N mutant enzyme had almost similar catalytic constant, 
kcat, to the wild-type DHFR but was about 2 to 3-fold more resistant to pyrimethamine 
than S108N. C59R/S108N had a significantly reduced kcat compared to wild-type and 
S108N DHFR, but was 5-fold more resistant to pyrimethamine than S108N.
The triple mutant N108S/N51I/C59R had a significantly reduced kcut compared 
to the wild-type DHFR, but its inhibition constant, Ki, by pyrimethamine was
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approximately 80-fold that of the wild-type DHFR (Sirawaraporn et ah, 1997). This 
would offer it a huge selective advantage over the wild-type in a pyrimetham ine 
environment. The same was observed for the quadriple mutant 
S108N/N51FC59R/I164L whose koA was almost six-fold lower than that of wild-type 
DHFR but had a Ki by pyrimethamine about 600-fold higher than that of the wild-type 
DFiFR (Sirawaraporn et a l,  1997).
The mutations appear sequentially in treated populations, with the serine- 
asparagine mutation at codon 108 appearing first, followed by asparagine- isoleucine 
(codon 51) or cysteine-arginine (codon 59), and finally isoleucine-leucine (codon 164) 
(Plowe et aL, 1998). In all parasite isolates studied to date, only the S108N mutation has 
been found to occur singly in nature. The mutations at codon 51 and 59 are always 
found to occur together with S108N (as N51I + S108N, C59R + S108N or triple 
mutant) but never singly. In fact, the enzymes from genes containing these single 
mutations were found to remain highly sensitive to both pyrimethamine and 
cycloguanil, with one (N51I) also showing significantly reduced catalytic properties 
(Sirawaraporn et aL, 1997). This has led to the suggestion that mutations either or both 
at codons 51 and 59 act predominantly by restoring the enzymatic defects that occur as a 
consequence of the original mutation at position 108 (Hastings & Donnelly 2005).
Infections with parasites carrying single (AsnlOS) or double mutations in dhfr 
(encoding Asn 108 plus either lie 51 or Arg 59) show increased parasite clearance times 
following treatment with SP than wild-type parasites (Mendez et aL, 2002; Su & 
Wellems 1996), and parasites with three or four resistance mutations are refractory to 
treatment (Plowe et aL, 1998). Some of the isolates with various combinations of 
mutations at dhfr and their levels of pyrimethamine resistance are shown in Table 1.
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^"^'''-sQodons
Isolates
16 51 59 108 164 Level of 
Pyrimetham ine 
resistance “
3D7, SLD6, 
T9/96
A N C S I 0.025
HB3, PA2 A N C N I 1.5
FAC3, FAC8, 
ItG2F6, FCB
V N C T I 0.006
7G8, ItD12 A I C N I 12
K I, VI A N R N I 20
W2, Dd2, N Tl A I R N I 25
C sI2 A N R N L 40
V l/S , VP35 A I R N L 40
Table 1: Common laboratory isolates with their variant amino acids and IC50 to 
Pyrimethamine in vitro.
The variant conferring resistance is indicated in bold.
“The figures indicated for levels of resistance are approximate values for the 
concentration of pyrimethamine (pM) required to reduce parasitaemias by more 
than 50% relative to untreated controls (Hyde 1989).
Another polymorphism has also been observed in dhfr sequences of samples 
obtained from Bolivia, which is an insertion coding for a five-amino acid repeat after 
codon 30, termed the Bolivia repeat (Plowe et a l ,  1997). However this polymorphism 
has only been observed in Bolivia and its role in pyrimethamine resistance is not yet 
known.
1.8.5.3 Mechanisms of action and resistance to DHPS inhibitors
Comparisons of dhps alleles from lines of P. falciparum  with different IC50 
values to sulfadoxine in vitro pinpointed amino acid differences suggested to be 
important in resistance (Brooks et a l ,  1994; Triglia & Cowman 1994). There was no 
apparent amplification of the gene or increased expression of the PPPK-DHPS enzyme 
in sulfadoxine-resistant isolates.
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Polymorphisms in codons 436, 437, 581 and 613 in the dhps domain of cultured 
parasite lines have been broadly correlated with estimated levels of sulfadoxine 
resistance in vitro (e.g. (Brooks et aL, 1994; Triglia & Cowman 1994). Later studies 
revealed that polymorphism in codon 540 was also commonly observed in field samples 
(e.g. (Plowe et aL, 1997; Triglia et aL, 1997; Wang et aL, 1997a)), with some 
association to SP treatment failure. Trials in East Africa and elsewhere attested to the 
enhanced effectiveness of the SP combination (Nguyen-Dinh et aL, 1982) compared 
with monotherapy with either agent, even where pyrimethamine resistance was already 
prevalent. Sulphadoxine is never used as a single antimalarial as it is quite ineffective 
and therefore all field data is from SP treatment failures. To date, only changes in these 
five codons have been observed in a large number of field samples of diverse 
geographical origins, (e.g. (Plowe et aL, 1997; Reeder et aL, 1996). Codon 436 appears 
to be tetramorphic, with alternative alleles encoding alanine, phenylalanine, cysteine, or 
serine. S436 is usually associated with sensitivity to SP and for the purposes of this 
thesis it is considered as the wild type allele. Three alternative amino acids are encoded 
by different alleles at codon 613: serine, threonine and alanine. Codons 437, 540 and 
581 appear to be dimorphic, with codons 437 and 581 both encoding either alanine or 
glycine, while codon 540 encodes either lysine or glutamine (Table 2).
The most common polymorphism in dhps is the one coding for 437G. Of the 13 
fully characterized resistance-associated alleles described to date, 10 involve this 
polymorphism, although parasites with DHPS 437G in the absence of other changes 
appear to be rare. Alleles defined by 437G/540E and 437G/581G are common in SP 
resistant parasites from East African patients (Nzila et aL, 2000a; Plowe et aL, 1997; 
Wang et aL, 1997a). The allele encoding 437G/581G is also common overall in South- 
East Asian populations (Wang et aL, 1997a), while in areas of South America, parasites
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from patients with SP treatment failure are frequently found to have all three of these 
mutations (encoding 437G/540E/581G) (Kublin et aL, 1998; Plowe et aL, 1997).
While the mutations affecting codons 436, 437 and 540 can occur singly within 
an allele, the data so far suggest that the 581G variation is always found with 437G, and 
that the 613S/T alterations must also be coupled to changes in either residue 436 or 437, 
presumably reflecting steric constraints of the enzyme (Plowe et aL, 1998). However, 
this has not been confirmed by any kinetic data due to the difficulties of working with 
sulfadoxine in vitro.
The role of dhps mutations in sulfadoxine resistance is not certain, partly 
because in vitro assays for sulfadoxine have been done under varying folate conditions 
(Wang et aL, 1997b), and also the use of host folate by some parasite isolates 
antagonises sulfa drugs irrespective of their dhps genotype (Milhous et aL, 1985; 
Watkins et aL, 1985). Analysis of a genetic cross between two parasites differeing in 
IC50 to sulfadoxine showed direct conelation of inheritance of dhps allele and IC50 
(Wang et aL, 1997b). Consistently reproducible results showing large differences 
between the most sensitive and most resistant strains were obtained as a result of using 
an improved drug assay in the absence of folate (Triglia et aL, 1997; Wang et aL, 
1997b).
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^ " '\ ^ o d o n s
Iso la tes/o rigm "\.^
436 437 540
3D7
(Netherlands)
Serine Glycine Lysine
Dd2
(IndoChina)
Phenylalanine Glycine Lysine
T9-96
(Thailand)
Alanine Glycine Lysine
SL/D6
(SieiTa Leone)
Phenylalanine Alanine Lysine
HB3
(Honduras)
Serine Alanine Lysine
IEC513/86 
(Brazil)
n.d. n.d. Glutamine
Table 2; DHPS variants in common laboratory isolates. 
n.d.= not determined
Another mechanism associated with folate uptake and utilisation is thought to 
have an effect on sulfadoxineresistance levels (Wang et ah, 1999). A reduction in the 
susceptibility of parasites to sulfadoxine inhibition as a result of low levels of folate 
(folate effect) was displayed in the Dd2 (mutant) clone, producing marked changes in 
IC50 values. A very small change or no change in the IC50 values was observed for the 
HB3 clone under varying folate concentrations. This difference is thought to be due to 
another gene that strongly influences resistance of a specific clone to sulfadoxine 
depending on the usage of exogenous folate.
1.8.5.4 Correlations of dhfr and dhps mutations with SP treatment response
Wang and colleagues made the first attempt to define a set of dhfr and dhps 
mutations predictive of SP treatment (Wang et ah, 1997a). Using samples for SP drug 
efficacy trials, they found that all infections that cleared totally had wild type dhfr and 
dhps sequences. Those that cleared initially but recurred, or did not clear at all earned a
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variety of dhfr and/or dhps mutations, with no clear set of mutations accounting for 
initial or no clearance (Wang et aL, 1997a).
Several studies have shown that treatment with antifolate drugs results in the 
selection of parasites with dhfr and dhps mutations. The study by Wang (Wang et aL, 
1997a) described 18 previously exam ined Tanzanian samples taken on the day of SP 
treatment and 13 that were again positive during the 28 days following treatment (Wang 
et aL, 1997a). Even with this relatively small sample size, analysis of the data shows 
that dhfr coding for 108N, and dhps coding for 437G and 58IG  were significantly more 
prevalent in the post-treatment infections (Plowe et aL, 1998), and dhfr encoding 511 
and 59R were also more common post-treatment. A second study in Tanzania found 
that SP selected for dhfr encoding 511, 59R and 108N as well as dhps encoding 436S 
(thought to be wild-type), 437G and 540K (Curtis et aL, 1998).
A study in Peru provided the first evidence of a distinct set of dhfr and dhps 
mutations that is strongly associated with in vivo SP resistance (Kublin et aL, 1998). 
The genotype dhfr coding for 511, 108N, 164L and dhps coding for 437G, 540K, 58IG  
was highly conelated with the level of in vivo resistance. This resistant genotype was 
present in seven out of eight cases (87.5%) of RIII resistance, nine out of 13 cases 
(69.2%) of RII resistance, 5 out of 13 cases (38.5%) of RI resistance, and 0/11 cases 
(0.0%) sensitive to SP treatment. The Bolivia repeat was less frequent at higher levels 
of resistance, consistent with in vitro evidence that it does not play a direct role in 
resistance to pyrimethamine (Cortese & Plowe 1998). Dhfr coding for 108N was 
present in all sensitive and resistant cases, demonstrating clearly that this mutation is 
not a suitable marker for SP resistance, despite having been used for this purpose in 
several studies (Curtis et al., 1996; Edoh et aL, 1997; Peterson et aL, 1991; Plowe et aL, 
1996). A drug-sensitive genotype consisting of DHFR Asn-108 and no other dhfr or
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dhps mutations was present in all sensitive infections, 61.5% of RI infections, 23.1% of 
RII infections and in only a single RIII infection (Cortese & Plowe 1998).
It is important to emphasize that the resistance of parasites to drugs in vitro is 
not synonymous with clinical failure of pyrimethamine-sulfadoxine treatment. This is 
especially clear in endemic areas in which semi-immune individuals compose a 
majority of the population at risk. For example, on the coast of Kenya, the triple-mutant 
allele of dhfr is observed in -90%  of the parasites but SP treatment failure rates are 
about 40%. Double-mutant alleles of dhps are also common (Nzila et aL, 2000a). Semi- 
immune patients who carry parasites with resistant genotypes very often do resolve any 
fever or other clinical manifestations. These patients aie classified as having an 
adequate clinical response to the therapy (no visible parasites or clinical manifestations 
at day 7), even though some resistant parasites might escape from the drug action, 
remain at a low level for a time and then cause a new malaria episode (Jelinek et aL, 
1998; Plowe et aL, 1998; White 1998).
The relationship of the parasite genotype to the outcome of pyrimethamine- 
sulfadoxine treatment in an individual patient is influenced by many factors; the 
genotype of the parasite is only one determinant. The complexity of the parasite 
infection and the genotype, the nutritional status and the immune response of the host, 
as well as the rates of drug metabolism, are all critical in deteimining whether a patient 
will clear the infection (Plowe et aL, 1998; White 1998). In the following section, a 
discussion is offered on the determination of ‘tm e’ drug resistance.
1,8,6 Molecular assays for determination of Hrue’ drug resistance
Until recently, our knowledge of the epidemiology of drug-resistant malaria was 
based on the collection of in vivo data from symptomatic patients to whom different 
antimalarial drugs were administered and, to a lesser extent, on in vitro dmg sensitivity
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assays. The limitations of these methods for studying drug-resistant malaria and 
elucidating molecular mechanisms of resistance to some antimalarial drugs have 
stimulated the use of a third approach based on molecular markers (Greenwood, 2002).
The standard in vivo method of testing for drug resistance involves the exam ination of a <|
blood film for parasites 14 or 28 days after an infection is diagnosed and treated, the 
detection of parasites at this time being considered an indication of treatment failure or 
recrudescence of drug resistant parasites (WHO, 1996). In high transm ission areas such 
as tropical Africa, most people are bitten by malaria-infected mosquitoes almost every 
night (Greenwood 2002). Parasites found in the peripheral blood during the follow-up 
period could therefore, represent new and possibly drug-sensitive infections, and not 
recrudescence of resistant parasites. Estimates of the frequency of drug resistance based 
on uncontrolled tests in vivo in highly endemic areas may therefore be exaggerated. In 
order to determine true drug resistance levels, it is important to differentiate between 
true recrudescence (treatment failure) and reinfection.
Moleculai* genotyping is increasingly being used to help distinguish 
recrudescence from reinfection in antimalarial drug efficacy studies. Infecting malaria 
parasites can be “fingerprinted” through polymerase chain reaction (PCR) amplification 
of polymorphic genes. The “fingerprint” patterns of isolates causing successive episodes 
of malaria can then be compared to distinguish recrudescent from newly infecting 
parasites (Babiker et al. 1994; Ohrt et al. 1997; Ranford-Cartwright et al. 1997). The
' - gtechnique involves amplification by the polymerase chain reaction (PCR) of regions of 
highly polymorphic parasite genes. The likelihood of a patient being reinfected with a 
parasite containing exactly the same ‘alleles at each of 2-3 loci is very small. If the 
parasites present on follow-up are genetically identical at all loci to the parasites found |
on presentation then it is assumed that the infection has recrudesced and that persisting ii
f : : ;
,
66
parasites are resistant to the drug. If the parasites are genetically different, it is assumed 
that the original parasites were cleared by the drug treatment, and the parasites present 
during the follow-up period are the result of a re-infection. The loci commonly 
employed in this work include the M spl, Msp2 and glurp (Babiker et aL, 1994; Babiker 
& Walliker 1997; Brockman et aL, 1999; Ranford-Cartwright et aL, 1997).
There is abundant evidence that these loci are under rather strong immune 
selection. A comparison of ratios of synonymous and non-synonymous mutations in 
various genes reveals that strong selective constraints against silent variation in P. 
falciparum, a fact that has been attributed to immune selection (Escalante et aL, 1998; 
Hughes 1991; Hughes & Hughes 1995). Additional evidence that these maikers are 
under strong immune selection comes from experimental immunology studies. For 
M spl, vaccination with the recombinant protein was shown to be protective in monkeys 
(Etlinger et aL, 1991), while antibodies against it protect against clinical disease (Egan 
et al. 1996). Antibodies to MSP2 have been shown to inhibit parasite invasion of red 
blood cells (Epping et aL, 1988), and are associated with protection from clinical 
disease (A1 Yaman et aL, 1994; A1 Yaman et aL, 1995; Taylor et aL, 1998). This 
protection appears to be dependent on MSP2 genotype (A1 Yaman et aL, 1994; 
Ranford-Cartwright et aL, 1996).
Recently, after the discovery of microsatellites, some malariologists have started 
to question epidemiological data generated by the use of antigenic loci under strong 
immune selection. The argument is that selected loci might be giving a distorted view of 
population structure and transmission dynamics, since selection rather than population 
history may determine the patterns of allele distribution within populations for these 
loci (Anderson et aL, 1999; Hastings 1996; Mcdonald 1994).
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In this thesis the antigen-coding loci; M spl, Msp2 and glurp have been 
compared with five putatively neutral m icrosatellite loci in their ability to differentiate 
recrudescences from reinfections in P. falciparum  infections from Kenya.
1.9 Drug resistance and selective sweeps
When a beneficial mutation spreads through a population, flanking neutral 
mutations ‘hitchhike’, resulting in removal of genetic variation from the chromosomal 
regions surrounding the selected site (Barton 2000; Maynard Smith & Haigh 1974). The 
extent to which this happens depends on when in the history of the sample population 
the selected substitutions happen, the strength of positive selection and the amount of 
crossing over between the flanking locus and the locus at which the selected 
substitutions occur (Kaplan et aL, 1989). The spread of the favoured allele also results 
in increased linkage disequilibrium (LD) with flanking markers (Sabeti et aL, 2002; 
Tishkoff et aL, 2001) and skews in the allele frequencies observed at loci neai'by on the 
chromosome (Payseur et aL, 2002). The size of genomic regions affected is influenced 
by the strength of the selection, as well as the rates of recombination and mutation. 
There is currently great interest in using such characteristic patterns of variation to 
identify regions of the genome that are under selection (Harr et aL, 2002; K im & 
Stephan 2002; Kohn et aL, 2000; Schlotterer 2003; Vigouroux et aL, 2002; Vigouroux 
et aL, 2005).
Antimalarial drug resistance provides an excellent system for investigating the 
genomic effects of selection events in a recombining eukaryote, and the scars left in the 
Plasmodium falciparum  genome by drug selection may serve as a useful tool for 
locating drug resistance genes (Anderson et aL, 2000a; Wootton et aL, 2002). 
Fortunately the date of introduction of new antimalaiials is usually known with some 
accuracy, allowing the rate of spread of resistance to be calculated.
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Recombination and mutation rates have been estimated from a genetic cross (Mu 
et aL, 2002; Su et aL, 1999), and haplotypes can easily be constructed using haploid 
blood stage parasites. This aids in the estimation of the rates of spread of resistance 
through calculations of selection intensities driving resistance to the drugs (Wiehe,
1998).
The repeated appearance throughout global malaria endemic regions of drug- 
resistant phenotypes, determined by nonsynonymous substitutions at the Dhfr, Dhps, 
Pfcrt and other loci, is most likely due to natural selection (Roper et aL, 2004; Wootton 
et aL, 2002). Selection sweeps are known in other organisms, such as Drosophila 
melanogaster, where a single nucleotide sequence at the Sod  locus is present in about 
50% of all haplotypes throughout the world, without any silent substitutions along the 
1,500-bp sequence (Hudson et aL, 1997; Hudson 1994).
The worldwide geographical prevalence of the alleles of dhfr and dhps 
associated with SP treatment failure reflects both the duration of antifolate use and the 
level of therapeutic resistance. However, at the time the research for this thesis was 
begun, the modes by which antifolate resistance develops had not been elucidated. For 
example it was not clear whether resistance mutations could repeatedly aiise de novo or 
spread by dissemination after rare or infrequent mutation events (Cortese & Plowe 
1998; Nair et aL, 2003; Nash et aL, 2005; Pearce et aL, 2005; Roper et aL, 2003; Roper 
et aL, 2004). Molecular analysis of the chloroquine-resistance transporter (Pfcrt) gene 
have suggested that all extant CQ resistant parasites originate from only four separate 
mutational events, two of which are believed to have occuixed in South America, one in 
Southeast Asia and one in Papua New Guinea (Wellems & Plowe 2001). These mutant 
alleles are thought to have subsequently spread over large geographical 
distances (Wootton et aL, 2002). Interestingly, it appears that CQ resistance did not arise
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de novo in Africa, where most P. falciparum  mortality occurs, despite wide-scale 
deployment of the drug (Wellems & Plowe 2001). Analysis of the Pfcrt gene and 
flanking markers suggests that CQ resistant parasites in Africa are most similar to those 
in Southeast Asia, suggesting the spread of resistance from countries in this area. The 
usual explanation for resistance occurring so rarely is that CQ resistance is a complex 
trait, requiring several sequential mutations in the Pfcrt gene (Wellems & Plowe 2001) 
and, arguably, requiring mutations in other genes (Hastings 2003), perhaps such as 
pfm drl (Babiker et aL, 2001). By contrast, the genetic basis of resistance to SP is 
known in detail, and simple logic leads to the a priori expectation that SP resistance 
originates from numerous mutational events. Resistance arises extremely rapidly after 
the introduction of pyrimethamine treatment (Clyde & Shute 1957; Doumbo et aL, 
2000; Molineaux & Gramiccia 1980) and the mutations involved can be selected readily 
in the laboratory (Paget-McNicol & Saul 2001). Thus it was generally assumed that dhfr 
mutations underlying resistance evolved multiple times in nature. Since infected people 
contain 10*  ^ to 10^  ^ pai’asites, and key point mutations in dhfr conferring resistance to 
pyrimethamine occur at frequencies as high as 2.5 X 10'^ per parasite replication in the 
laboratory (Paget-McNicol & Saul 2001), we might expect such mutations to arise 
independently in every treated malaria patient. In this case, we would expect resistant 
dhfr alleles to be associated with different alleles at flanking microsatellite loci and to 
see little evidence for diminished variation around dhfr (Doumbo et aL, 2000). 
However, three recent publications have disproved this conjecture (Cortese et aL, 2002; 
Nair et aL, 2003; Roper et aL, 2003). Molecular analyses of the dhfr gene and flanking 
regions have shown that high level resistance to SP in South America appears to have 
spread from a single mutational event in dhfr (Cortese et aL, 2002) a pattern now known
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to have also occurred in Southeast Asia (Nair et aL, 2003) and southern Africa (Roper et 
aL, 2003).
In a study conducted using samples from Thailand/Myanmar border, Nair and 
colleagues found minimal variation in m icrosatellite markers over a 12 kb region (0.7 
cM) immediately suirounding dhfr, and variation was reduced in a region 
approximately 100 kb (6 cM) around this locus (Nair et aL, 2003). In comparison 
expected heterozygosity (Hf) at markers situated more than 58 kb from the 5’ end and 
more than 40 kb from the 3’ end of dhfr was high {He = 0.81), and these were not 
significantly different from He at 56 unlinked dinucleotide microsatellites {He= 0.80) 
sampled from chromosomes 1, 2, 3 and 12 and genotyped from the same parasite 
collection (Nair et aL, 2003).
In a study of P. falciparum  populations from 5 locations in S. America (Brazil, 
Colombia, Haiti, Peru and Venezuela), Cortese and colleagues showed that the 
mutations dhfr C50R, dhfr I164L, dhps K540E, and dhps A581G, (denoted RLEG) 
confeiTing mid- and high-level SP resistance have a common origin (Cortese et aL, 
2002). First, sequences in coding and noncoding regions within or flanking these genes 
show identical or neaily identical polymorphic patterns among South American 
parasites harboring these alleles. Second, alleles of 2 genes involved in chloroquine 
resistance that are not linked to dhfr and dhps tracked with the RLEG alleles. Either of 2 
Pfcrt alleles first identified in Brazilian parasite lines from the 1980s and subsequently 
detected in all or most Brazilian and Bolivian isolates from the 1990s were found in all 
of the P. falciparum  isolates cairying these alleles but only in a minority without the 
mutations. Pfmdrl D 1246Y also was predominant among RLEG malaiia parasites. The 
association of the RLEGs with the mutant pfm drl allele, as well as with 2 resistant Pfcrt 
alleles carrying a unique C72S consequent to mutually exclusive nucleotide
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substitutions, suggests that the RLEGs may have spread by the selective pressures of 
both the antifolates and the 4-am inoquinolines in S. America (Cortese et aL, 2002).
In another study done in South Africa, Roper and colleagues (Roper et aL, 2003) 
showed that only a single haplotype of microsatellite loci flanking a region of 8 kb 
upstream of dhfr gene, in 43 samples, was associated with the triple dhfr mutant coding 
for 51I/59R/108N. The double mutants encoding 51I/108N and 59R/108N were found 
to be associated with one and two haplotypes respectively. This is in contrast with 8 and 
31 haplotypes associated with the single mutant coding for 108N and sensitive alleles 
respectively in the same region (Roper et al. 2003). Likewise, analysis of an 8 kb region 
flanking the dhps gene (downstream) showed that isolates with double mutations coding 
for 437G/540E were associated with just a single flanking haplotype. By contrast, the 
single mutant (coding for 436A) isolates were associated with 3 unrelated flanking 
haplotypes (Roper et aL, 2003).
The alleles with several resistance-confeiring mutations in both of these genes 
showed a high degree of conservation in the flanking sequences. In fact, a comparison 
of the flanking sequences with isolates from northern Tanzania revealed that these 
isolates had the same flanking haplotype as those found in South African isolates, 4000 
km apart. This suggests that rather than arising many times, a few mutant alleles have 
been subject to positive drug selection and have introgressed through large geographic 
regions, a fact that can only be attributed to the use of sulphadoxine/pyrimethamine in 
these areas (Roper et aL, 2003). Although single mutants seem to have arisen 
independently on multiple occasions, the fitness benefits they confer are perhaps too 
weak to overcome the associated fitness costs, and thus do not seem to be strongly 
selected for. On the rare occasions where a multiple mutant arises, it has high relative 
fitness and can spread rapidly through large geographic regions (Roper et aL, 2004).
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In parasite populations such as those in South America (Anderson et aL, 2000a; 
Cortese et aL, 2002), Southeast Asia (Anderson et aL, 2000a; Nair et aL, 2003) and 
even some parts of Africa where transmission is low (Roper et aL, 2003), self- 
fertilization events predominate, and levels of recombination are consequently much 
lower. Most of the studies that have looked at the evolution of drug resistance have 
used isolates from these areas and thus an understanding of the evolution and spread of 
drug resistance in high transmission areas, where recombination is high, is still lacking.
1.10 Rationale I for this thesis
The molecular genotyping analyses have largely used the antigen-coding loci 
encoding merozoite surface proteins 1 and 2 (M SPl and MSP2 respectively) and the 
glutamate-rich protein (GLURP). The fact that these genetic markers encode antigens 
that are under immune selection has led some malaria researchers to question the data 
generated by their use (Hughes and Hughes 1995; Anthony et aL 2000). Microsatellites, 
which have recently been discovered to be abundant in the genome of P. falciparum, are 
usually in non-coding regions of DNA, and are therefore assumed to be selectively 
neutral (Goldstein & Schlotterer 1999).
In this study we set out to compare the effectiveness of the antigenic loci markers m spl, 
msp2 and glurp with five microsatellite markers, in differentiating recrudescence from 
re-infection in field isolates from Kenya.
1.11 Rationale [[
Malaria is for the most part endemic in developing countries with limited 
budgets, and there is a need to extend the useful life of cheaper antimalarial drugs. An 
understanding of the evolution and spread of resistance will enable the effective 
monitoring of resistance patterns and inform policy changes and better interventions.
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The studies on the evolution and spread of antimalarial drug resistance published to date 
have been conducted in areas with low malaria transmission. A more extensive study 
involving both low and high transm ission areas needs to be conducted to exam ine the 
effects of antimalarial drugs in ai'eas with varying transm ission indices, especially in 
high transm ission areas, where recombination is high. Therefore, we set out to compare 
the rates of evolution and spread of SP resistance in malaiia endemic areas of Kenya.
SP was officially introduced as the first-line antimalarial treatment in Kenya in 1997 
though it was being widely used before then by most people, especially those visiting 
private health facilities, due to the ineffectiveness of chloroquine. By the time it will be 
replaced as the official first-line antimalarial by Artemisinin/lumefantrine (Coartem® 
[Norvatis]) in 2006, treatment failure rates (from in vivo data) with SP in most endemic 
areas might be well over 60% (EANMAT data at http://www.eanmat.org).
1.12 Research objectives
1.12.1 General objective
To investigate the evolution and spread of antimalarial drug resistance in Kenya and the 
effect of drug resistance mutations on the general population of P. falciparum  in Kenya.
1.12.2 Specific objectives
i) To study the evolution of SP-resistant parasites and their spread in Kenya 
as a consequence of SP use.
ii) To compare the effectiveness of unlinked microsatellite markers with 
antigenic markers of M spl, Msp2 and glurp to differentiate between 
recrudescence and reinfection in malaria field isolates.
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iii) To compare the genotypes of malaria parasites, and their population 
structure, collected from three different locations (with varying 
geographical settings and transm ission intensities) in Kenya.
iv) To study the relationship between the spread of drug-resistance and the 
different transm ission intensities.
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2.0 CHAPTER TWO...Materials and m ethods
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2.1 Comparing uniinked microsateiiites with antigenic loci
2.1.1 Study sites
The samples used in this study were collected from regions designated as 
sentinel sites for monitoring drug resistance established by the Kenyan M inistry of 
Health and the East African Network for Monitoring Antimalarial Treatment 
(EANMAT). The three areas represent varying geographical features and degrees of 
malaria endemicity. The studies were part of in vivo efficacy tests for antimalaiials and 
were performed according to standard guidelines (World Health Organization 1996). 
Ethical clearance for the studies was obtained from the Kenya Medical Research 
Institute and the University of Glasgow Ethical Review Committee.
The study in Mwea (n= 68 samples) was carried out between October and November 
2001. Mwea area (IS  37W) lies at an altitude of 1200m in central Kenya (Figure 5), in a 
region that is mostly reliant on agriculture by irrigation. Malaria in this area is classified 
as ‘irrigation, seasonal endemic’ (http://www.eanmat.orgk meaning that the vector 
environment is maintained by the im gation agriculture. Malaria transmission is seasonal 
and the infections prevalence is between 30-40%, (meso-endemic). The maximum 
temperature can be as high as 33°C. In this region, P. falciparum  is highly resistant to 
SP, with early treatment failure rate (ETF) of more than 35%, (EANMAT, 2003) that 
indirectly or directly impacts on the increased number of malaria illnesses and malaria- 
related deaths in this region.
Anopheles arabiensis (73%), An. pharoensis (7%) and An. funestus (3%) have 
been identified as the principal vectors of malaria in this area (Rapuoda 1995). Studies 
conducted between 1989 & 1990 showed the parasite rates among children aged 1-9 
years to be between 0.7% and 5.4% (Ijumba et al., 1990). Malaria in this area appears to 
affect both adults and children (52% of admissions were below 15 years between 1996
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and 1997) (Division of Malaria Control 1998). At the time of this study the SP 
treatment failure rate was 24%.
The studies in Tiwi (n= 60 samples) and Bondo (n= 60 samples) were carried out 
between October and December 2000. Tiwi area is located in the coastal region of 
Kenya, 4S and 39W (Figure 5), where malaria is holoendemic. It lies at an altitude of 
just 2m above sea level. Tiwi has an annual entomologie inoculation rate (EIR) of four 
infective bites per year (range 0-18) (Mbogo et aL, 1995). An annual EIR of 120 has 
been recorded for a site with the highest transmission intensity in this region (Mbogo et 
aL, 2003). This area is characterized by continuous malaria transmission with 
pronounced seasonal variation and relatively high incidence of severe disease occurring 
in time-space clusters, and patients frequently carry polyclonal isolates (Kyes et aL, 
1997). At the time of this study SP in vivo failure rate was about 30% in Tiwi. Bondo is 
located in the western zone of Kenya (Figure 5) in an area where malaiia is 
hyperendemic with very high transmission rates. It lies at ON and 34W at an altitude of 
about 1230m. At the time of this study the SP in vivo failure rate in Bondo was about 
40%. Parasite prevalence rates in these two areas are >90% especially in children less 
than five years (Division of Malaria Control 1998).
2.1.2 Patient recruitment and management
All studies were carried out using the same inclusion criteria. Patients who 
presented at the respective hospitals with symptoms suggestive of malaria had a blood 
smear undertaken and were later considered for recruitment if they fulfilled the 
following inclusion criteria: 6-59 (6-120 for Mwea) months of age; positive blood 
smears with P. falciparum  monoinfection and parasite density of between 2000- 
100,000 asexual parasites per microliter of blood; uncomplicated malaria with absence 
of symptoms of severe malaria or danger signs e.g. convulsions, excessive vomiting,
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drowsiness or inability to feed; axillary temperature of 37.5 “C and above or history of
fever in the last 48 h; absence of history of allergy to sulfa drugs; hemoglobin level of 
5g/dl or more; residence within an accessible address and agreement to return to the 
clinic for follow-up and provision of informed consent.
Clinical history was taken from the recruited patients including anti-malarial 
therapy in the last 72 h. A physical examination was earned out and the axillary 
(armpit) temperature was measured using a clinical thermometer. Fever was defined as
axillary temperature of 37.5 ° C and above.
Patients who fulfilled the inclusion criteria and agreed to participate in the study 
were treated with the standard paediatric dose of Sulfadoxine 25mg/kg and 
Pyrimethamine 1.25mg/kg (SP) as a fixed-dose combination. Patients were asked to 
return for follow-up on days 1, 3, 7 and 14 for the Bondo and Tiwi studies and on days 
1, 2, 3, 7, 14, 21 and 28 for the Mwea study. The Mwea study was extended to 28 days 
followup because of lower transmission intensity in this region (World Health 
Organization 1996).
79
;
On each day of follow-up, thin and thick blood smears were prepared and is
examined, hemoglobin concentration in the blood was measured on days 0 and 14 and 
also day 28 for Mwea using a haemoglobinometer. On each appointed day of the 
follow-up period, and on any other day if the patient returned to the clinic with fever
exam ination. Patients who failed to return on the designated days were found and
was evaluated.
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during this period, the patient’s history was taken and they were given a physical
requested to return to the health unit by the assigned social worker/health visitor. A 
thick blood smear from a fingerprick sample was prepared and exam ined to assess 
parasitaemia. Thick smears were stained with 10% Giemsa’s stain for 10 minutes, and
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Figure 5: Map of Kenya showing the areas endemic for malaria (shaded brown) 
and the study sites
The parasite count obtained was then multiplied by a factor of 40 in order to 
obtain number of circulating parasites per microliter of blood, assuming a WBC count 
of 8000/pL of blood (World Health Organization 1991a). In the case of a positive 
smear, alternative drug treatment was provided according to the treating physician, and 
severe cases were referred to hospitals.
Approximately 2-3 drops of the fingerprick blood collected on day 0 and on the 
follow-up days was spotted on Whatman 3M filter paper, allowed to dry, and then
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packaged individually in sealed plastic bags for molecular analysis as part of this PhD. 
Project. These samples were marked with the patient identification number and the date 
of sample, and were stored with desiccant at 4°C.
All outcomes were registered on a case record form labeled with the patient’s 
study identification number.
2,1.3 DNA extraction
2.1.3.1 DNA from cultured material
DNA was extracted from in vitro cultures of laboratory lines originating from 
various geographic origins and this was used to optimize and select the microsatellite 
markers for the study. The parasite lines chosen were K1 (Thailand), R 033 (Ghana), 
7 0 8  (Brazil), HB3 (Honduras), 3D7 (The Netherlands), SL-D6 (Sierra Leone), ÎTG2F6 
(Brazil), Dd2 (Indo-China), ZIM V160 (Zimbabwe), V IS (Vietnam), FCBl 
(Colombia), lEC 513/86 (Brazil), F32 (Tanzania), K28 (Thailand), and SUD106/11, 
SUD 124/8, SUD 126/1, and SUD 128/5 (all from Sudan). The isolates had been grown in 
vitro according to the standaid methods (Trager & Jensen 1976). Culture material was 
centrifuged at 1500 x g, the supernatant removed and the red blood cell pellet used for 
DNA extraction. Each culture was at around 6% parasitaemia at the time of extraction. 3 
pL of the red cell material was used for DNA extraction. The Instagene® (Bio-Rad, UK) 
extraction kit was used to extract DNA from the pellet following the manufacturer’s 
instructions. The DNA was not quantified using a spectrophotometer since it is 
normally too impure to get an accurate reading.
2.1.3.2 DNA extraction from filter papers
DNA from the filter papers was extracted using the Chelex-100 method (Plowe 
et a l ,  1995). An approximate 4 mm^ of the blood-soaked filter paper was excised using
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a sterile scalpel blade. This was used for extraction of DNA according to the protocol 
(Plowe et ah, 1995). The extracted DNA (approx. volume 200ul) was divided into 20 pi 
aliquots to avoid repeated freeze-thaw cycles and degradation. These aliquots were 
stored at -80°C and the aliquot in immediate use was stored at -20®C.
2.1.4 Microsatellite markers
Over 900 microsatellite loci have been mapped in the genome of P. falciparum  
with at least one every 2-3 kb (Su et al., 1999). The sizes of PCR products for all of 
these loci are known for the 3D7 clone. However, there is little information on the 
population size diversity for most microsatellite mai'kers except for twelve that have 
been used for the population studies that have been carried out to date (Anderson et al., 
1999). Of these 12 markers used previously, some have been shown to be located in 
introns of genes (Anderson et al., 1999), or very close to coding regions, and were 
therefore not considered suitable for this work.
2.1.4.1 Selection of microsatellite markers
Initially, ten microsatellite loci were selected on the basis of (i) not being in 
coding sequence or very close to an open reading frame (ORE), (ii) having a PCR 
product of at least 200 bp with clone 3D7 (www.ncbi.nlm.nih.gov/Malaria/ index.html), 
and (iii) consisting of trinucleotide repeats. Microsatellites located in chromosomes 4 
and 7 were also avoided since these chromosomes are known to code for drug targets 
which might interfere with normal Mendelian inheritance of alleles through selective 
sweeps or ‘hitchhiking’. The chosen markers and their chromosomal locations are 
given in Table 3. Five of these mai'kers, C2M3, C3M85, TA48, TA17 and C14M108, 
have not been used in previous studies.
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2.1.4.2 Optimisation of amplification conditions for microsatellite loci
The initial optimisation using DNA extracted from in vitro cultures was done 
using a single round of PCR using the primers designed by Su and colleagues (Su et a l, 
1999). This is because, with the high parasitaemia present in in vitro cultures, one round 
of PCR is sufficient to generate enough PCR product to visualise on agarose gels. The 
ten microsatellites were amplified from DNA extracted from 18 laboratory-cultured 
isolates, with a wide range of geographical locations, 50% coming from East and 
Southern Africa, as described in section 2.1.3. One round of amplification (30 cycles) 
was perfoiTned for each DNA sample, using 1 pi of DNA extracted previously.
Approximately 5 p i of the PCR product were mixed with 1-2 pi of 6X loading 
dye (Promega: 0.4% orange G, 0.03% bromophenol blue, 0.03% xylene cyanol FF, 15% 
Ficoll® 400, lOmM Tris-HCl (pH 7.5) and 50mM EDTA (pH 8.0)) and analysed by 
agarose gel electrophoresis on a 3% Metaphor® agarose gel (supplier) in IX  Tris- 
borate-EDTA (TBE) buffer (prepared as one litre lOX stock with 108gm Tris base, 
55gm boric acid and 40 ml 0.5 M EDTA). Metaphor® is a high-resolution agarose that 
enables better resolution than standard agarose, allowing discrimination of PCR 
products with small size differences (4-10 bp). Although polyacrylamide gels or 
automatic sequencing machines give excellent resolution of very small differences in 
PCR product size, this benefit is outweighed by their high cost, toxicity of reagents and 
relatively low throughput. High-resolution agarose gels provide almost the same level 
of resolution for a lower cost without the need to purchase expensive equipment and 
reagents and may therefore be more suitable for use in laboratories in malaria-endemic 
countries. Stutter bands are also not seen with Metaphor agarose, whereas these can 
cause problems of interpretation on polyacrylamide gels.
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After electrophoresis, the gel was stained with Ipg/m l solution of ethidium 
bromide for 45 minutes. The DNA was visualised by ultraviolet transillumination and 
band sizes determined by comparison with a standaid 100-base pair DNA ladder 
(Promega) run at each side of the gel. The sizes were calculated using a gel 
documentation package, Labworks 3.0 Image Acquisition and Analysis Software (UVP 
Inc., Upland California, USA).
DNA from any parasite line that failed to amplify at any locus after repeating the 
amplification reaction a second time was scored as a null allele at the specific locus.
Five of the markers were chosen for the field analysis on the basis of having the widest 
range of product sizes, highest degree of polymoiphism, and lowest number of null 
alleles when tested with the 18 laboratory isolates. The loci chosen, with their repeat 
units and size of the respective 3D7 PCR product, are shown in Table 4. A 
microsatellite locus with dinucleotide repeats, C2M3 (chr2), was included for 
comparison with the trinucleotide repeat loci.
2.1.4.2.1 Basic PCR conditions
The cycling parameters for all loci were optimised to work with the same 
concentrations of PCR reagents. These were final concentrations of IX  buffer, 200 uM 
dNTPs, 100 nM of each primer and 1 unit of Taq polymerase. A PCR machine (M l 
Research) fitted with a gradient block was used to define the optimum annealing 
temperatures. The full primer sequences and PCR conditions for each of the selected 
loci are listed in (Table 4 and Table 5).
2.1.4.2.2 Design of primers and optimisation for nested PCR
Field isolates generally have lower parasite densities (normally 0.1- 3%) 
compared to those found in cultures (about 6%) and thus require two rounds of PCR to 
get adequate DNA for visualisation. Therefore a nested PCR reaction was used with the
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extra primers being designed outside the first pair using the 3D7 sequence available at 
WWW.PIasmoDB.org. The primers were designed such that the primary PCR product 
was bigger than the secondary product by at least 150 bp. This was to aid in better 
resolution in case of carry-over PCR material from the primary PCR during template 
addition.
These PCR conditions for the reactions were optimised using a few of the culture 
isolates and are shown in Table 5.
Microsatellite loci Chromosome 3D7 PCR product
C2M3 2 340
C3M85 3 270
POLYu 4 224
TA42 5 183
TA l 6 198
TA17 8 199
TA40 10 210
TA48 12 253
TA60 13 202
C14M108 14 241
Table 3: List of microsatellite loci, chromosomal location and size of the 3D7 PCR 
product
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Marker Repeat Outer Primers (shown 5’ to 3’) Nested Primers (shown 5’ to 3’)
C2M3 TA F-CACTTATGTTATGACAAGAAC
R-GTGAAAAGGATATGCTTCC
F-AAAGTGGGATTCATCCAG
R-TCGGGGTATTATTAACATG
C3M85 TTA F-CTTAACCGTTCAGGAGAT
R-GAGTTGATAACTTGTTGGT
F-AAGGGATTGCTGCAAGGT
R-CATCAATAAAATCACTACTA
TA48 TAA F-AATCTATCGGCGTTGGTAGA
R-TGGGTTGTGTTACATGAACG
F-TTTTGATATCTCTCAATCAT
R-CTTCACGACAGAGGTGTC
TA17 TTA F-GTATCTCTTAGATGTTAG
R-CTTATGGATGTTAATGAC
F-CTGTACCTTTAGGTATCATA
R-GAAAATAAAACATTAAAACTATG
TA40 TAA F-TGGAAAATACAGCAACGGAG
R-AGCCAAATCAAAAAGGAATC
F-GGTTAATATGATCACAAAATG
R-ATTGTTGATTCATGAAATGCA
Table 4: Microsatellite markers used in the study, their repeat unit, and the 
sequences of the outer and nested primers
Marker
C2M3
C3M85
TA48
TA17
TA40
Cycling Parameters
94°C for 2 min, then 30 cycles of 94°C for 40 sec, 45"C for 40 sec and 
60“C for 1 min.
94°C for 2 min, then 30 cycles each of 94“C for 40C sec, 50°C for 1 
min and 60°C for 1 min
94°C for 2 min, then 30 cycles each of 94°C for 40 sec, 49“C for 40 sec 
and 60° C for 1 min.
94°C for 2 min then 30 cycles of 94°C for 40 sec, 50°C for 40 sec and 
60°C for 1 min.
94°C for 2 min, then 30 cycles each of 94°C for 40 sec, 47°C for 40 sec 
and 60°C for 1 min.
Table 5: Microsatellite markers chosen, and the optimised cycling conditions for 
each locus.
The same conditions were used for both primary and secondary (nested) reactions
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2.1.5 Distinguishing recrudescence from new reinfections
To distinguish genuine recrudescence of resistant parasites from new 
reinfections arising during the follow-up period, day 0 (DO, pre-treatment) and the 
positive follow-up (post treatment) isolates (R) were genotyped at three highly 
polymorphic gene loci, merozoite surface protein-1 (M spl), rnerozoite surface protein-2 
(Msp2) and the glutamate-rich protein (glurp), as described (Ranford-Cartwright et a l  
1997).
The isolates were also genotyped with the five polymorphic microsatellite loci, 
C2M3, C3M85, TA40, TA17 and TA48, as selected in section 2.1.4 above, to compare 
with the results obtained with the gene loci.
2.1.5.1 Genotyping at the Mspl, Msp2 and glurp loci
DNA extracted from patient samples at the time of admission to the study (day
0) and at the time of reappearance of parasites and/or symptoms (R) was amplified at 
the M spl, Msp2 and glurp loci using previously published conditions (Ranford- 
Cartwright et a l  1997). Two microlitres of parasite DNA was used as template in the 
primary reaction, and 3 ju-l of the primary PCR product was used as template in the 
nested reaction. Amplifications were performed using a PTC-100™ thermocycler (MJ 
Research, Inc., Waltham, MA, USA). Primer sequences and reaction conditions are 
given in Table 6.
Locus Primers Outer PCR 
parameters
Nested PCR 
parameters
M spl
01 -C AC ATG A A AGTTATC A AGA ACTTGTC 
02-GTACGTCTAATTCATTTGCACG
N1 -GCAGTATTGACAGGTT ATGG 
N2-GATTGAAAGGTATTTGAC
94°C for 3 min, 
30 cycles each of 
94°C for 25S, 
50oC for 35S 
and 68°C for 2.5 
min, then ÔS^ ’C 
for 8 min
-As for 
primary 
reaction
Msp2 52-GAGGGATGTTGCTGCTCCACAG53-GAAGGTAATTAAAACATTGTC
S1 -GAGTAT AAGGAG A AG TATG
54-CTAGAACCATGCATATGT CC
30 cycles each of 
94°C for 25S, 
42‘’C for 60S; 
65®C for 2 min, 
then a final 
extension at 
65°C 8min
30 cycles each 
of94"Cfor 
25S, 50°C for 
60S, 70”C 60S 
then final 
extension at 
70°C 8 min
Glurp G4-ACATGCAAGTGTTGATCCG5-GATGGTTTGGGAGTAACG
G3-TGTAGGTACCACGGGTTCTTGTGG
GLTGAATTCGAAGATGTTCACACTGAAC
94 °C, 3 min, 30 
cycles each of 94 
"C, 25S, 45°C, 
60S, 68°C, 2min; 
then final 
extension at 
72"C, 3 min
30 cycles each 
of94°C, 60S 
55°C, 2 min 
70 "C,
2min,then final 
extension 72 
”C, 3 min
Table 6: Primers and PCR cycling conditions for the antigen-coding loci
Ten microlitres of the nested PCR product were mixed with 1-2 ul of 6X loading 
dye (0.4% orange G, 0.03% bromophenol blue, 0.03% xylene cyanol FF, 15% Ficoll® 
400, lOmM Tris-HCl (pH 7.5) and 50mM EDTA (pH 8.0), Promega) and analysed by 
agarose gel electrophoresis on a 1.5% agarose gel stained with 0.5 pg/ml ethidium 
bromide in IX  Tris-borate-EDTA (TBE) buffer. Each A or day 0 (DO) isolate was run 
alongside its post treatment (R) isolate for ease of comparison. DNA was visualised by 
ultraviolet transillumination and band sizes determined by comparison with a standard 
100-base pair DNA ladder (Promega) run at each side of the gel. The sizes were 
calculated using a gel documentation package, Labworks 3.0 Image Acquisition and 
Analysis Software (UVP Inc., Upland California, USA).
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If there was no amplification for any sample, the PCR was repeated with up to 2.5 times 
the quantity of template DNA in the primary reaction. If no amplification was detected 
after this second reaction, genotyping was classified as unsuccessful.
2.1.5.2 Genotyping at microsatellite loci
Each pair of patient samples (A or DO and R) was subjected to PCR 
amplification with each of the five microsatellite loci described in section 2.1.4. As for 
the antigenic loci M spl, Msp2 and glurp, two microlitres of parasite DNA was used as 
template in the primary reaction, and 3 pi of the primary PCR product was used as 
template in the nested reaction. After amplification the PCR products were subjected to 
electrophoresis on 3% Metaphor® agarose gels (EMC Bioproducts) in 1 x TBE buffer. 
Metaphor® enables better resolution than standard agarose, allowing discrimination of 
products with small size differences (5-lObp.). The DNA was stained with 0.5 pg/ml 
ethidium bromide and visualised using UV illumination. PCR product sizes were calculated 
using Labworks 3.0 Image Acquisition and Analysis Software (UVP Inc., Upland 
California, USA) by comparison with molecular weight markers (lOObp ladder, Promega) 
run on each gel.
2.1.6 Analysis of results
2.1.6.1 Definition of recrudescence or reinfection
It was assumed that after a patient was initially treated for malaria, a subsequent 
episode was caused by either the same parasite genotype(s) present before treatment 
(recrudescence) or by parasites acquired after treatment (reinfection) or by a mixture of 
the two (recrudescence plus reinfection). An outcome was defined as recrudescence if a 
follow-up sample contained identical alleles or a subset of the alleles present in the 
admission sample. An outcome was defined as reinfection if a follow-up sample 
contained only new alleles. If a follow-up sample contained alleles present in the first
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sample in addition to new alleles, the outcome was considered as both recrudescence 
and reinfection.
2.1.6.2 Comparison of the two classes of marker
The comparison of the two sets of the results of the two sets of markers was 
done using the Cohen’s Kappa ( k )  test of agreement in the SAS/STAT software 
program version 8.2 (SAS Institute Inc. Cary, North Carolina, USA 1999- 2001).
Possible values of K are constrained to the interval 0 to 1; where K=0 means no 
agreement above that expected by chance, and k=1 means perfect agreement. A value of 
k=0.5 and above was considered indicative of significant agreement (Cohen J. 1960). I
The likelihood of the null hypothesis that K=0, i.e. no agreement above that expected by 
chance, was also calculated. Mathematically, kappa is defined as the improvement upon 
chance agreement, divided by the maximum possible improvement upon chance 
agreement: K = P(A) -  P(E)/1 - P(E) where P(A) is observed agreement and P(E) is 
agreement expected by chance. The method used to find P(E) is the same as that used in 
the chi-squared test (Fleiss et al., 1979).
2.1.6.3 Multiple clone infections
Plasmodium falciparum  isolates were characterised according to the size of the
fragment at each locus. DNA fragments were categorised into different size classes 
(bins) for the statistical analyses. DNA fragments were allocated into bins of 10 bp for 
the antigen gene loci, and 6 bp for the microsatellite loci, as described by Brockman 
(Brockman et al., 1999) and by Paul (Paul et al., 1998). The reason different bin sizes 
were used for the two sets of markers is because of the use of gels with different 
resolving powers. The multiplicity of infection (MOI) was estimated by taking the 
highest number of alleles (bands) per individual. For example, if an isolate had one 
allele at each of the loci, the MOI was taken to be one, and if the isolate had two alleles
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at two loci but three at a third, then the MOI was three. Mean MOI was calculating by 
dividing the total MOI by the number of individuals analysed.
Since malaria infections in humans are caused by the haploid stage of the 
parasite, the presence of two or more differently sized PCR products in the same sample 
using single copy markers indicates a multiple clone infection. Multiple alleles were 
scored if two or more alleles of the same locus could be distinctly observed on the gel.
2.1.7 Genetic diversity
An analysis of the genetic structure of the studied populations was conducted 
using only the alleles of the microsatellite loci. While a lot of software programs are 
freely available for population genetics data, there are very few that can be used for the 
analysis of population genetics of P. falciparum  and even these require a lot of 
reorganization of data and, most times, the exclusion of some. This is mostly due to the 
genetics of the parasite especially its haploid nature (one allele per locus per parasite), 
while most software was designed for diploid organisms, and also its multiple clone 
infections (difficult to tell which allele goes with which in multilocus genotyping). This 
analysis used some of the software that can analyse haploid data although some of the 
data had to be excluded or reorganised to fit the programs’ requirements.
2.1.7.1 Allele numbers and Heterozygosity
The mean number of alleles (MNA) detected in each population and the 
expected heterozygosity {He) are good indicators of the genetic polymorphism within 
the populations under study. The MNA is the average number of alleles, at all loci 
studied, observed in a population (Nei 1987a).
Generally the MNA is highly dependent on the sample size because of the 
presence of unique alleles that occur in low frequencies, which are less likely to be 
detected in small samples. In addition, the number of observed alleles tends to increase
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as sample size increases, in populations with a large effective population {Né) size (Nei 
1987b). Therefore the comparison of the MNA between populations may not be 
meaningful unless sample sizes are more or less the same (Haiti & Clark 1989; Nei 
1987b).
Since the malaria parasites studied in this case were haploid, expected 
heterozygosity {Be) for each locus is defined as the probability of drawing 2 alleles of 
different length from a population sample and is calculated as follows (Anderson et a l ,
1999):
H,=[n/(n-l)][l-S",=i
where P  is the frequency of the  ^ ' th allele and n is the number of alleles in the 
sample.The MNA and expected heterozygosity were calculated using the program 
Microsatellite Toolkit (http://oscar.gen.tcd.ie/~sdepark/ms-toolkit/index.html) .
2.1.7,2 Linkage disequilibrium
In the study described here, allele frequencies were calculated using only the 
predominant allele present at each locus within each infection (Anderson et al., 1999). 
The predominant allele at each locus was defined as the brightest band on the gel under 
UV illumination. While this procedure results in unbiased estimation of allele 
frequencies within a population if we assume the composition of PCR products is 
representative of the composition of templates, it is not the most ideal since the most 
common parasite in an infection might not be reflected in the gametocyte numbers and 
therefore in the next generation.
The predominant allele detected at each locus was used to construct “ infection 
haplotypes” . Where blood samples contain a single parasite clone, this results in 
recovery of true parasite haplotypes. Where two or more clones are present, the 
infection haplotypes may be a composite of alleles from two or more clones. This may
93
impose additional recombination on the data and bias the data against detection of LD 
although the reverse may be true where detection of LD is missed due to exclusion of 
m inor alleles.
Genotypic linkage disequilibrium was tested by the exact probability test 
performed using GENEPOP software (Raymond & Rousset 1995). The null hypothesis 
is that genotypes at one locus are independent of genotypes at the other locus. This test 
computed unbiased estimates by randomization (2,000,000 iterations) and by the 
Markov-chain method for the exact probabilities of random association for all 
contingency tables corresponding to all possible loci pairs within the combined 
populations.
The program LIAN, version 3 (Haubold & Hudson 2000), was used to compute 
the number of alleles shared between all pairwise comparisons of complete 5-locus 
haplotypes and to calculate the variance, Vd, of these pairwise differences. The sample 
vaiiance was then compared with the variance expected under linkage equilibrium, Ve. 
To investigate if the observed data differed from random expectations, the observed Vp 
was compared with the distribution of Vp values in 10,000 simulated data sets in which 
alleles at each locus were randomly reshuffled among genotypes. The index of 
association (7^) was used to measure the strength of LD. The “ classical”  Ia was defined 
as I  A = (VpfVe - I), where Ve is the mean variance of the reshuffled data sets (Brown et 
al., 1980). However, since this statistic scales with r  - 1, where r is the number of loci 
analyzed (Hudson 1994), a “ standardized” IA  statistic (Ias), calculated as Ias =(Vd/Ee-
l)/(r  - 1) was used. A measure of haplotype-wide linkage and 95% confidence limits, 
Lmc, was determined by Monte Carlo simulations.
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2.1.7.3 Genetic differentiation of the populations
The understanding of genetic structuring or differentiation within and between 
populations is of interest to population geneticists because it reflects the number of 
alleles exchanged between populations, which influences the genetic composition of 
individuals within these populations (Balloux & Lugon-Moulin 2002; Souza e t a l., 
1992). Gene flow between populations determines the effects of selection and genetic 
drift, generates new polymorphisms and increases the local effective population size 
(Balloux & Lugon-Moulin 2002; Souza e t a l., 1992). Fst and G st are very commonly 
used to describe population differentiation (Nei 1973).
2.1.7.3.1 The fixation index, Fst
Fst is a fixation index that was developed by Wright (Wright 1921) to account 
for inbreeding within samples. Wright (Wright 1951; Wright 1965) defined Fsr as the 
relatedness between two alleles chosen at random within sub-populations relative to 
alleles sampled at random from the total population. Fsr therefore measures inbreeding 
due to the relatedness among alleles because they are found in the same sub-population. 
Fst can be defined as:
F st -  (H t -  H s)/ Hg
Where Ht is the expected total heterozygosity and Hs is the observed within- 
population heterozygosity,
Fst estimates were calculated using the programs FSTAT 2.9.3 (Goudet 2000) 
and GENEPOP (Raymond & Rousset 1995).
2.1.7.3.2 The coefficient of gene differentiation, G st
The coefficient of gene differentiation {G st) developed by Nei, (Nei 1973) is an 
extension of his genetic theory to apply to a pair of populations applied to the structured 
populations (Nei & Feldman 1972). G st can be computed directly from allele
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frequencies in terms of expected heterozygosities within and between populations. 
Unlike F st, the estimation of G st relies only on allele frequencies (Nei 1987a). This 
method offers several advantages because the number of alleles at the locus does not 
affect the value and neither do evolutionary forces such as mutation, selection and 
migration.
G s t  can be defined as:
G st = D s t /H t
Where D st is the average gene diversity between and within sub-populations and H t is 
the mean heterozygosity among the populations studied. G st estimates in this study 
were calculated using the program FSTAT (Ota 1993).
2.1.7.4 Population subdivision
The isolation by distance model of population structure was used to test for 
population subdivision. This model assumes that mobile ‘propagules’ with continuous 
geographical distribution in an undifferentiated environment distribute themselves at 
various distances from their origin (Rousset 1997). There are no discrete boundaries 
between different parts of the range and allele frequencies change gradually w ithout any 
discontinuities (Nadler 1995). The extent of population subdivision as calculated by 
isolation by distance was performed using the ISOLDE program incorporated in the 
GENEPOP software (Raymond & Rousset 1995). The subdivision analysis was done 
per population/site.
2.2 Analysis of loci linked to drug resistance
The samples taken at admission were subjected to PCR amplification of two 
genes linked to resistance of SP, which is the drug the patients were treated with. This 
section describes the analysis of the genes dhfr and dhps and the loci flanking 
approximately 8 kb on either side of each gene. The genes were analysed using dot blot
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hybridization with oligonucleotide probes specific to different mutations previously 
linked to drug resistance (Abdel-Muhsin et al., 2002).
2.2.1 Analysis at the dhfr locus
A  700 bp fragment of dhfr was amplified from each admission sample using a fully 
nested PCR, as previously described (Plowe et a l, 1995). DNA from parasites 3D7, 
Dd2 and T994 were included as controls for each of the alleles at positions 51, 59 and 
108 of dhfr (Table 9). The outer PCR was performed with primers A M Pl and AMP2 
with the reagents and cycling parameters shown in Table 7. 2-5 ul of DNA was added as 
template to each outer PCR.
The nested PCR was prepared using the SP l and SP2 primers as shown in Table 7, 
in a final reaction volume of 30ul. 2 pi of the outer PCR product was used as the 
template. The reaction parameters of the nested PCR are outlined in Table 7.
5 pi of the PCR product was mixed w ithl pi gel loading buffer (Promega) and 
subjected to electrophoresis through a 1.5% agarose gel in IX  TBE buffer with 
0.5pg/ml ethidium bromide. A 100 bp molecular weight marker was included in the gel 
to help with product sizing. PCR products were visualised by UV transillumination.
The remaining 25pi of PCR product was stored at -20°C prior to preparation of the dot 
blot.
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PRIMERS REAGENTS
CONC.
PCR
PARAMETERS
Outer
AMPl- TTTATATTTTCTCCTTT
TTA
AMP2-
CATTTTATTATTCGTTTTCT
lOOnM of 
primers, 200 
pM  dNTPs,
1 unit Taq, 
1.5mM 
MgCla"  ^and 
IX  PCR 
buffer
95°C for 3 min 
[92°C for 30 sec, 
45“C for 45 sec and 
72°C for45 sec] 45 
then 72°C for 3 min
Nested
SPl- ATGATGGAACAAGTCTG 
CGAC
SP2 -ACATTTTATTATTCGTTTTC
-As above-
95°C for 3 min 
[92°C for 30 sec, 
45*’C for 30 sec, 
72°C for 30 sec] 30 
then 12°C for 3 min
Table 7: PCR reagents and cycling parameters for dhfr.
The primers are shown in the 5’ to 3’ orientation. * The MgCL was included in the 
PCR buffer.
2.2.2 Analysis at the dhps locus
An 1152 bp fragment of dhps was amplified for each isolate using a fully nested 
PCR as previously described (Abdel-Muhsin et al., 2002). In addition to the field 
samples, control samples to be used in each blot were included. The parasite lines 3D7, 
Dd2, T996, SLD6, HB3 and IEC513/86 were used as controls as they have various 
combinations of mutations at the dhps locus Table 9. The outer PCR was performed 
using primers 186 and M3717 with the other PCR reagents as shown in Table5. 2 pi of 
the sample DNA were added to the premix before amplification using the cycling 
parameters shown in Table 8.
The nested PCR premix was prepared using primers 185 and 218 and the PCR reaction 
performed with the cycling parameters shown in Table 8, in a final volume of 30ul. 2-5 
ul of the outer PCR product were used as template.
Analysis of the PCR products was performed as described earlier (section 2.2.1).
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Reaction PRIMERS REAGENTS
CONC.
PCR
PARAMETERS
Primai'y
186
GTTTAATCACATGTTTGCACTTTC
M3717
CCATTCCTCATGTGTATACACAC
lOOnM each 
primer, IX  
PCR buffer, 
1.5mM 
MgCE*,
200pM dNTPs, 
1 unit of Taq
95°C for 3 min 
[92'"C for 30 sec, 
50°C for 45 sec 
and 72°C for 60 
sec] X30 then 
72”C for 3 min.
Secondary
185
TGATACCCGAATATAAGCATAATG
218
ATAATAGCTGTAGGAAGCAAT TG
-As above-
95°C, 3 min
[92°C for 30 sec, 
48°C for 30 sec 
72®C for 30 sec] 
X30 then 72°C 
for 3 min
Table 8; PCR reagents and cycling parameters for dhfr.
The primers are shown in the 5’ to 3’ orientation. * The MgCE was included in the 
PCR buffer.
Parasite Dhfr51 Dhfr59 DhfrlOS Dhps436/37
combination
Dhps540
3D7 Asn Cys Ser Ser/Gly Lys
Dd2 He Arg Asn Phe/Gly Lys
T9-94 Asn Cys Thr
T9-96 Ala/Gly Lys
SL/D6 Phe/Ala Lys
HB3 Ser/Ala Lys
IEC5I3/86 n.d. Glu
Table 9: The parasite isolates used as controls, with the amino acids present at 
specific codons in dhfr and dhps.
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2,2,3 Dot Blot Hybridization
2.2.3.1 Preparation of samples for dot blot
For each sample that gave a positive result by nested PCR, 20 pi of PCR product 
was denatured with EDTA and NaOH to final concentrations of lOmM EDTA and 
0.4M NaOH. To ensure complete dénaturation, the mixture was boiled at 100°C for 10 
minutes in a boiling waterbath. The tubes were then spun briefly in a microfuge.
The mixture was neutralised using an equal volume of 2M ammonium acetate, pH 7 and 
blotted onto Genescreen nylon membrane (New England Nuclear, Houndslow, United 
Kingdom) using a dot-blotting apparatus (Bio-Rad, Hemel Hempstead, United 
Kingdom) according to the manufacturer’s instructions. Each PCR product was loaded 
into two different wells of the dotblotter, with half of the remaining PCR product (30ul) 
being placed into each well, and the duplicates being placed in different parts of the 
blot. After DNA transfer, the membrane was rinsed in 2X SSC (0.15M sodium chloride, 
15mM Trisodium citrate) for 1 minute, denatured in 0.4M NaOH for 1 m inute and 
finally neutralized in a mixture of IM  Tris-HCl and 1.5 M NaCl, pH 8, for 30 seconds. 
To fix the PCR products on to the membrane, the blot was then exposed to ultraviolet 
light in a UV crosslinker (Stratalinker, Stratagene, Amsterdam, The Netherlands) 
according to the manufacturer’s instructions.
2.2.3.2 Oligonucleotide probe labelling and hybridisation
In order to detect the dhfr and dhps alleles associated with changes at amino acid 
positions 51, 59 and 108 by the dot-blot hybridisation technique, specific probes were 
designed and labelled with [y-^^P]-ATP (Amersham Pharmacia Biotech Inc, Little 
Chalfont, United Kingdom) (Abdel-Muhsin et at., 2002). The sequences of the probes 
and the specific hybridisation conditions aie given in Table 10 and Table 11.
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Ten picomoles (pmol) of each probe were labelled using a single Ready-To-Go 
polynucleotide kinase reaction mix (Amersham Pharmacia Biotech Inc, Little Chalfont, 
United Kingdom) containing 10 units of T4 polynucleotide kinase, 50 mM Tris-HCl, 
(pH 7.6), lOmM MgClz, 5mM DTT, O.lmM spermidine, O.lmM EDTA (pH 8.0),
0.2|u.M ATP and stabilizers in a total volume of 50 pi, to which 0.37 MBq of [y-^^P]- 
ATP was added. Each probe was incubated with the labelling m ixture at 37°C for 30 
minutes and the unincorporated [y-^^PJ-ATP was removed using M icrospin G-25 
columns (Amersham Pharmacia Biotech Inc, Little Chalfont, United Kingdom) 
according to the manufacturer’s instructions. The labelled probes were stored at -20°C 
until required.
The membrane was prehybridised with hybridisation buffer [5 X SSPE (0.15M 
NaCl, lOmM sodium phosphate, ImM  EDTA), 5 X Denhardt’s reagent, 0.5% sodium 
dodecyl sulphate (SDS), 0.02 mg/ml of sonicated salmon sperm DNA] using 0.25-0.125 
ml of hybridisation solution per cm^ of membrane. The membrane and the buffer were 
incubated in a hybridisation oven with rôtisserie (Grant Boekel HIR 12, Cambridge, 
England) for at least 30 minutes at a temperature specific for the respective probe Table 
10 and Table 11. The labelled and purified oligonucleotide probe was added to the 
hybridisation buffer (I pi probe for every 1 ml of the hybridisation buffer) and the blot 
hybridised overnight at a temperature specific for the probe used. The blot was washed 
once with 2 X SSC for 20 minutes and twice for 10 minutes in 1 X SSC/ 0.1% SDS or
0.5 X SSC/ 0.1% SDS, at the temperature specific for the respective probe (Table 10 
and Table II).
The blot was wrapped in cling film and taped into an autoradiography cassette 
complete with intensifying screens. Location markers (Glogos II markers, Stratagene, 
Amsterdam, The Netherlands) were used to allow accurate positioning of the
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autoradiograph and blot. Each blot was exposed to Kodak MXB X-ray film overnight at 
-80°C after which the X-ray film was developed using an automatic developer (X- 
OGRAPH Imaging System Compact X4). The probe was stripped from the blot with 
two washes in O.IM NaOH for 15 m inutes each at room temperature. The blot was then 
rinsed briefly in 5 X SSC, air-dried and then re- hybridised with other probes or kept at 
room temperature until required. Each blot was hybridised with each of the probes in 
Table 10 or Table 11 according to whether the PCR product was from the dhfr or dhps 
locus.
Probe Sequence (5’ to 3’) Hybridisation
temperature
Stringent washes
DHFR 108
Ser-specific
(wild-type)
AACAAGCTGCGAAAGCATTCCAA 50”C [(1XSSC/0.1%S 
DS) iOmin] X2
Asn-specific
(mutant)
AACAAACTGGGAAAACATTCCAA 54.5“C [(1XSSC/0.1%S 
DS) lOmin] X2
DHFR-51
Asn-specific
(wild-type)
ATGGAAATGTAATTCCCTAGAT 50“C [(0.5XSSC/0.1% 
SDS) lOmin] X2
lie-specific
(mutant)
ATGGAAATGTATTTCCCTAGAT 50"C [(0.5XSSC/0.1% 
SDS) 10 min] X2
DHFR-59
Cys-specific
(wild-type)
GAAATATTTTTGTGCAGTTAC 52“C [(0.5XSSC/0.1% 
SDS) 10 min] X2
Arg-specific
(mutant)
GAAATATTTTCGTGCAGTTAC 50“C [0.5XSSC/0.1%S 
DS] 10 min X2
Table 10: Dhfr variant codons with their specific oligonucleotide probes and 
hybridisation and washing conditions
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Probe Sequence (5’ to 3’) Hybridisation
temperature
Stringent washes
DHPS 436/437
Ser/Gly-specific
(mutant)
GAATCTTCTGGTCCTTTT 42.5”C [(1XSSC/0.1%SDS) 
lOmin] X2
Ala/Gly-specific
(mutant)
GAATCCGCTGGTCCTTTT 52”C [(1XSSC/0.1%SDS) 
lOmin] X2
Ser/Ala-specific
(wild-type)
GAATCCTCTGCTCCTTTT 50”C [(1XSSC/0.1%SDS) 
lOmin] X2
DHPS-540
Glu-specific
(mutant)
CAATGGATGAACTAACAA 35“C [(lXSSC/0.i%SDS) 
lOmin] X2
Lys-specific (wild- 
type)
CAATGGATAAACTAACAA 35“C [(1XSSC/0.1%SDS) 
lOmin] X2
Table 11: Dhps variant codons with their specific oligonucleotide probes and 
hybridisation and washing conditions.
The blots were scored based on the specificity of the controls. Experimental 
samples and controls were dot-blotted in duplicate to reinforce correct scoring. Blots 
that had autoradiograph results with controls showing non-specific hybridisation were 
given an extra stringent wash to ensure specificity. If this was not successful in 
removing the non-specific hybridisation, then the hybridisation and washing steps were 
re-optimised.
2.2.4 Selective sweep due to SP use
2.2.4.1 Analysis of microsatellite loci around Dhfr
The DNA samples were typed at variable microsatellite loci flanking both sides 
of the dhfr gene. The microsatellite sequences analysed are located at 0.3 kb, 4.7 kb, 7.0 
kb and 8.0 kb and 0.5 kb, 4,0 kb, 6.5 kb and 8.0 kb, downstream and upstream of the
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dhfr gene, respectively (Table 12 and Table 13). A semi-nested PCR protocol was used 
to amplify each locus using primers designed from the sequence obtained from parasite 
clone 3D7 on the PlasmoDb database (Bahl et aL, 2002) except DHFR.3F and 
DHFR.3R which were described by Su and Wellems ( 1996), and DHFR.3R* which 
was described by Roper and colleagues (Roper et aL, 2003).
The optimised primary reaction contained 2 pi template, IX  PCR buffer, 200 
pM  dNTPs, 3.0 nM MgCE, 100 nM of each primer and 0.5 units Taq polymerase. The 
secondary reaction was performed in a total volume of 20 pi made up of 3 pi of primary 
PCR product, IX  PCR buffer, 200 pM  dNTPs, 3.0 mM MgClz, 100 nM of each primer 
and 1 unit Taq polymerase. The cycling conditions are as shown in Table 14.
The PCR products were analysed using Spreadex SEL 500® gels (Elchrom 
scientific, Switzerland) by electrophoresis in IX  Tris-Acetate EDTA (TAE) buffer 
supplied with the gels by the manufacturer. The precast Spreadex® gels ai*e made of new 
types of matrices with unique properties that make it possible to get better results by 
submarine electrophoresis than by vertical or flat-bed electrophoresis using m ini gels. 
These gels are recommended for applications that require the highest resolution in a 
narrow DNA size range (Kapitanovic et aL, 2001). The gels were stained in freshly 
prepared 0.4 pg/ml ethidium bromide solution in distilled water for 35 minutes. The 
staining was carried out in a shaker away from direct light according to the
Upstream region of Dhfr Downstream Region of Dhfr
DhfrD4 
8.0 kb
DhfrD3 
7.0 kb
DhfrD2 
4.7 kb
DhfrDl 
0.3 kb
Dhfr
Gene
DhfrUl 
0.5 kb
DhfrU2 
4.0 kb
DhfrU3 
6.5 kb
DhfrU4 
8.0 kb
Table 12: A diagram showing the location of microsatellite markers selected and 
their location from the ends of the dhfr gene.
104
Locus DHFR primers (shown 5’ to 3’)
DOWNSTREAM
DHFRUl F-ATTCCAACATTTTCAAGA
R-GGCATAAATATCGAAAAC
R*-TCCATCATAAAAAGGAGA
DHFRU2 R-TATACAGGACGACGTTCT 
F- CAATCTCATGTAGACAAA 
F*-TGGTTTCTGCGATGAAACG
DHFRU3 F*-GCCTTCTTATTTTAAAGGG
R-CTTCAAATATATGATGACAT
F-GAAATATGTTTACAAGGAGG
DHFRU4 R-TTCCATGCTACAGATAAAACG
F-GTTCCTGTTATTTGTTTG
F*-GACATGTCTTCACTTTTAG
UPSTREAM
DHFRDl F-ATTTTACAATTTCGGATTTTAC
R-CATTGAGATAAATAAGTGTTCA
F*-TAAAGAAGGCATAATTTTCA
DHFRD2 F-GTATTATATACATGGATCAC
R-CTATACATTTCTTTTTCA
R*-CACCTTATTTTATTTGAAGGC
DHFRD3 F-GTGATGATATACCAAGCAG
R-ATACTTATATCATCAACCT
R*-CCGTGTTATTATCTATTC
DHFRD4 F-CATACGATATATGAAGCT
R-TCATCCATACAATTCATAT
F*-AATAAGAATAAATCAGGAGG
Table 13: Microsatellite loci flanking dhfr and their primers.
The study used a seminested PCR strategy. The F and R primers were used in the 
primary PCR while the* Primer with its corresponding primer (also used in the 
primary PCR) were used in the secondary reaction.
manufacturer’s instructions. They were then destained in distilled water for 30 minutes 
before visualisation by UV transillumination. The bands were analysed for size 
variation using Labworks 3.0 Image Acquisition and Analysis Software (UVP Inc., 
Upland California, USA) by comparison with M3 DNA ladder (Elchrom scientific). 
This marker contains over 50 DNA fragments in the size range from 50 to 622 bp 
specially designed for precise estimation of the size of unknown DNA fragments on 
Spreadex® gels. These are fragments produced from the digestion of pBR322 by 
Haelll, Mspl and Hhal enzymes.
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Markers Primary reaction parameters Nested reaction parameters
DHFRUl 94°C for 2 mins, 35X [94"C for 
30S, 47°C and 65°C for 1 min], 
then 65°C for 2 mins.
94”C for 2 mins, 30X [94^C for 
30S, 47“C and 65"C for 1 min], 
then 65°C for 2 mins.
DHFRU2 94°C for 2 mins, 30X [94°C for 
30S, 48°C and 65°C for 1 min], 
then 65°C for 2 mins.
94°C for 2 mins, 30X [94°C for 
30S, 50°C and 65"C for 1 min], 
then 65“C for 2 mins.
DHFRU3 94“C for 2 mins, 35X [94°C for 
30S, 48®C and 65°C for 1 min], 
then 65°C for 2 mins.
94°C for 2 mins, 30X [94"C for 
30S, 49°C and 65"C for 1 min], 
then 65”C for 2 mins.
DHFRU4 94°C for 2 mins, 30X [94“C for 
30S, 47“C and 65°C for 1 min], 
then 65”C for 2 mins.
94"C for 2 mins, 30X [94‘’C for 
30S, 50"C and 65"C for 1 min], 
then 65°C for 2 mins.
DHFRDl 94°C for 2 mins, 35X [94°C for 
30S, 48°C and 65°C for 1 min], 
then 65°C for 2 mins.
9 4 T  for 2 mins, 30X [94“C for 
30S, 50”C and 65°C for 1 min], 
then 65"C for 2 mins.
DHFRD2 94°C for 2 mins, 35X [94“C for 
30S, 45°C and 65“C for 1 min], 
then 65°C for 2 mins.
94^ ’C for 2 mins, 30X [94°C for 
30S, 50‘^ C and 6 5 T  for 1 min], 
then 65®C for 2 mins.
DHFRD3 94°C for 2 mins, 30X [9 4 T  for 
30S, 46“C and 65°C for 1 min], 
then 65”C for 2 mins.
9 4 T  for 2 mins, 30X [94°C for 
30S, 48*^ C and 65“C for 1 min], 
then 65“C for 2 mins.
DHFRD4 94"C for 2 mins, 35X [9 4 T  for 
30S, 47"C and 65°C for 1 min], 
then 65°C for 2 mins.
94°C for 2 mins, 30X [94‘^ C for 
30S, 48"C and 65°C for 1 min], 
then 65”C for 2 mins.
Table 14: PCR parameters for the microsatellite loci flanking dhfr
2.2.4.2 Analysis of microsatellite loci around dhps
The analysed microsatellites sequences for dhps are located at 0.4 kb, 3.7 kb, 7.3 kb 
and 8.5 kb, and 0.1 kb, 3.8 kb, 6.5 kb and 8.7, upstream and downstream of the dhps 
gene, respectively (Table 15 and Table 16). The PCR mixtures were all set up as above 
described for dhfr loci and the cycling parameters are listed in Table 17.
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Upstream region of Dhps Downstream Region of Dhps
DhfrD4 
8.5 kb
DhfrDS 
7.3 kb
DhfrD2 
3.7 kb
DhfrDl 
0.4 kb
Dhps
Gene
D hfrUl 
0.1 kb
DhfrU2 
3.8 kb
DhfrU3 
6.5 kb
DhfrU4 
8.5 kb
Table 15: A diagram showing the location of microsatellite markers selected and 
their location from the ends of the dhfr  gene.
Locus PRIMERS
DOWNSTREAM
DHPSUl F-CTTGACATATAATGAGCATG
R-ATTGTGGACAAATCACAC
R*-GGAAAGTGCAAACATGTG
DHPSU2 F-TCTATAGTATACATGGAT
R a t t t c a a a t t g t t c g t c c
F*-CAATGTCCATTGTGCATCA
DHPSU3 F-ATGTACATATTGATAACC
R-ATTGTTAATCTTCCTTAG
F*~CAATAACCTGAAAAGTGA
DHPSU4 F-GAATAAATTAATTACACACGG
R-GTAATACACATAAAACAACAG
R*-TGTACATTTAAAGATAGATG
UPSTREAM
DHPSDl F-AGTTCTTGTATAGTTTCC
R-TCTATAATCGATACCAAG
F*-CACTTTTATAGTTTAAGTTG
DHPSD2 F- CAACTTATATCTGAATGG
R-CATACAGCAAGTGCAAGAGC
F*-GATTGTAATTACTAAATGG
DHPSD3 F-CACTTAATGTAAATGGAG 
R- ATATTAAGCTTGTACATG 
F*-CACATATATATGTACGTAGT
DHPSD4 F-CATACAAAACAAAATGCG
R-AATATACAAATAGCTAAG
R*-CATATGTTTTTAAGATATAAGC
Table 16: Microsatellite loci flanking dhps and their primer sequences.
The study used a seminested PCR strategy. The F and R primers were used in the 
primary PCR while the* Primer with its corresponding primer (also used in the 
primary PCR) were used in the secondary reaction.
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Marker Primary reaction parameters Nested reaction 
parameters
D HPSU l 94°C for 2 mins, 35X [94"C for 30S, 
48°C and 65°C for 1 min], then 65°C 
for 2 mins.
94"C for 2 mins, 30X [94”C 
for 30S, 5UC and 65°C for 
1 min], then 65°C for 2 
mins.
DHPSU2 94‘’C for 2 mins, 35X [94°C for 30S, 
46T  and 6 5 T  for 1 min], then 6 5 T  
for 2 mins.
94°C for 2 mins, 30X [94"C 
for 30S, 5 r C  and 65”C for 
1 min], then 65°C for 2 
mins.
DHPSU3 94«C for 2 mins, 35X [9 4 T  for 30S, 
40®C and 65°C for 1 min], then 65°C 
for 2 mins.
94°C for 2 mins, 30X [9 4 T  
for 30S, 45 ’^C and 65°C for 
1 min], then 65”C for 2 
mins.
DHPSU4 94 ’^C for 2 mins, 35X [94"C for 30S, 
SO'^C and 65®C for 1 min], then 65®C 
for 2 mins.
94'^C for 2 mins, 30X [94“C 
for 30S, 48°C and 65°C for 
1 min], then 65“C for 2 
mins.
D HPSDl 94”C for 2 mins, 35X [94”C for 30S, 
48^0 and 65"’C for 1 min], then 65°C 
for 2 mins.
94‘’C for 2 mins, 30X [94'‘C 
for 30S, 47°C and 65°C for 
1 min], then 65°C for 2 
mins.
DHPSD2 9 4 T  for 2 mins, 35X [9 4 T  for 30S, 
4 T C  and 65T for 1 min], then 65”C 
for 2 mins.
94°C for 2 mins, 30X [94^C 
for 30S, 48"C and 65T for 
1 min], then 65®C for 2 
mins.
DHPSD3 94°C for 2 mins, 35X [94*^ C for 30S, 
46”C and 65"C for 1 min], then 65°C 
for 2 mins.
94°C for 2 mins, 30X [94^'C 
for 30S, 47T  and 65°C for 
1 min], then 65“C for 2 
mins.
DHPSD4 9 4 T  for 2 mins, 35X [94“C for 30S, 
43°C and 65®C for 1 min], then 65®C 
for 2 mins.
94°C for 2 mins, 30X [94°C 
for 30S, 4 8 T  and 65°C for 
1 min], then 65°C for 2 
mins.
Table 17: PCR cycling parameters for the dhps flanking markers
2.2.5 Drug resistance selective sweep analysis
2.2.5.1 Drug resistant mutants per site
The frequencies of the drug resistant alleles at dhfr and dhps were compared 
among the three sites using F isher’s Exact statistical test. This was to determine whether 
there were any statistically significant differences in the distribution of drug resistant
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alleles among the three sites. The R X C package (downloadable free software 
rhttp://www.marksgeneticsoft ware.netl) for the analysis of contingency tables (Miller 
1997) was used for Fisher’s Exact statistical test since some of the expected values were 
less than 5.
2.2.5.2 Expected Heterozygosity
Expected heterozygosity {He) at each m icrosatellite locus was measured as 
described above (section 2.1.7.1). He was used in preference to variance in repeat 
number because P. falciparum  microsatellites frequently contain indels in the flanking 
regions or have complex repeat structure (Anderson et ah, 2000b). Hence, inference 
from number of repeats from PCR product length results in frequent errors. These errors 
are due to indels, which might not be the same size as the repeat unit or, where the 
repeat structure is made up of mixed repeat units e.g. di- and trinucleotides. This means 
that use of repeat number is difficult to ascertain in these cases.
2.2.5.3 Testing for population bottlenecks
It has been noted that allelic diversity is reduced faster than heterozygosity 
during a bottleneck. If a population has gone through a bottleneck, it is found to retain 
the excess heterozygosity (Nei et al. 1975).
To test whether the population had undergone a recent bottleneck, the presence 
of excess of heterozygosity was tested for using the software 'bottleneck’ (Cornuet & 
Luikart 1996). This softwaie carries out a W ilcoxon signed rank test comparing 
observed heterozygosity at each locus across the -16  kb region of both triple mutant 
dhfr and double mutant dhps loci. Expected values are generated under infinite allele 
(JAM) and step-wise allele models (SMM).
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2.2.S.4 Linkage disequilibrium for measuring selective sweeps
Linkage disequilibrium (LD) at a distance x from the core region was measured 
by calculating the extended haplotype homozygosity (EHH) (Sabeti et aL, 2002). EHH 
is defined as the probability that two randomly chosen chromosomes carrying the core 
haplotype of interest are identical by descent (as assayed by homozygosity at all loci) 
for the entire interval from the core region to the point x. Homozygosity was used as a 
multilocus measure of linkage disequilibrium (Sabatti & Risch 2002). Haplotype 
homozygosity (HH) measures the variation at linked sites and this is exactly what is 
affected by selection on one locus within a chromosome, an observation termed 
‘hitchhiking’. HH was evaluated for all haplotypes for wild type, single, double and 
triple mutants for dhfr and wild type, single and double mutants for dhps. This was done 
across the whole gene sequence inclusive of the flanking loci (referred to as EHH). HH 
is evaluated as:
HH = -  1/n) /  ( l  -  l /n )
with Pi being the relative haplotype frequency and n the sample size. In this way, the 
calculation corrects for sampling effects (Sabatti & Risch 2002). The variance of each 
HH [Var(HH)] was estimated according to Nei (1975).
Var(HH) = 2(« -  1) { 2(« -  2)[Ep>- { l l p l f ]  + 'Lp? -  (Z p ,")"  }
EHH thus detects the transm ission of an extended haplotype without recombination. 
This test for positive selection involves finding a core haplotype with a combination of 
high frequency and high EHH, as compared with other core haplotypes at the locus. We 
used a web-tool to calculate EHH (Mueller & Andreoli 2004) available at 
http://ihg.gsf.de/cgi-bin/mueller/webehh.pl
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2.2.S.5 Strength of selective sweep in Kenyan parasite populations
Selection coefficients (s), which measure the stability of the selected allele in a 
population, were estimated from SP efficacy studies done by the East African Network 
for Monitoring Antimalarial Treatment (EANMAT). EANMAT has been canying out 
antimalarial efficacy testing studies in the three East African countries of Kenya, 
Uganda and Tanzania since 1999 (EANMAT 2001) and the data has been compiled and 
made available on their website (www.eanmat.org). This data is grouped according to 
the recent WHO classification guidelines on treatment response (World Health 
Organization 2003b). For this analysis it was assumed that all patients who did not 
achieve an adequate clinical and parasitological response (ACPR) (negative blood 
smear with no clinical signs on day 14 or 28) was a treatment failure. This is probably 
an overestimation of treatment failures and so the calculated selection coefficients might 
be overestimates. The frequencies of resistant (p) and sensitive (q) alleles were inferred 
by assuming that the frequency of treatment failures is proportional to p  and that ^ = 1- 
p. We plotted Ixiip/q) against time in generations using an estimate of six generations 
per year (Joy et a l, 2003). The gradient of the slope, which is the rate at which drug 
sensitive alleles are replaced by drug-resistant ones, is the selection coefficient, s (Hartl 
& Dykhuizen 1981; Nair et a l,  2003).
I l l
3.0 Results
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3.1 Introduction
The results section has been divided into three parts. The first part deals with 
compaiison of the results of the antigen-coding loci with those of the microsatellite loci 
in differentiating recrudescence versus reinfection. This work has already been 
published ((Mwangi et aL, 2006); Publication annexed). The second pait deals with the 
genetic diversity of P. falciparum  in Kenya, and the relationships within and between 
the Kenyan parasite populations. The third part deals with SP resistance in Kenya and 
the selective sweep driven by both pyrimetham ine and sulphadoxine treatment in the 
Kenyan malaria parasite populations.
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3.2 Recrudescence versus Reinfection
Most clinical studies of malaria drug resistance, which apply the WHO guidelines 
of assessing clinical or parasitological outcome (WHO, 2001), do not distinguish 
recrudescence of resistant parasites from re-infection by new par asite strains. The use of 
molecular genotyping to distinguish recrudescence from new infections has become 
increasingly common in antimalarial drug efficacy studies, but questions still remain 
regarding the most suitable markers to be used.
In this study, we evaluated molecular genotyping results using two types of markers 
using samples collected as part of a large national drug efficacy study. One set of 
markers was the antigenic loci {M spl, Msp2 and glurp), and the other markers were 
microsatellite loci.
The key questions addressed here are:
i. Since the antigenic gene loci are under selection, are they effective in 
differentiating recrudescence from  reinfections? This was determined by 
comparing their results with those of five putatively neutral m icrosatellite 
loci.
a. How do the two sets o f  markers compare in their ability to pick out 
multiclonal infections? This was determined by looking at the multiplicity of 
infection (MOI) values generated using the two sets of markers.
The study used 42, 44 and 47 samples of P, falciparum  from Tiwi, Hondo and 
Mwea respectively. The samples were taken from patients both before treatment began 
(denoted admission, DO or A sample), and after treatment failure (denoted R sample). 
For each locus, the PCR products from the two samples, collected before and after 
treatment, were loaded next to each other on electrophoresis gels. The presence of the
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same sized PCR products in the admission sample and its follow-up R sample was 
scored as recrudescence. If all of the PCR products in the A sample were of a different 
size to those in the R sample, this was scored as reinfection. In most cases there was a 
m ixture of the two, meaning that the individual didn’t clear the initial infection even 
after treatment, and in addition acquired infections with novel parasites (Figure 6). A 
comparison of the results obtained using both sets of markers is provided in Table 18.
3.2.1 Msplf Msp2 and glurp
Using the antigen-coding loci 40, 40 and 45 samples from Bondo, Tiwi and 
Mwea respectively were successfully typed and classified into the three groups, namely 
recrudescence, recrudescence and reinfection, or pure reinfection (Table 18).
Most of the samples were typed as containing both recrudescent and reinfecting 
genotypes (42%, 46% and 70% in Tiwi, Mwea and Bondo respectively) (Table 18).
In all three areas, there were more samples typed as pure recrudescence than there were 
pure reinfections (Fisher’s Exact, P=0.00058).
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300 bp
Figure 6: An example of an agarose gel of TA 17 locus for various samples with 
both recrudescent and reinfecting parasites.
Adjacent lanes are loaded with the PCR product obtained from the Admission (A 
or DO) or R samples. The lane labelled M contains a lOObp ladder molecular 
weight marker (Promega). Sizes are indicated in base pairs. Sample pairs 
displaying patterns interpreted as recrudescent are 3A/3R, 5A/5R and 7A/7R. 
Sample pairs displaying patterns interpreted as reinfection are 4A/4R and 8A/8R. 
Sample pairs showing a mixture of recrudescence and reinfection are lA /lR  and 
6A/6R. The 2A sample did not amplify in this case.
3.2.2 Microsatellites
41, 42 and 46 samples from Tiwi, Bondo and Mwea, respectively, were 
successftilly typed with the fivemicrosatellite loci. Only a few samples could not be 
fully resolved with the microsatellite markers (Table 18). As observed with the antigen- 
coding loci most samples were typed as containing both recrudescences and reinfections 
(RE+Rl) (Ranges 47.62% in Tiwi to 79.55% in Bondo).
More samples were also typed as being pure recrudescence in all the three areas 
than those typed as pure reinfections. Recrudescences ranged from 11.26% in Bondo to 
33.33% in Tiwi. Reinfections ranged from 4.54% in Bondo to 16.67% in Tiwi.
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\  SITES MWEA (n=47) TIWI (n=42) BONDO (n=44)
OUTCOlsi^K Ags M icrosats Ags Microsats Ags Microsats
Re 13
(27.65%)
10
(21.28%)
13
(30.95%)
14
(33.33%)
5
(11.36%)
5
(11.36%)
Re + RI 22
(46.81%)
32
(68.09%)
18
(42.86%)
20
(47.62%)
31
(70.45%)
35
(79.55%)
RI 10
(21.28%)
4
(8.51%)
9
(21.43%)
7
(16.67%)
4
(9.09%)
2
(4.54%)
Indeterminate 2
(4.26%)
1
(2.13%)
2
(4.76%)
1
(2.38%)
4
(9.09%)
2
(4.54%)
Table 18: A summary of the results comparing microsatellites and antigen-loci 
typing for the samples of the patients who did not clear their parasitaemia 
following SP treatment.
Each pair of samples was classified as recrudescence (RE), reinfection (RI) or both 
recrudescence plus reinfection (Re + RI). Indeterminate means samples that could 
not be resolved as either RE or RI or both. Values in parentheses indicate 
percentages, n= sample sizes, Ags= antigen-coding loci, microsats= microsatellites.
3.2.3 Microsatellite versus antigen^coding loci
We assessed the extent of the agreement between the two sets of markers using 
the Cohen’s Kappa ( k )  test of agreement in the S AS/ST AT software program version
8.2 (SAS Institute Inc. Cary, North Carolina, USA 1999- 2001). The k  values for all the 
three populations studied were higher than 0.5 (range 0.559-0.606) (Table 19). We 
obtained significant agreement between the two sets of markers for all three sites than 
what might be expected from chance alone {P<0.001 - P^O.0056) (Table 19),
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TESTS OF AGREEMENT
Antigen-coding vs. m icrosatellite loci
Mwea
kappa coeff. 0.606
95% Cl 0.391 -0.821
P < 0.0001
Bondo
kappa coeff. 0.559
95% Cl 0.233- 0.884
P 0.0056
Tiwi
kappa coeff. 0.602
95% Cl 0.388 -0.815
P <0.0001
Table 19; Results for the tests of agreement between the two marker subsets using 
the Kappa test for each collection site.
The P  value given represents the probability of obtaining the k  value by chance 
alone
3.3 Multiplicity of Infection (MOI)
All the three sites showed high levels of multiple infections, which were 
measured by counting the number of samples showing two or more distinctive alleles 
per locus (Section 2.1.6,3). The mean MOI values were calculated by dividing the total 
number of highest alleles per individual by the number of samples analysed .
The MOI values ranged from 1.56 (C2M3, Tiwi) to 6.12 (C3M85, Bondo). The 
average MOI values for the eight markers combined were 2.87, 3.61 and 3.99 for 
Mwea, Tiwi and Bondo respectively. The marker with the lowest MOI values was
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C2M3 with 1.56, 1.88 and 2.01 in Tiwi, Mwea and Bondo respectively. The marker that 
gave the highest MOI values was C3M85 with 4.42, 5.7 and 6.12 for Mwea, Tiwi and 
Bondo respectively (Figure 7).
The five microsatellite markers combined had a MOI for all sites of 3.84 
compared to that of antigen coding loci of 2.91. The average MOI for the three most 
polymorphic of the microsatellite loci was 4.69.
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Figure 7: A chart showing the average multiplicities of infection (MOI) for the 
three areas studied with the two sets of markers.
Also included is the average MOI for the three areas with all the eight markers.
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3.4 Genetic diversity study
3.4.1 Introduction
The key questions to be addressed in this section are:
i. What is the extent o f  the genetic diversity o f  the Kenyan P. falciparu?n
populations? This was determined by calculating the heterozygosities and 
the mean number of alleles of the three Kenyan P. falciparum  populations 
studied.
i t  What is the level o f  association among loci in Kenyan parasite populations?
This was determined through the calculation of linkage disequilibrium 
between all possible pairs of loci.
Hi. How genetically differentiated are the Kenyan malaria populations from
each other? This was determined through the calculation of Fst and Gst.
The results of the microsatellite typing were used to analyse the population structures in 
the three areas studied. Three measures of diversity of the populations were analysed: 
the number of alleles per locus, expected heterozygosity and variance (range) in allele 
length.
3.4.2 Genetic diversity
3.4.2.1 Mean Number of Alleles (MNA)
MNA is a measure of the average number of alleles found in a population (see 
section 2.1.7.1). The MNA ranged from 12.94 in Tiwi to 15.12 in Bondo when all the 
individuals within the population were considered (Figure 8). The most polymorphic 
marker of all eight studied was the microsatellite C3M85 with a mean number of alleles 
per population of 23.1 in both Tiwi and Bondo, while the least polymorphic marker was 
C2M3 with 5.1 alleles per population.
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MEAN NUMBER OF ALLELES
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Figure 8: Average mean number of alleles per site for the two sets of markers. 
These were calculated using the dominant allele per isolate (section 2.1.7.1). Grey
bars represent the MNA for the five microsatellite loci while white bars represent
the three antigen-coding loci. The y bars show the standard error of the means.
3.4.2,2 Expected Heterozygosities (He)
The expected heterozygosities {He) were calculated for each locus for each site. 
The values of mean He (± S.d.) obtained ranged from 0.63 ± 0.006 in Mwea to 0.82± 
0.005 in Bondo. The locus with the highest He was C3M85 with 0.960 ± 0.006 in Tiwi 
while the lowest He was at locus C2M3 with 0.5 ± 0.003 in Mwea (Figure 9).
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Figure 9: Values of expected heterozygosity {He)  for the three areas using 
microsatellite loci and antigen-coding markers.
Av. H represents the average He across all loci per site
3,4.3 Multilocus Linkage Disequilibrium
The program GENEPOP was used to test for linkage disequilibrium where the 
null hypothesis is that genotypes at one locus are independent from genotypes at the 
other locus (see section 2.1.7.2 for methodology). Results of GENEPOP for all possible 
pairs of loci and their P  values are presented in Table 20.
A Monte Carlo simulation method was also used to test the significance of 
linkage disequilibrium for each locus pair for the complete data set, using the program 
LIAN version 3 (Haubold & Hudson 2000). The observed mismatch variance of the 
distance between all pairwise comparisons of complete 5-locus compaiisons, Vo, was 
0.2970. This was similar to the expected mean variance of the reshuffled data (10,000 
times), Ve, which was 0.2925, indicating lack of LD at these loci. The “standardized”
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index of association, was 0.0039 (P=0.2427). The I^a measures the strength of the 
linkage disequilibrium; in this case the value obtained is not significant suggesting there 
is no LD. Therefore for this data set, no significant linkage disequilibrium was observed 
between any of the markers used by both methods using GENEPOP and LIAN 
programs. This was expected for these populations where the high recombination driven 
by the high transm ission breaks down any linkage between unlinked loci.
Locus pair P-value
C2M3 & C3M85 0.124
C M 3& T A 40 0.728
C 2M 3& TA 17 0.961
C2M3 & TA48 0.547
C3M85 & TA40 0.914
C3M85 & TA17 0.292
C3M85 & TA48 0.211
TA 40& T A 17 0.720
TA 40& T A 48 0.468
TA 17& T A 48 0.242
Table 20: P-values for linkage disequilibrium between various locus pairs using 
GENEPOP.
3.4.4 Genetic differentiation
3.4.4,1 F s t  and G s t
Fst and Gst measures inbreeding due to the relatedness among alleles because they are 
found in the same sub-population. These were calculated according to section 2.1.7.2.
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The Fst and Gsr estimates for all five loci are presented in Table 21.
The Fst values ranged from 0.002 (TA40) to 0.211 (C2M3) with an overall Fst of
0.048. These F st are very low and indicate that there is little if any substructuring of the 
population between the three sites. The G st values are also very low which means that 
while there is a lot of diversity among individuals within the same population, there is 
less diversity among the individual populations.
H e Ho D st Gst Fst
C2M3 0.520 0.630 0.141 0.141 0.211
C3M85 0.933 0.988 0.002 0.002 0.003
TA40 0.763 0.765 0.002 0.002 0.002
TA17 0.867 0.872 0.004 0.004 0.007
TA48 0.693 0.710 0.013 0.014 0.020
OVERALL 0.757 0.793 0.0332 0.0332 0.0486±0.0093
Table 21; Population genetics parameters for the combined populations per locus 
and also the overall parameters.
He = Expected Heterozygosity; Ho = Observed Heterozygosity; Dst = Average gene 
diversity between subpopulations; G s t  ~ coefficient of gene differentiation; F s t  = 
fixation index. Values were obtained using the program ESTAT.
124
3.4.5 Isolation by distance
A  graph showing the results of the test for population sub-structuring and its 
relationship to the geographic distance is presented in Figure 10.
ISOLATION BY DISTANCE
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Figure 10: Graph showing isolation by distance between the Kenyan malaria 
populations studied.
The distance has been transformed using natural logarithm.
The correlation coefficient, = 0.1387 (P=0.B354). The R^, which is the fit of points 
to the line, indicates that the line is not a good relationship between the points. Although 
there are only three sites to compare it emphasizes the finding that there is no 
relationship between geographic and genetic distance.
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3.4.8 Summary and conclusion
The main results and of this section are summarized here.
The high MNA and expected heterozygosities observed with the three Kenyan 
P. falciparum  populations, is indicative of the high levels of genetic diversity of malaria 
parasites in Kenya.
The results obtained using the GENEPOP and LIAN programs confirm the 
observation of no linkage disequilibrium of the 5-locus haplotypes. A ‘standai’dized’ 
(see section 2.1.7.2) measure of the strength of LD, the index of association fA  gave a 
value of 0.0039, with no significance (P= 0.2427). The simulated vatiance of distance 
measure (Vg) was similar to the observed one (Tg). This reveals a lack of LD in these 
Kenyan populations, an observation that is consistent with population data from Uganda 
and Congo (Anderson et aL, 2000a), that in regions of high transm ission, there is 
random association among loci (low LD) due to frequent recombination which breaks 
down any association between unlinked loci.
The results of the genetic differentiation {Fst and G st) show that the populations 
studied are not sub-structured (Figure 10 and Table 21) and can be said to be 
undifferentiated. This is confirmed by the test for isolation by distance that reveals a 
negligible 13% of the variation in these three parasite populations can be attributed to 
their geographical areas (Figure 10).
The results suggest that there is a lot of out crossing among these three populations. 
Since the populations are separated by up to 800 km and the range of the mosquito 
vector is very limited (up to 6km) it seems most likely that the human host, through 
migration, facilitates outcrossing between parasites from different geographical origins 
across the studied areas.
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3.5 Drug resistance and selective sweeps
3.5.1 Introduction
The key questions to be addressed in this chapter are the following;
1. What is the prevalence o f  the mutations in Pfdhfr and  Pfdhps that confer 
pyrimethamine resistance? This was determined by typing samples from 
patients who did not clear the parasites after treatment with SP, using dot blot 
hybridization.
2. Do all resistant parasites from  Kenya have the same alleles at Pfdhfr and 
Pfdhps flanking micro satellite loci?
3. Do all Kenyan Pfdhfr and Pfdhps mutants have the same evolutionary origin? 
This was determined by exam ining the haplotypes of resistant isolates compared 
to those of sensitive ones for relatedness.
4. Does the triple mutant Pfdhfr and the double mutant Pfdhps have an ancestral 
origin from  among the extant wild type Pfdhfr in Kenya?
These four questions were addressed by analysing each of the samples (with mutations 
at codons 51, 59 or 108 for dhfr and 437/540 for dhps) at microsatellite loci up and 
downstream of the resistance-associated locus. Haplotypes were then compaied between 
samples with different dhfr and dhps alleles. Samples with multiple genotypes present 
were excluded from the analysis, as it is difficult to determine which allele to associate 
with which at the respective codons.
3.5.2 Dhfr dot blot hybridization
43, 57 and 60 isolates from Tiwi, Bondo and Mwea respectively were 
successfully typed for the three codons in dhfr associated with SP drug resistance in P. 
falciparum. The samples were classified as either mutant or wild-type based on their 
respectively genotypes at codons 51, 59 and 108 based on their signals, following
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probe-specific radiolabelling, of the dot blot on an autoradiograph (Figure 11). The 
samples were further classified as having single, double or triple mutations. The results 
for the vaiious dhfr genotypes are summarised in Table 22.
3.5.2.1 Prevalence of dhfr mutations
All the samples successfully typed from the two most endemic areas, Bondo and 
Tiwi, had only the allele encoding Asn at codon 108. 20 % of the samples from Mwea 
were typed as w ild type (encoding serine) at this codon (Table 22 and Figure 12). There 
were 7%, 8% and 10% samples with mutations at codons 51 and 108, while 14%, 11% 
and 18% of the samples had mutations at codons 59 and 108 in Bondo, Tiwi and Mwea 
respectively. Samples with the triple mutation (108, 51 and 59) were found at a 
prevalence of 33%, 63% and 70% in Mwea, Tiwi and Bondo respectively (Table 22 and 
Figure 12).
Sites/ genotypes Mwea (n=60) Tiwi (n=43) Bondo (n=57)
Dhfr W ild-type 12 (20%) 0 0
Dhfr 108N 
(Single mutant)
11 (18%) 5(11% ) 9 (16%)
Dhfr 108N/51I 
(Double mutant 1)
6 (10%) 3 (8%) 4 (7%)
Dhfr 108N/59R 
(Double mutant 2)
11 (18%) 5(11% ) 8 (14%)
Dhfr 108N/51F59R 
(Triple mutant)
20 (33%) 30 (70%) 36 (63%)
Table 22: Prevalence (and percentage) of the dhfr alleles in the three study sites of 
Kenya.
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Figure 11 : An example of an autoradiograph following hybridization of a dotblot 
with a radiolabelled probe for 59R DHFR.
Amplification reactions were loaded in duplicate with the negative control and the 
positive controls 307, T996 and Dd2 loaded in wells A l, A2, A3 and A4 
respectively and then in H12, H ll, HIO and H9 respectively. Note the positive 
hybridisation with Dd2 control in wells A4 and H9.
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Figure 12: Frequencies of the dhfr allelic haplotypes for the three study areas.
Frequency values are shown with 95% C! (bars) calculated by multinomial (3 
cases) exact method.
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3.5.3 Dhps dot blot hybridization
37, 39 and 56 samples from Bondo, Tiwi and Mwea respectively were included 
in the analysis for dhps alleles. The two codons exam ined, A437G and K540E, have 
been associated with resistance to sulphadoxine in P. falciparum  (Curtis, et al. 1998).
13%, 27% and 39% of amplified samples from Tiwi, Bondo and Mwea 
respectively had wild-type alleles at both codons typed (Table 23 and Figure 13).
Study Sites
Genotypes Bondo (n=37) Tiwi (n=39) Mwea (n=56)
Dhps 437A/540K 
(W ild-type)
10 (27%) 5 (13%) 22 (39%)
Dhps437G/540K 
(Single mutant)
19 (51%) 14 (36%) 10 (18%)
Dhps437G/540E
(Double mutant)
8 (22%) 20 (51%) 24 (43%)
Table 23: Results of dhps genotyping of samples from the three study sites.
The A437G mutation was found as a single mutant (i.e. wild-type at codon 540) in all 
the three areas, at a frequency of 18%, 36% and 51% in Mwea, Tiwi and Bondo 
respectively. No samples had the wild-type codon at 437 and a mutated codon 540.
43%, 51% and 22% of samples in Mwea, Tiwi and Bondo respectively had 
mutant codons at both position 437 and 540 (double mutants) (Figure 13).
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Figure 13: Frequencies of the dhps alleles in the three study sites.
Frequency values are shown with 95% Cl (bars) calculated by multinomial (3
cases) exact method.
3.5.4 Comparison o f  the frequencies o f  dhfr and dhps alleles per site
The distribution o f alleles was analysed using the Fisher’s Exact test. A 
comparison o f the distribution o f the dhfr alleles revealed highly significant differences 
(P'^0.001) among the three sites (Table 22). The distribution o f the dhps alleles was also 
significantly different between sites (Fisher’s exact, P= 0.0023) (Table 23). When the 
analysis was repeated with the exclusion o f Mwea (since this where most o f the 
differences were) there were no significant differences between Bondo and Tiwi in the 
distribution o f the genotypes (Fisher’s Exact, P= 0.733 for dhfr and P= 0.0567 for 
dhps).
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Study sites
Genotypes Tiwi (n=39) Bondo (n=37) Mwea (n=56)
DhfrW/DhpsW 0 0 3
DhfrM/DhpsW 5 10 22
DhfrW/DhpsM 0 0 12
DhfrM/DhpsM 34 27 19
Table 24: Multilocus genotypes per study site.
Samples were classified into four categories; those that had no mutations in the 
two genes (WAV), those with at least one mutation in dhjr with none in dhps 
(DhfrM/DhpsW), those with no mutation in dhfr but at least one in dhps 
(DhfrW/DhpsM) and those that had at least one mutation in each gene 
(DhfrM/DhpsM)
The combined distribution of the alleles defined by all codons exam ined at both 
genes (multilocus genotype) was analysed by scoring whether samples had at least one 
mutation in dhfr and none in dhps (dhfrM/dhpsW), at least one mutation in dhps but 
none in dhfr (dhfrW/dhpsM), at least one mutation in both genes (dhfrM/dhpsM) or 
wild-type in both genes (dhfrW/dhpsW) (Table 24). An analysis using this 
classification revealed highly significant differences (Fishers Exact, F<0.0001) between 
the three sites. A comparison between Tiwi and Bondo found no significant differences 
(Fisher’s Exact, P  = 0.1557) in the distribution of substituted alleles.
A comparison between Mwea and either Tiwi or Bondo found highly significant 
differences (Fisher’s Exact, P< 0.0001; Table 24) in genotype frequencies in Mwea and 
in either of the other two sites.
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3.5.5 Microsatellite loci around Dhfr
Four microsatellite loci were identified within an 8kb region downstream, and 
four within an 8kb region downstream of dhfr on chromosome 4. Microsatellite 
DHFRUl is situated 0.3kb downstream of dhfr in the 3D7 genome. Analysis of this 
locus in the Kenyan samples revealed 24 distinguishable alleles ranging in size from 
107 -  152 bp. Analysis of microsatellite locus DHFRU2, located 4.7kb downstream of 
dhfr, revealed 22 alleles of 158 -  192 bp. Similar analysis of microsatellite DHFRU3, 
located 7.0kb downstream of dhfr, revealed 21 alleles of 170- 195 bp, and of DHFRU4, 
located 8.0kb downstream of dhfr, revealed 24 distinguishable alleles of 187-238 bp.
Upstream of dhfr, analysis of microsatellite DHFRDl (located 0.5kb) revealed 
24 alleles of 88-152 bp, DHFRD2 (located 4.0kb) had 26 alleles of 230-269 bp, 
DHFRD3 (located 6.5kb) had 28 alleles of 175-229 bp, and DHFRD4 (located S.Okb) 
had 17 alleles of 263-300 bp. The number of alleles could be an underestimation as all 
the sizes were determined following electrophoresis on Spreadex gels, where the 
minimum size difference distinguishable is 4bp.
3.5.5.1 Microsatellite haplotypes and dhfr mutations
Samples with multiple alleles at more than one of the microsatellite loci 
preclude the construction of unambiguous haplotypes. Therefore only samples with 
single alleles at the microsatellite loci were used to construct microsatellite haplotypes. 
Haplotypes were ranked according to allele size at D HFRU l, then at DHFRU2, 
DHFRU3, etc. until finally at DHFRD4 loci, and numbered 1-59 when all the three sites 
(n=160 samples) were combined. Full haplotype descriptions are provided in Appendix 
2.
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Haplotype cod es
DHFR allele Overall 
(n= 131)
Mwea (n=60) Tiwi (n=43) Bondo (n=57)
lo s s
(W ild-Type)
3, 15, 19, 
20, 22, 30, 
48, 49, 53, 
55, 58, 59
Mwea had 
each of these 
haplotypes 
each w ith n= l
None None
108N/51N/59C 1, 4, 6, 1 , 8, 6 (n=l) 2 (n=l) 1 (n=l)
(single mutant) 9, 15, 16, 17 (n=l) 4 (n=l) 4 (n=l)
17, 18, 21, 18 (n=l) 7 (n=l) 8 (n=l)
23, 24, 25, 23 (n=l) 15 (n=l) 9 (n=l)
31, 46, 
51, 52,
56, 57
47,
54,
31 (n=l) 
47 (n=l)
51 (n=l)
52 (n=l) 
54 (n=l) 
57 (n=l)
16 (n=l) 21 (n=l)
24 (n=l)
25 (n=l) 
46 (n=l) 
56 (n=l)
108N/51I/59C
(Double mutant)
10, 12, 
14
13, 12 (n=2)
13 (n=3)
14 (n=l)
10 (n=3) 12 (n=l)
13 (n=l)
14 (n=3)
108N/51N/59R 11, 26, 27, 26 (n=l) 26 (n=3) 11 (n-1)
(Double mutant) 29, 50 27 (n=2) 
29 (n=8)
27 (n=2) 27 (n=l) 
29 (n=3) 
50 (n=3)
108N/51I/59R 5, 28, 33, 33 (n=19) 35 (n=25) 5 (n=l)
(Triple mutant) 34, 35, 36, 
37, 38, 39, 
40, 41, 42, 
43,44, 45
43 (n=l) 37 (n=l)
38 (n=l)
43 (n=l)
44 (n=l)
45 (n=l)
28 (n=l) 
3 3 (n=16)
34 (n=2)
35 (n=5)
36 (n=4)
39 (n=4)
40 (n=l)
41 (n=2)
Table 25: Microsatellite haplotypes associated with different dhfr alleles per study 
site.
The major allele (with at least 50% of samples with a particular dhfr allele per site) 
is indicated in bold.
The results are shown in Table 25 and the haplotype frequencies for each allele of dhfr 
(as defined by polymorphism at codons 5 1 ,5 9  and 108) are presented in figures 14 -  
17. Overall 59 haplotypes were identified in the 160 samples from Tiwi, Mwea and
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Bondo. There were 13 distinguishable haplotypes in the samples from Tiwi, 20 from 
Bondo and 30 from Mwea.
The dhfr triple mutant encoding N51I, C59R and S108N was associated with 15 
microsatellite haplotypes (Table 25). Out of the 86 samples typed as triple mutants, 35 
samples (43.75%) had haplotype 33 (composed of alleles 133 bp/174 bp/188 bp/212 
bp/100 bp/244 bp/183 bp/283 bp at the D HFRU l, DHFRU2, DHFRU3, DHFRU4, 
D HFRDl, DHFRD2, DHFRD3, DHFRD4 respectively) while 30 samples (35.71%) had 
haplotype 35 (133 bp/174 bp/188 bp/212 bp/100 bp/244 bp/183 bp/291 bp). Haplotypes 
37, 38, 43, 44 and 45 were detected only in Tiwi at quite low frequencies (Table 25). 
Haplotypes 36, 39, 40 and 41 were detected only in Bondo in 4, 4, 1 and 2 samples 
respectively. 19 out of 20 and 16 out of 34 triple mutant samples from Mwea and Bondo 
respectively contained parasites with haplotype 33. 25 out of 30 (95%) samples from 
Tiwi contained parasites with haplotype 35 (Table 25).
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3.5.S.2 Haplotype distribution among sites
Some haplotypes were found in more than one o f the three sites while others 
were unique to one o f the sites (‘private haplotypes’). Eleven haplotypes were shared 
between the sites but only one haplotype was found to be common in the three sites 
studied: haplotype 27, which was associated with the 108N/59R double mutant (Figure 
18). The site with the highest number o f private haplotypes was Mwea with 22, while 
the site with the lowest number o f private haplotypes was Tiwi, which had 8. Bondo had 
17 private haplotypes (Figure 18).
n= 43
Bondo
Mwea 
n= 60
Figure 18: Distribution of haplotypes in the three study sites
Only 11 out of the total 59 haplotypes observed are shared between sites out of 
which only one (no. 27) is common among all three sites, n = number of haplotypes
seen.
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The two sites with the highest number of shared haplotypes were Bondo and 
Mwea with 5 shared haplotypes. Tiwi shared two and three haplotypes with Bondo and 
Mwea respectively (Figure 18).
3.5.6 Microsatellite loci around dhps
Several m icrosatellite loci were identified around dhps and eight (four on either 
side of the gene) were selected for this study. Downstream of the gene, 23 alleles with 
PCR products ranging in size from 120-165 bp were found in the 131 samples analysed 
at DHPSUl (located 0.1 kb downstream of dhps). Similarly, 19 alleles of 192- 232 bp 
were found at DHPSU2 (located 3.8kb downstream), 20 alleles of 113-170 bp at 
DHPSU3 (located 6.5kb downstream), and 22 alleles of 185-240 bp at DHPSU4 
(located 8.7kb downstream).
Upstream of the dhps gene, 20 alleles of 104-124 bp were observed in the 
samples at the D HPSDl locus (at 0.4kb), 24 alleles of 205-280 bp at DHPSD2 (at 
3.7kb), 17 alleles of 190-246 bp at DHPSD3 (at 7.3kb), and 18 alleles of 189-230 bp at 
DHPSD4 (at 8.5kb).
Haplotypes observed from all the three sites (n=131 samples) were combined for 
numbering purposes. Haplotypes were ranked according to allele size at D HPSU l, then 
at DHPSU2, DHPSU3, and finally at DHPSD4 loci. The haplotypes were then 
numbered 1-82. Most of the haplotypes (49) were associated with the samples from the 
Mwea site (Table 26).
Full haplotype descriptions are provided in Appendix 3.
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Haplotype codings
Dhps alleles Overall (n=131) Bondo
(n=37)
Tiwi 
(n= 38)
Mwea (n=56)
W ild-Type 1,25, 4 ,5 ,6 ,1 % 8, 1 (n=l), 4 (n=l) 6, 12, 18, 26, 27, 39,
12, 17, 18, 22, 2 (n=l) 6 (n=l) 46, 50, 51, 52, 53, 55,
23, 26, 27, 39, 5 (n=l) 17 (n=l) 56, 58, 67, 70, 71, 73,
46, 49, 50, 51, 7 (n=2) 59 (n=l) 74, 77, 78, 82 (n=l for
52, 53, 55, 56, 8 (n=l) 61 (n=l) each)
58, 59, 61, 67, 22 (n=l)
70, 71, 73, 74, 23 (n=l)
75, 77, 78, 82 49 (n=l)
75 (n=l)
437G/540K 3, 10, 14, 16, 3 (n=l) 3 (n=l) 14, 20, 5 0 ,5 1 , 62, 64,
Single mutant 19, 20, 21, 28, 9 (n=3) 10 (n=2) 65, 76, 79, 80 (n=l for
30, 31, 32, 33, 16 (n=l) 16 (n=l) each)
35, 36, 45, 50, 28 (n=4) 19 (n=4)
51, 62, 64, 65, 30 (n=l) 21 (n=2)
66, 76, 79, 80 31 (n=l) 32 (n=l)
35 (n=4) 33 (n=l)
36 (n=2) 36 (n=l)
66 (n=l) 66 (n=l)
437G/540E 11, 13, 15, 24, 41 (n=l) 40 (n=l) 11 ,13 ,15 , 24 (n=2).
Double 25, 29, 34, 37, 4 2 (n=5) 41 (n=3) 25, 29, 34, 37, 38, 44,
Mutant 38, 40, 41, 42, 43 (n=2) 4 2 (n=14) 47, 51 (n=2), 53, 54,
43, 44, 47, 48, 48 (n=l) 43 (n=l) 57, 60 63,68 (n=2), 69,
51, 53, 54, 57, 48 (n=l) 72, 81 (n=l for each
60, 63, 68, 69, except for those
72, 81 indicated in brackets)
Table 26: Codes for haplotypes and their prevalence in the 3 study sites
The wild-type dhps alleles (n=37) from all three sites were not found to be 
strongly associated with any particular m icrosatellite haplotype; a wide range of 
haplotypes was observed and no one haplotype predominated (Table 26 and Figure 21).
The allele of dhps encoding the 437G change (n=42) was associated with 29 
haplotypes. All the alleles with the single dhps mutation from Mwea had different 
haplotypes (Table 26 and Figure 22). In Tiwi and Bondo some haplotypes were 
observed to be more prevalent in the single mutant dhps than others (Figure 22). The 
most common haplotype found in samples from the Tiwi site with the 437G allele was 
haplotype 19 (42.86%). The two most common haplotypes associated with the 437G
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dhps mutant in Bondo were haplotype 28 (22.22%) and haplotype 35 (22.22%). These 
two haplotypes were not found in Tiwi while haplotype 13 was not found with the 
Bondo samples. Four haplotypes (3, 16, 36 and 66) were found in single mutant dhps 
alleles from both Tiwi and Bondo but in quite low frequencies (Figure 22).
The 437G/540E dhps double substituted allele in Tiwi and Bondo (n= 28) was 
associated with haplotypes 40, 41, 42, 43 and 48 (Figure 19 and Figure 23). The most 
common haplotype associated with the double mutant dhps allele was haplotype 42 with 
a frequency of 56% and 79% in Bondo and Tiwi respectively (Figure 23). There was no 
dominant haplotype associated with the double substitute dhps allele in Mwea (Figure 
23).
While there seemed to be apparent reduction in the number of haplotypes associated 
with the single and double mutant dhps samples from Bondo and Tiwi, those from 
Mwea seemed to have multiple haplotypes, all found at very low frequencies. For 
example, the 437G/540E allele found in Mwea was associated with 21 haplotypes in 24 
samples, all with frequencies <0.1. (Table 26, Figure 20, Figure 22 and Figure 23).
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3.5.6.1 Z>/ip5-linked microsatellite haplotype sharing among the three sites
There was less sharing of haplotypes of the dhps-Xmktd microsatellites than was 
observed with the c//^-linked ones. Mwea did not share any haplotype with Bondo and 
was only found to share one haplotype with Tiwi (Figure 19). Tiwi and Bondo shared 8 
of the total haplotypes of the microsatellites flanking the dhps gene. 50% of the shared 
haplotypes between Bondo and Tiwi were those associated with the double-substituted 
dhps allele (Table 26 and Figure 19) indicating a close relationship of the double mutant 
dhps allele between the two sites.
Tiwi 
n= 38
Mwea 
n= 56
Bondo
n= 37 1, 2,3, 5, 7, 8, 9, 
16, 22, 23, 28,
Figure 19: DAp^-linked microsatellite haplotype distribution in the 3 sites.
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3.5.7 Expected Heterozygosity in the flanking microsatellites
Expected heterozygosity {He) at each m icrosatellite locus was calculated as 
explained in section 2.1.7.1. Alleles of microsatellites were categorised according to the 
variation at all three of the codons exam ined for dhfr and two codons exam ined for 
dhps. Thus, for dhfr there were four categories of alleles; wild-type, single mutants 
(108N/51N/59C), double mutants (108N/51I/59C and/or 108N/51N/59R) and triple 
mutants (108N/51N/59R). For dhps there were three categories of alleles; wild-type, 
single mutants (437G/540K) and double mutants (437G/540E). Based on these 
categories, He at the genes (both dhfr and dhps) was set at zero, as it is presumed there 
is no valuation within the gene when the same alleles aie considered. A comparison of 
the He values of the microsatellites between the wild-type and triple mutant alleles 
revealed markedly reduced variation around the dhfr alleles carrying the triple 
mutations. The reduction in variation was more pronounced upstream of the gene 
compared to the downstream region. He values were lower nearer the gene than further 
from it (Figure 24). This is in agreement with the expectations of a selective sweep 
where the regions carried over depend largely on the strength of the selective force (i.e. 
antimalarial use) and the strength of recombination. In contrast the wild-type alleles 
show almost equal variation (as measured by He) with the unlinked microsatellites. This 
is discussed further in Section 4.5. A similar scenario was observed with the dhps 
alleles where those cany ing the double mutations have reduced He at markers flanking 
the gene compared to those carrying the wild-type gene Figure 25.
145
H  ^ for Wild-type & Triple Mutant dhft alleles
i o O . 7  
o 0.6
-o-
“ 0“  Wild-Type 
-•-Tripie-Mutant'V 0.4 - 
^ 0 . 3 -
W 0.2 -
0.1
8.0 -6.5 -4.0 -0.5 DHFR 0.3 4.7 7.0 8.0
Distance from d J i£ r  Locus (kb)
Figure 24: Microsatellites flanking dhfr resistant alleles (triple mutant) show 
reduced He compared with those flanking wild-type dhfr alleles.
All sites have been combined for this analysis. The X-axis refers to the location (in 
Kb) of the microsatellite loci used with respect to the dhfr gene. Filled dots 
represent He of microsatellite markers flanking dhfr triple mutant alleles and open 
dots represent He of microsatellites flanking wild-type dhfr alleles from the three 
study areas. Note the pronounced asymmetry of the mutant allele curve.
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H e fot Wild and Double mutant Dhps alleles fot Tiwi and
Bondo
0.9
0.5
0.4 - •O—W ild type 
-X— double m utant
0.2 -
0.1
-7.3 -3.7 6.5
Distance from dhfr locus (kb)
Figure 25: Variation ijie) at microsatellite loci flanking wild-type and double 
mutant dhps alleles in Tiwi and Bondo
The x-axis refers to the location (in kb) of the microsatellite loci used with respect 
to the dhps gene. Note the variation at the gene is set at 0.
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3.5.8 Extended Haplotype Homozygosity
To explore how linkage disequilibrium breaks down with increasing distance to 
a specified core region, haplotype homozygosity (HH) was calculated in a stepwise 
manner for each haplotype length (extended HH, EHH) according to published methods 
(Sabeti et ah, 2002). HH is calculated between a distance x  and the specified core region 
for a chromosome population caiTying a single core haplotype. Distance x  increases 
stepwise to the most outlying marker. The procedure was repeated for each core 
haplotype. If the candidate region is not at the margin of the genotyped range, linkage 
disequilibrium patterns can be estimated on both sides of each core haplotype. In other 
words, the extended HH estimates the level of haplotype splitting due to recombination 
and mutation at each distance to the core haplotype. An attractive aspect of this 
approach is that the various core haplotypes at a locus serve as internal controls for one 
another at the same chromosomal region. This is important given the variability of local 
recombination rates across genomic regions. The values of EHH range from 0 to 1 with 
a high EHH (approaching 1) indicating complete linkage disequilibrium (LD) between 
the marker and the gene and vice versa. The results of EHH are given in Figure 26and 
Figure 27.
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E X TEN D ED HAPLOTYPE HOMOZYGOSITY FOR DHFR LOCUS
1
0.9
0.8
0.7
0.6
X
r - '
0.4
0.3
0.2 
0.1
0
-8.0 -6.5 -4.0 -0.5 D H FR  0.3 4.7
Loci distance from d h fr  (kb)
•TRIPLES
•DOUBLE2
•WILD
•SINGLES
DOUBLEl
7.0 8.0
Figure 26: LD, measured by EHH, in dhfr wild-type and mutant parasites from 
Tiwi, Bondo and Mwea.
EHH for was set at 1. ‘Doublel’ and ‘DoubIe2’ refer to the mutants having 
51I/108N and 59R/108N mutations respectively. ‘Singles’ refer to parasites with 
the 108N mutation only. Triples refer to parasites with the dhfr allele 
51I/59R/108N.
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E H H  FOR DHPS LOCUS
Xa
8
0.7
0.6
5
0.4
3
0.2
0.1
0
^
Locus distance from D hps
DOUBLES
SINGLES
W ILD -ITPE
Figure 27: LD, measured by EHH, for dhps wild-type and mutant parasites from 
Tiwi, Bondo.
Wild-type refer to parasites with no mutations in dhps  ^singles are those parasites 
with the 437G while doubles are the ones with the allele 437G/540E.
EHH for dhps was set at 1.
3.5.9 Testing for population bottlenecks
It has been noted that allelic diversity is reduced faster than heterozygosity 
during a bottleneck (Nei et al. 1975). If a population has gone through a bottleneck, it is 
found to retain the excess heterozygosity.
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To test whether the population of substituted dhfr alleles had undergone a recent 
bottleneck, the presence of excess of heterozygosity was determined using the software 
"bottleneck' (Comuet and Luikart 1996). This software carries out a W ilcoxon signed 
rank test comparing observed heterozygosity at each locus across the -1 7  kb region 
flanking the triple mutant dhfr. The same analysis was repeated for double mutant dhps 
loci. These analyses were carried out using the both the site-specific and pooled data for 
dhfr, and with the exclusion of Mwea for the pooled dhps data due to the observation 
that M wea’s double mutant dhps mutants had not been selected for. Expected values are 
generated under infinite allele model (lAM) and step-wise allele model (SMM).
It was found that under both JAM and SMM there was no significant excess of 
expected heterozygosity for the triple mutant dhfr isolates from all three areas 
(W ilcoxon test one tail P=0.99 [lAM] and f = 1.000 [SMM]) indicating that the 
population had not recently undergone a reduction in size (Table 27).
The same result was observed when analysing samples with the double mutant dhps 
allele from Bondo and Tiwi, excluding Mwea (W ilcoxon test one tail f =0.22 [lAM] 
and f =0.34 [SMM]) (Table 28).
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3.5,10 Modeling for selective sweep in Kenyan parasite populations
A very basic model was employed to investigate the rate at which drug- 
resistance alleles replace drug-sensitive ones in areas of Kenya with different 
endemicity of P. falciparum, under drug pressure with SP. This model was also used to 
determine rate of selection using SP data collected over the years in the three areas. This 
model is described in section 2.2.5.5. For the coefficient to be significant the fit of the 
points (R^) has to be >0.80 (Hartl & Dykhuizen 1981). The results are presented in 
Figure 28, Figure 29 and Figure 30.
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Tiwi
y = 0.217 7 x -436.64 
= 0.8254- 0.2 -
-0.4 -
- 0.6  -
“ 1.6
- 1.8
1998 2000 20042002
Year
Figure 28; Estimation of selection coefficient {s) driving SP resistance in Tiwi. 
p is the frequency of resistant alleles inferred from treatment failure rate data,
and q (=l-p) is the inferred frequency of sensitive alleles. The x-axis shows the
generation number (assuming six generations per year (Joy et a t, 2003). The slope
gives an estimate ofa = 0.2177.
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Bondo
- 0.1
y= 0.1047x-210.34  
= 0.8587
-0.5 -
5  -0.7 -
-0.9 -
-1.5
1998 20022000 2004
YEAR
Figure 29: Estimation of selection coefficient (s) driving SP resistance in Bondo. 
p  is the frequency of resistant alleles inferred from treatment failure rate data, and
q (=!"/?) is the inferred frequency of sensitive alleles. The x-axis shows the
generation number (assuming six generations per year). The slope gives an
estimate of s = 0.1047,
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Mwea
y = 0 .264x-529,08 
R^  = 0.8783
- 0.2  -
•0.4 -
- 0.6 -
- 0.8 -
cr
- 1.2
1998 2000 2002 2004
YEAR
Figure 30: Estimation of selection coefficient (s) driving SP resistance in Mwea.
P is the frequency of resistant alleles inferred from treatment failure rate data, and 
q (-1-p) is the inferred frequency of sensitive alleles. The x-axis shows the 
generation number (assuming six generations per year). The slope gives an 
estimate of s = 0.264.
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4.1 Recrudescence versus reinfection
In this study two different sets of genetic markers used to distinguish 
recrudescences from reinfections were compared: five putatively neutral m icrosatellites 
and three antigen coding loci that are thought to be under strong natural selection 
(Hughes 1992;Hughes & Hughes 1995;Conway 1997;Escalante et al. 1998). The 
antigen-coding loci were found to be as effective as m icrosatellites in differentiating 
recrudescence from reinfection, despite the fact that antigen-coding loci are likely to be 
under strong selection pressure while the microsatellite loci are presumably not (Table 
19).
More alleles were observed at the microsatellite loci than at the antigen-coding 
loci in the populations studied (Figure 8 and Figure 9). There are three possible 
nonexclusive hypotheses for this; a) that the microsatellites are more polymorphic than 
the antigen loci; b) that selection within partially immune hosts removes certain 
parasites from infections on the basis of their antigens, whereas there is no selection 
based on m icrosatellite alleles (since they are non-coding); c) that microsatellite loci are 
unstable.
An assumption of the second hypothesis is that these parasite populations are 
recombining frequently. Therefore, there is a m ixture of all m icrosatellite/antigen allele 
combinations, and when immunity removes a subset of parasites based on a particular 
antigen, all the microsatellites are still represented in combination with the non-selected 
antigen alleles.
Microsatellite loci could behave in an unstable manner for two reasons. 
Recombination may occur in vitro (during PCR); recombination, or chimera formation, 
has been shown to occur between related template sequences present in a single PCR 
amplification (Judo et al. 1998). This phenomenon has also been observed in P.
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4.0 DISCUSSION AND SUMMARY
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falciparum  especially for the antigen gene M spl (Tanabe et al. 2002), although this was 
over a much longer distance with long stretches of homologous DNA. The PCR used in 
this study for the antigen-coding loci are much shorter and do not contain long stretches 
of homologous DNA thus there are reduced chances of recombination. Loci may also be 
unstable in vivo within an asexual infection or during meiosis in the mosquito. The 
number of repeats within a m icrosatellite locus may change during an infection, 
possibly during mitotic replication, giving rise to parasites genetically identical at all 
loci except that particular' m icrosatellite, although this does not appear to be the case in 
this study, as there were no parasites observed with multiple bands at only one 
microsatellite locus.
Genetic markers should be chosen based on the research question being asked 
(Sunnucks 2000). Each genetic marker has a range over which it can usefully detect 
genetic variation (Thompson et al. 1998). If the marker is too polymorphic, either the 
required sample size to describe diversity will be too high, or the samples will be too 
different resulting in homoplasy. If the marker has little polymorphism, as we have seen 
with C2M3 (Figure 7 and Figure 9), it might misrepresent some differences between the 
samples, and more so in a field setting.
We still do not know much about evolution of microsatellites and even their 
neutrality and hence data from their use should be treated with caution especially when 
that data is meant to inform policy change. From the results of this work it is clear that 
microsatellites might be the better markers for population analysis but more work 
remains to be done to justify their application as markers for monitoring dmg efficacy 
in malaria.
Another potential problem with microsatellites is the issue of null alleles, which 
was noted with some of the microsatellites used in this study, where they failed to
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amplify DNA from some samples, including laboratory isolates, despite repeated 
attempts. This is often caused by polymotphism in the primer recognition sequences in 
non-coding DNA. Since non-coding DNA is usually under less constraint because it 
does not encode proteins, mutations that occur have a greater chance of remaining 
within the population. This is in contrast with antigen loci where primers are in coding 
regions within blocks of sequences with 90% conservation of nucleotides in well 
studied genes where many allele sequences are available (Miller et al., 1993).
4.2 MOI and transmission intensities
Is there a relationship between the numbers of clones per infection (MOI) and 
the transm ission rate of malaiia? In the study presented in this thesis, the MOI values 
seem to increase with increased levels of EIR (Figure 7), although it is hard to be certain 
of this trend, as there are only three sites to compare.
One fact that emerges in this study is that the average MOI values with both sets 
of markers do not reflect the intensity of transm ission. This is because the transm ission 
intensities of, for instance Bondo are over 1000 infective bites per person annually 
compared to Mwea where the rate is about 100 but the difference in mean MOI levels in 
the two areas is just one (Figure 7). This finding is in broad agreement with previous 
work, which indicated that increasing entomological inoculation rates (EIRs) were 
associated with progressively smaller increases in the average number of clones per host 
(MOI) (Arnot 1998).
The transm ission rate of malaria is measured in entomological inoculation rate 
(EIR), which is a product of the proportion of mosquitoes containing sporozoites (the 
sporozoite rate) and the human biting rate. The human biting rate is usually estimated 
from the landing rate on collectors (Burkot & Graves 1995). EIR is also a fairly crude 
estimate, and infection rates will vary in time, especially in areas with seasonal
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rains/changes in mosquito density. However, our estimates of strain diversity may have 
underestimated the true probability of two infections having the same genotype due to 
clustering of parasite strains in time and space, as well as the frequency of infections 
containing multiple strains.
Another inherent limitation of genotyping is the assumption that parasite strains 
detected in pretreatment samples reflect the complete population of infecting parasites. 
It is possible that strains circulating at low parasite density, or sequestered at the time of 
sampling, are not detected in pretreatment samples but could emerge to cause treatment 
failure, leading to the misclassification of a recrudescence as a new infection. Even if 
this was the case, the average number of clones detected in the patients under study in 
the two higher transm ission areas of Bondo and Tiwi do not approach the potential 
number of input clones implied by the high EIRs of the two areas. The same 
observation was made in a study of infection complexity in Thailand (Paul et al., 1998), 
but can be explained by some nonexclusive hypotheses.
Measurements of clone multiplicities are affected by the sensitivity and kinetics 
of PCR. The rapid DNA extraction methods used for the large numbers of small blood 
samples generated by field studies are known to limit the sensitivity of the method 
(Bottius et a l ,  1996; Roper et al., 1996). Ordinary PCR methods might fail to detect 
parasite clones with fewer than 5 m illion circulating parasites (genomes) per individual 
infection (equivalent to 1 parasite/ pi of blood).
PCR-derived estimates of the number of clones per individual can also be biased 
when alleles originating from different genomes are present in a sample in unequal 
concentrations (Amot 1998). If one sequence dominates in the reaction mixture (>90%), 
it will tend to obscure minority sequences, which will fail to be amplified due to the 
stochastic nature of sampling in the early reaction cycles (Ranford-Cartwright et a l.
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2002). This problem will be compounded if the same primers are amplifying two or 
more different sequences of unequal length, since the PCR is known to amplify 
preferentially smaller, more rapidly synthesized sequences (Lukyanov et a l ,  1997). 
Underestimation of the true MOI values through such biases has been noted as a 
possible cause of the tendency for PCR to detect fewer genetically complex infections 
during clinical episodes than during asymptomatic infections (Roper et ah, 1998). This 
observation could also be an artefact due to fast-growing ‘dominant’ populations of 
parasites overgrowing ‘resident’ clones during the clinical attack, and not necessarily an 
indication that clinical infections actually contain fewer clones than asymptomatic 
infections (Contamin et ah, 1996; Mercereau-Puijalon 1996).
Parasite sequestration is also a factor that contributes to the low MOI values 
observed. The parasite population in an individual has been shown to vary on a day-to- 
day basis in asymptomatically infected children in Tanzania (Famert et al., 1997), 
presumably due to synchronicity of parasite populations of a particular genotype.
The origin of the genetic diversity itself could also play a part in the 
observations recorded. It is generally considered that the presence of genetically distinct 
parasite clones in patient infections results from one of two routes. The first is where the 
patient is inoculated with mixed genotype sporozoites derived from mosquitoes 
containing at least one hybrid oocyst. In hybrid oocysts, sporogony m itotically amplifies 
the meiotic products of a transiently diploid zygote/ookinete derived from the fusion of 
genetically different gametes (Ranford-Cartwright et ah, 1993). The second is simply 
superinfection with novel clones from inoculations from different infectious 
mosquitoes. This assumption that all genetic diversity originates from either meiotic 
recombination or superinfection has been queried by other authors (Dmilhe et a l ,  
1998), who suggest that mitotic recombination may also play a role. The results of the
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study presented in this thesis, that there is wide diversity of parasites even within 
populations with low transm ission, suggest that mitotic recombination, or other 
mechanisms leading to a change in length of repetitive regions of DNA, during the 
various multiplication cycles in the vertebrate host (Amot & Gull 1998) might 
contribute to the observed parasite diversity.
On the other hand, the observations may have nothing to do with experimental 
biases and may be a true picture of the MOI. If so then the lack of correlation between 
MOI and EIR could be explained by:(i) a high proportion of sporozoite inoculations 
either fail to initiate, or to complete successfully, intrahepatocytic development and thus 
do not mature into erythrocytic infections; (ii) most sporozoite inoculations successfully 
invade hepatocytes and complete exo-erythrocytic schizogony but result in short-lived, 
and usually low level, erythrocytic infections (de Roode et al., 2004).
The possibility of sporozoites not completing the intrahepatocytic schizogony 
would be of interest for vaccine development against exo-erythrocytic stages (Frevert et 
al., 1998), because it suggests some form of pre-erythrocytic stage immunity as a major 
component of natural immunity capable of preventing a high proportion of the 
genotypes inoculated as sporozoites from developing into bloodstream infections (Amot 
1998).
However, if the average number of clones is controlled by the immune response 
to erythrocytic stage antigens (e.g. M SPl, MSP2 and GLURP, and especially PfEM Pl), 
the establishment of new clones would require them to have novel variants of these 
protective antigens not recognised by the existing host immunity. If the parasite 
population ‘m ix’ of such polymorphic antigens were finite, increasing the infection 
pressure would expose the host to more antigenic variants and ultimately make it more 
difficult for new parasite clones to establish (Amot 1998). This translates into a scenario
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where older individuals, particularly in high transm ission areas, harbour lower average 
MOI than children. Interestingly such a scenario has been observed in a holoendemic 
area in Senegal (Ntoumi et a l,  1995), but not in a hypoendemic aiea in Sudan (Roper et 
a l ,  1998).
Natural immunity to malaria remains poorly understood. Various models 
involving eventual acquisition of long-teim immunity have been advanced. The most 
populai' seems to be the premunition hypothesis. This proposes that protection from 
clinical disease operates largely via a blockade against superinfection maintained by 
established chronic infections composed of numerous clones. Alternative models 
involving the acquisition of immunity to diverse variable antigens (Gupta & Day 1994; 
Hviid 1998), immunity to relatively conserved parasite antigens (Druilhe & Perignon 
1997), or mechanisms dependent on age and immunological maturity (Baird et a l ,  
1991; Ntoumi et a l ,  1995) have also been proposed. This study seems to reinforce the 
findings of others in Africa that showed most individuals harbour more than one 
parasite clone. It also seems to reinforce the fact that in African malaria endemic 
situations, the average MOIs are quite high (<2 clones per individual per infection) and 
this reflects the rates of transmission.
4.3 Genetic Diversity
In this study, microsatellite markers have been used to study the population 
structure of P. falciparum  from geographical areas with varying transm ission dynam ics 
in Kenya. The data obtained seem to agree with others (Anderson et a l, 2000) that have 
suggested very high diversity levels of P. falciparum  in African populations (Figure 9). 
Lack of LD was also observed in physically unlinked markers suggesting high levels of 
recombination in these areas (Table 20). The study areas are as far apart as 800 km but 
there seems to be no population genetic subdivision between the sites {Fst = 0.008
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(excluding C2M3) Table 21), and no correlation with distance between the sites (Figure
10) suggesting that the Kenyan P. falciparum  populations studied are in effective 
panm ixia
W ith a maximum flying range of approximately 6 km, it is unlikely that the 
mosquito vector is responsible for this observed panm ixia, and it can only be attributed 
to the human host through migration and inter-regional travel. A closer look at the areas 
under the study reveals a lot of human movement especially between Bondo and Tiwi. 
Tiwi is located on the South Coast of Kenya, an area that is quite popular with tourism. 
This means there is frequent movement of people from upcountry to this area in search 
of jobs and business opportunities. The immigrants noimally leave their families 
upcountry thus necessitating frequent travel back home. This perhaps explains the 
parasite gene flow and the almost indistinguishable parasite populations among these 
three areas.
A striking observation from the microsatellite analyses is that while the 
trinucleotide loci showed high levels of variation and low levels of diversity between 
subpopulations {Gst = 0.006) (Figure 9 and Table 21), the dinucleotide marker C2M3 
revealed low levels of variation with higher levels of G st {G st = 0.141) (Table 21). 
Studies of P. falciparum  suggest that dinucleotide repeat microsatellites evolve up to 
twice as fast as trinucleotide repeats (Anderson et a l  2000b), which would be expected 
to translate into more variation for the dinucleotides. However, the dinucleotide repeat 
locus C2M3 revealed lower levels of variation (heterozygosity) and diversity (as 
measured by G$t) than the trinucleotide repeats (Figure 9 and Table 21). This 
contradictory observation could be explained by the fact that the locus C2M3 is not a 
peifect microsatellite. In the 3D7 clone, C2M3 has two repeat runs; (TA)is and (TA )%4 
with an insert of about 90bp in between. This insert contains various combinations of
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bases including mono- and trinucleotide repeats, but is not a pure repetitive sequence. 
Although no C2M3 alleles were sequenced, it is possible that the non-repetitive middle 
sequence has affected the mutation/slippage rate and hence the variation at this locus.
4.3.1 Genetic differentiation and drug resistance
The Fst IGst values are indicators of population differentiation. The lower the 
values, the more closely related are the parasite populations under consideration. The 
results of the study presented in this thesis reveal that the three Kenyan parasite 
populations are almost indistinguishable with very low levels of differentiation {Fst < 
0.008). In fact, the Kenyan parasite populations act as a single large gene pool. This 
finding is very important when considering drug resistance.
It would be expected that with the low differentiation of the Kenyan malaria 
parasite populations, drug resistance would spread quite fast once it has evolved or been 
introduced, since there seems to be a high gene flow between the geographically 
separated populations. This is consistent with the proposal that in populations with low 
Fst, newly arising resistance alleles will spread more rapidly than in populations with 
higher Fst- However, other factors will also determine the spread of these alleles within 
a population and these include the relative fitness of the alleles in the drug environment, 
transm ission intensity, and recombination.
4.4 Drug resistance
Mutations in the parasite genes Pfdhfr and Pfdhps genes are associated with SP 
treatment failure, although their relative contribution to SP clinical treatment failure is 
not completely understood (Nash et al., 2005; Roper et a l ,  2003; Roper et a l ,  2004). In 
the three Kenyan sites studied, SP treatment failure rates varied between 30% and 40 %, 
and this was reflected in the absence of wild-type alleles of Pfdhfr in two of the sites 
studied, Tiwi and Bondo. Wild-type alleles of both genes were seen in the third site.
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Mwea, where SP treatment failure rates are lower (between 18 and 25%), The variation 
in the rates of treatment failure was reflected in the differences between the prevalence 
and combinations of mutations in the two genes studied. Mwea had the lowest 
percentage of triple mutant dhfr alleles (33%) thus reflecting the low treatment failure 
rates (TFR) in vivo while Tiwi, with the higher TFR, had 70% of the analysed samples 
having the triple mutant dhfr allele (Table 22). Bondo with the highest TFR had 63% 
prevalence of the triple mutant dhfr (Table 22), which is slightly lower than Tiwi (which 
has a slightly lower TFR than Bondo). Again the same pattern was observed with dhps 
alleles. Mwea had a prevalence of the double mutant dhps at 43%, Bondo had 22% 
while Tiwi had the highest with 51%. This difference is probably because the analysis 
excluded the multiple clone infections and, as can be expected most of these were from 
Bondo thus biasing the sample.
All of the parasites from Bondo and Tiwi with single and double mutant dhps 
alleles had the triple mutant dhfr allele, suggesting that in these two ai'eas, dhps mutants 
occur against a background of dhfr mutations. However, in the Mwea site 12 isolates 
with the dhps A437G single mutation were found to have a wild-type dhfr allele (Table
24). It is commonly thought that dhps mutations arise against a background of dhfr 
mutant alleles (Plowe et al,, 1996), implying that resistance to SP requires the presence 
of mutations in dhfr. Field studies in Africa have clearly shown association of the dhfr 
triple mutant with increased likelihood of treatment failure following SP treatment 
(Nzila et al., 2000b; Omai* et al., 2001a) and the odds ratio (OR) is usually slightly 
higher when mutations at dhps are included. However it has not been possible to obtain 
OR for dhps mutations alone because they are usually found only in association with 
substituted dhfr alleles.
168
A few recent studies have reported parasites with dhps mutant alleles with no 
corresponding mutations in their dhfr genes. In a recent study in Uganda, which is very 
close to our Bondo site, Sendagire and colleagues observed very high levels of the dhps 
mutants at codons 437 and 540 (89% and 74.6% respectively), compared to the most 
prevalent (63.6%) dhfr mutation at codon 108 (Sendagire et ah, 2005). One parasite 
sample out of 113 described was identified with wildtype Dhfr coupled with a single 
mutant (437G) dhps, and two samples had wildtype dhfr with double mutant dhps. One 
hypothesis for this observation is that SP is not the only drug driving the selection of 
dhps mutant alleles (see section 4.9).
While the Fst levels are quite low among the three sites (Table 21), signifying 
adequate gene flow among them, the prevalence of dhfr alleles and also the TFR do not 
support this. For instance, the observation of w ild-type dhfr in Mwea but none in the 
other two sites and also the unequal distribution of the triple substituted dhfr and double 
substituted dhps alleles (Table 22 and Table 23). While the prevalence of alleles in 
Bondo and Tiwi show no significant differences (Fisher’s Exact, P= 0.733 for dhfr and 
P -  0.0567 for dhps), there are highly significant differences in allele prevalence 
between Mwea and the other two sites (Fisher’s exact, P<0.001 for dhfr and P<0.002 
for dhps). In an apparently panm ictic population it is expected that all the alleles would 
be equally distributed which is not the case in this data. A hypothesis for this is that 
panm ixia was established long before the introduction of the selection pressure in all the 
three populations. However sometime later the population in Mwea m ight have drifted 
apart from the other two with no apparent loss of the diversity in the noncoding DNA 
regions leading to the apparent panm ixia being observed. However, the introduction of 
SP in these now separate populations selects for drug resistant parasites at different rates 
leading to the differences being observed.
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In Kenya, SP was introduced as a first-line treatment in 1997. This means the 
useful therapeutic life for SP in Kenya has only been approximately four years although 
it was still available in private healthcare before its introduction as the first-line therapy 
for uncomplicated malaria in Kenya. At the outset, the long elimination half-life of SP 
was considered to be advantageous, since a single-dose cleared parasites, and prevented 
re-infection for a period of approximately 50 days. This relatively long period allowed 
patients to recover from the sequelae of malaiia infection, particularly anaemia 
(W instanley et al., 1992).
However, the long half-life of SP also appears to have had a detrimental effect: 
the rapid selection of resistance. SP is a long acting drug and will persist at sub- 
therapeutic concentrations for more than a month (Nzila et al., 2000b; W instanley et al., 
1992). Sub-therapeutic levels of drug may or may not clear fully sensitive parasites 
[depending on whether the level is higher than the minimum inhibitory concentration 
(MIC) (most therapeutic drug levels are higher than the MIC)], but not highly resistant 
ones, therefore exerting pressure for resistance. This selective pressure eventually 
eliminates the alleles conveying drug sensitivity in parasite populations, and leads to the 
fixation of drug resistant alleles. For SP in Kenya the selection appears to have taken 
about 4 years, as demonstrated by this study. In Asia and Southern Africa, the time 
taken for resistance alleles to spread to fixation was shown to be approximately 6 years 
(Nair et ah, 2003; White 1992), which is approximately 36 Plasmodium  generations 
assuming an estimate of six generations per year (Joy et ah, 2003).
As drug resistance spreads, it leaves genomic signatures that can be used to trace 
its evolution and introgression through a population. These signatures appear in the 
form of hitchhiking of genom ic sequences flanking the drug resistance-conferring loci.
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For SP resistance, the important loci are thought to be the Pfdhfr and Pfdhps genes 
(Nair et a l,  2003).
4.5 Evidence of selective sweep of resistant alleles
Microsatellite loci spanning a region approximately 17kb (both up and 
downstream) around the dhfr and dhps loci were used to construct haplotypes of 
parasites present in patients in three Kenyan sites.
The haplotype analysis provides evidence suggestive of selection around both 
dhfr and dhps loci in two of the sites, Bondo and Tiwi (Figure 17, Figure 23, Figure 24, 
Figure 25, Figure 26 and Figure 27). For the Mwea site evidence for selection was only 
observed on dhfr but not in dhps (Figure 17, Figure 20 and Figure 23). Although 
parasites bearing the wild-type dhfr were absent in Bondo and Tiwi, both wild-type and 
mutant dhfr and dhps alleles were found amongst the samples collected from Mwea. 
Hence, it was possible to compare patterns of m icrosatellite variation flanking both 
classes of alleles (Figure 24, Figure 25 and Figure 26). These data provide strong 
evidence of selection for the mutant dhfr allele, especially the triple mutant, in the three 
areas studied (Figure 17 and Figure 24). The results also suggest a strong selective 
pressure on the double mutant dhps in Bondo and Tiwi.
Markers flanking the triple mutant dhfr and the double mutant dhps alleles show 
an almost complete lack of diversity in Bondo and Tiwi (Figure 26 and Figure 27). The 
linkage disequilibrium (LD), as measured by EHH, across this -17kb haplotype is also 
very elevated with skewed allele frequency distributions relative to the markers flanking 
the wild-type and single mutant alleles (Figure 26 and Figure 27). While these paiasite 
isolates show a complete lack of LD w ith the unlinked markers in chromosomes 2, 3, 5,
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8 and 10, they show elevated LD with the markers flanking the two genes. This is 
suggestive of very strong selection of the dhfr and dhps loci.
Allele distributions also provide additional evidence for a recent selection of the 
resistant alleles. Microsatellites flanking the triple mutant dhfr showed three 
predominant allelic haplotypes varying by a single locus in the outeimost region of the 
sequence and occasional rare variants, indicative of a recent bottleneck (Comuet & 
Luikart 1996). This is in contrast with haplotypes flanking wild-type dhfr alleles, which 
showed a w ider variation of allele frequency distribution (Figure 24). Looking at the 
number of alleles observed at each locus, m icrosatellite He of haplotypes cany ing 
mutant dhfr alleles was significantly lower than expectation, assuming both infinite 
alleles (lAM) and stepwise mutation models (SMM) of microsatellite mutation 
(W ilcoxon test, P  <0.0039 [IAM]; P< 0.0020 [SMM]). In comparison, chromosomes 
carrying wild-type dhfr alleles showed no significant deviation from equilibrium 
expectations (W ilcoxon test, P < 0.056 [JAM]; P< 0.74 [SMM]). These findings 
suggest that triple mutant dhfr alleles have arisen on relatively few occasions, as 
evidenced by little variation in flanking markers. Different haplotypes are predominant 
in the three populations studied, which might indicate independent derivation of these 
mutants, or could indicate evolution w ithin the parasites in a particular area.
4.6 Origin of the mutant dhfr alleles
Analysis of the eight-locus microsatellite haplotype flanking triple mutant dhfr 
alleles provides strong evidence for a single or very limited origin of these alleles. Of 
the 86 isolates bearing the mutant dhfr alleles, 65 had either one of two eight-locus 
allelic haplotypes that differed at only one of the eight markers. Exclusion of the 
DHFRD4 outer locus (8.0 Kb upstream of dhfr) from the analysis showed that the 65/84 
isolates had a single seven-locus haplotype. O f the remaining 21, 13 differed at only
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two of the eight markers while the other 8 differed at a single locus but with different 
allelic combinations (Table 25). None of the isolates bearing the triple mutant dhfr 
allele differed at more than three of the eight markers. This variation was also only 
observed in the downstream region flanking the dhfr gene. Most of the 86 isolates 
bearing the triple dhfr mutant examined, showed very similar four-locus haplotype at 
the markers in the downstream region of the gene (see discussion on asymmetry on 
page 174 and Figure 24).
Compaiisons of microsatellite haplotype frequency distributions (Figure 14, 
Figure 15, Figure 16 and Figure 17) reveals that neither the haplotypes associated with 
the double mutant dhfr or those of the triple mutant dhfr alleles could be found 
associated with either the wild-type or single mutant haplotypes. Although the single 
mutants theoretically preceded the double and definitely the triple mutants, the extant 
single mutant allele haplotypes do not seem to be ancestral, on the basis of flanking 
markers, to either of the more substituted haplotypes. This finding is in agreement with 
the results of previous studies that have suggested that African dhfr double and triple 
mutants are possibly imported from elsewhere (Roper et al., 2003). It would also be in 
agreement with theoretical predictions that new resistance mutations are rare and even 
constrain the rate at which the parasite population can adapt to drug (Anderson & Roper 
2005; Hastings 2004; Hastings & Watkins 2005). However, a number of other triple 
mutant haplotypes were found to be present in the three areas but at very low 
frequencies, which would suggest that they are quite rare in the population. These rarer 
triple mutant haplotypes could have arisen through background mutation and have been 
selected by drug pressure. Single mutant alleles (coding for 108N) had unrelated 
flanking sequences, suggesting that they did arise independently and on multiple genetic 
backgrounds, although it is possible that the selection on them is too weak for the
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flanking sequences to be carried through. Although single mutations seem to have 
arisen independently on multiple occasions, the fitness benefits they confer aie perhaps 
too weak to overcome the associated fitness costs, and they do not seem to be strongly 
selected for at the population level. If, as has been postulated, there are additional 
compensatory mutations (Wang et al., 2004) elsewhere in the genome (Schrag et al., 
1997), required to limit the deleterious effects of mutations in dhfr, then we might 
expect that the S108N single mutant might not have developed these compensatory 
mutations to enable it overcome the fitness cost associated with the dhfr mutations even 
with the dmg pressure working to its advantage. Using this argument, the single mutant 
alleles seem unlikely to spread throughout the population or to persist long enough to 
accumulate more mutations. In contrast, when a multiple mutant allele arises, through 
successive selection and recombination of drug tolerant alleles, it has high relative 
fitness and can spread rapidly throughout large geographic regions (Roper et ah, 2003).
Due to time limitations, it was not possible to type samples from other areas such as 
Southeast Asia and Southern Africa to determine the possible geographical origin of the 
multiple mutant alleles observed in this study (assuming that the alleles spread into 
Kenya from other areas, rather than arising there). However, it is possible that their 
origin is in Southeast Asia, since another study has shown that Tanzanian (which 
borders Kenya to the south and is very close to one of the sites of this study) multiple 
mutants have a shared origin in Asia (Roper et a l ,  2004).
4.7 The selective sweep ‘valley’
The valley of reduced variation around the triple mutant dhfr alleles appears to 
be asymmetrical (Figure 24). This is in contrast with the symmetrical valley of reduced 
variation around the double mutant dhps alleles in Tiwi and Bondo (Figure 27) and also 
with what has been suggested by simulation studies (Kim & Stephan 2002). The valley
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of reduced variation around dhfr in other populations has been shown to extend to as 
much as 100 kb away from the gene (Nair et al., 2003) but the slopes of the valley on 
both sides of the gene do not appear to be symmetrical. The region of reduced diversity 
extends much more downstream than upstream with the dip being naiTower on the 
upstream side of the gene (Figure 24). Pearce and colleagues (Pearce et al., 2005) have 
hypothesized three explanations for this asymmetry;
i) Differing rates of recombination on either side of dhfr,
ii) Stochastic noise,
iii) Existence of a resistance enhancing or resistance-compensating gene 
downstream of dhfr.
It has been shown that varying distribution of crossover events, differing 
substantially from their genome average can reflect recombination hotspots as well as 
other genome features e.g. proximity to centromeres and telomeres (Barnes et al., 1995; 
Symington et al., 1991; Szankasi et al., 1988). Even certain nucleotide substitutions 
have been shown to create recombination hotspots (Ponticelli et al., 1988). The 
downstream region of dhfr does not appear to be refractory to recombination (for 
example, due to proximity to a centromere), since the samples with the wild-type dhfr 
still show high diversity (Figure 14 and Figure 24).
Asymmetry may also be caused by the stochastic nature of recombination events 
during short phases of intense selection. K im and Stephan used a model of genetic 
variation along a recombining chromosome to show that in a population where the time 
to fixation is short, e.g. when effective population {Ne) is small; the selective sweep 
could be asymmetrical around the selected site (Kim & Stephan 2002). The short period 
in which fixation is reached reduces the amount of time for recombination events to 
occur resulting in stochastic noise (Pearce et al., 2005). This fits with the scenario
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observed in Southeast Asia where fixation of resistance took only six years. In Africa 
where fixation of the triple mutant is yet to be achieved, it is not easy to explain. 
However, intense selection pressure may result in rapid epidemic expansions (Maynard 
Smith et a l ,  1993) of resistant parasites through introgression in local populations and 
as such this would lead to asymmetry (Pearce et a l,  2005). This hypothesis however 
assumes that asymmetry is random and therefore has appeared on the same side of dhfr 
in East and Southern Africa as it has in SE Asia by chance alone (Nair et a l ,  2003; 
Pearce et a l ,  2005).
There is some experimental evidence to support the third explanation. Wang and 
colleagues analysed a genetic cross between parasite lines HB3 and Dd2; in this cross 
the two parents differ in sensitivity to sulfadoxine (Wang et a l ,  2004). They identified a 
segregating modifier of sulfadoxine resistance, which they termed the ‘folate effect’. A 
48.6 kb region of chromosome 4 was found to be in complete linkage with the folate 
effect phenotype. It is tempting to speculate that a resistance-enhancing or fitness- 
compensating gene, such as the one proposed for folate salvage in the upstream region 
of the resistant dhfr allele, could explain the reduced variation observed in flanking 
m icrosatellite markers upstream dhfr. The existence of this ‘folate gene’ is yet to be 
proved (Pearce et a l ,  2005). However, if such an adaptation gene exists, we would 
expect it to be very close to the dhfr gene to prevent their linkage from being w iped out 
by recombination.
Nash and colleagues have observed the same phenomenon of asymmetry in an 
analysis of selective sweep of pfcrt on SE Asian isolates (Nash et a l ,  2005). Given 
these observations with two genes with different sources of selective pressure, the most 
probable cause of the asymmetry is heterogeneity in recombination rates on the two 
sides of dhfr.
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4.8 Drug resistance and selection on Pfdhps
In Tiwi and Bondo, the results of the analysis of microsatellites flanking the 
dhps gene reveal a similar pattern to that of the markers flanking dhfr, with a limited 
number of haplotypes flanking the double mutant {dhps A437G/K540E). A very 
different picture emerges with the isolates from Mwea. While the isolates bearing the 
double mutant dhps allele (A437G, K540E) from Bondo and Tiwi reveal signatures of 
selection (Figure 23, Figure 25 and Figure 27), the isolates with double mutant alleles 
from Mwea do not exhibit these signatures of selection (Figure 20 and Figure 23). 
When isolates {n =132) from all sites are analysed together for their allelic haplotypes, a 
total of 82 haplotypes are generated. When the Mwea isolates ai'e excluded only 31 
haplotypes are generated for the isolates from Bondo and Tiwi {n = 75). Dhps double 
mutants from Mwea are therefore present on a much larger genetic background, with no 
clear predominance of any one haplotype (Figure 20 and Figure 23). The distribution of 
m icrosatellite haplotypes around the single single (A437G) and double mutant dhps 
alleles from Mwea reveals a wide distribution of these alleles across all haplotypes. 
There are a large number of different haplotypes for each allele of dhps (wild-type, 
single, double), with no evidence of a reduction in haplotype diversity associated with 
increasing substitution at the dhps locus.
4.9 Lack of selective sweep around dhps in Mwea
Our observations in Mwea with regard to the distribution of drug resistance 
alleles require some explanation (Figure 20 and Figure 23). The uniform distribution of 
haplotypes associated with the wild-type, single and double mutant dhps alleles are 
significantly different findings to those observed in the other two sites in this study, and 
those reported elsewhere in the literature.
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The lack of a selective sweep on dhps in Mwea is also puzzling given the fact 
that the same isolates show a strong selective sweep around dhfr (Figure 17). One 
possible explanation for this observation is that SP is not the selective force driving the 
evolution of dhps mutation in P. falciparum, at least not in Mwea, and possibly not at 
all. Two other possible factors may also be responsible: antibiotic dmg use and diet.
Various antibiotics are known to affect the folic acid synthesis and some such as 
cotrimoxazole have even shown potential as antimalaiials (Omar et ah, 2001b; Saliba & 
Kirk 1998). These antibiotics, coupled with the widespread practice for self-medication, 
m ight have pushed the evolution of dhps in P. falciparum  in Mwea, perhaps even before 
the introduction of SP as an antimalarial. Cotrimoxazole is commonly used to treat 
acute respiratory tract infections (ARIs) especially pneumonia and its use is widespread 
in East Africa because of its lower cost (World Health Organization 1991b).
It has been shown that even in the presence of a biosynthetic synthesis for 
PABA, malaria parasites require exogenous dietary PABA for survival (Greene 1999; 
Ricska et ah, 2003; van Doorne et aL, 1998). As has been discussed previously, PABA 
and folate are competitive inhibitors of sulfadoxine (Peters 1997), so it is possible that 
in patients with high dietary folate/PABA, sulfadoxine will have no inhibitory effect on 
the parasite. Investigations of the dietary patterns of the inhabitants of Mwea reveal that 
most of their diet is composed of rice and/or maize taken with vegetables, as the 
farm ing in this area is rice irrigation. Leafy greens such as turnip greens (diet folate 
equivalent = 65 pg), orange juice (70 pg), peas (105 pg), beans (90 pg), and many other 
types of fmits and vegetables are rich sources of folate. The diet in Mwea is very low in 
animal proteins (Bwibo & Neumann 2003), suggesting that the source of protein is 
likely to be legumes, which are high in folates. This is in contrast to the diet of the 
populations of Tiwi and Bondo, whose diet is mainly fish and maize meal as they live
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very close to fishing areas. The vegetable intake in these other ai’eas is also poor as the 
soil is not suitable for horticulture.
It is possible therefore that parasites infecting the Mwea population encounter 
higher levels of physiological folate/PABA than those of Tiwi and Bondo, and that this 
removes the effectiveness of sulfadoxine in the combination drug SP. Mutations in dhps 
would therefore confer no selective advantage to parasites, and the gene would therefore 
not undergo a selective sweep. Further studies comparing PABA and folate levels 
between the three populations would be required to investigate this hypothesis further.
4.10 Transmission intensity and drug resistance
The areas in which this study was carried out have relative higher transm ission 
indices than the other areas of Southeast Asia and Southern Africa in which similar 
studies have been carried out. What is the link between transm ission and antimalarial 
drug resistance?
There are cuiTently two schools of thought concerning the link between transm ission 
intensity and evolution of drug resistance both of which are discussed below.
4,10.1 Low transmission increases drug resistance
In the mid-1990s it was proposed that parasite inbreeding could elevate 
multigenic drug resistance by preventing the breakdown and dilution of drug-resistant 
haplotypes that occur through genetic recombination (Schm idt 1995). Inbreeding is 
thought to be more frequent when transm ission is low, as this is predicted to lessen the 
likelihood of mixed infections comprising organisms carrying resistant and sensitive 
alleles (Curtis & Otoo 1986). The proponents of this hypothesis also argue that most 
infections in low-transm ission areas are in nonimmune people who become 
symptomatic and are then treated with the drug. The increased proportion of infections
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treated results in the selective advantage of the mutation being larger in areas of low 
transm ission than that in areas of high transm ission, so resistance mutations are more 
likely to survive and spread in such areas (Hastings 2004). Perusal of the survival 
probabilities suggest that, even if this was not the case, most origins of drug resistance 
might occur in areas of low transm ission because the differences in survival 
probabilities caused by their differing selective advantages will probably greatly 
outweigh any differences in their rate of input. For example, Nair and colleagues 
estimated the selective advantage of dhfr resistance mutations to be 10% in Southeast 
Asia, giving them an 18% chance of survival assuming a Poisson distribution, falling to 
2% under a more realistic assumption of highly heterogeneous malaria transm ission 
(Nair et aL, 2003). Similarly, Roper and colleagues calculated the selective advantage of 
the dhfr triple mutation in Southern Africa to be 5%, giving it a chance of survival of 
between 9% and 10%, depending on degree of transm ission heterogeneity (Roper et aL,
2003). Both studies (Roper et al., 2003) were carried out in areas of low transm ission 
where most infections are symptomatic, hence inducing the patient to seek treatment 
(Nair et al., 2003).
By contrast, many infections in areas of higher transm ission in Africa are 
asymptomatic and more likely to remain untreated (Ntoumi et al., 1995). This could 
substantially reduce selective advantage and hence the probability of a new mutation 
surviving (Hastings 2004). The ability of mutations to survive can therefore vary 
substantially depending on local epidemiology, which determines the selective 
advantage of the mutation and the degree of heterogeneity in the transm ission of the 
mutation.
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4.10.2 Low transmission decreases drug resistance
It has been proposed by theoretical argument (Hastings & Mackinnon 1998) and 
in a review paper (Molyneux et al., 1999) that low transm ission can decrease multigenic 
drug resistance. More direct field evidence has recently emerged in Zimbabwe, during a 
comprehensive vector control programme. In Zimbabwe, which lies on the southern 
fringes of malaria endemicity in Africa, transm ission is markedly seasonal and 
epidemic, and asymptomatic carriage is rare (Taylor & Mutambu 1986). Annual house 
spraying was selectively instituted (during 1995-1999) in one of two mesoendemic sites 
that both used chloroquine as first line treatment and had similar starting levels of 
chloroquine resistance. In the sprayed region during 4 years when annual spraying was 
used, the chloroquine failure rate decreased such that the odds of drug failure became 
four-fold lower than before spraying was instituted (Mharakurwa 2004). The odds of 
drug failure did not significantly change in the unsprayed site. After the selective 
spraying was stopped in 1999, drug failure odds for the sprayed area had increased four­
fold by 2003, back to the original level (Mharakurwa 2004). During the 1998-1999 
transm ission seasons, a cross-sectional assessment of parasite genotypes in the Pfm drl 
and Pfcrt showed higher likelihood for mixed infections, containing both mutated and 
wild-type variants at one or more loci, in the sprayed aiea. This was in spite of lower 
transm ission in the sprayed area (Mharakurwa 2004). Thus reduced transm ission, due to 
vector control, or environmental factors such as high altitude, appears to delay the 
escalation of dmg resistance.
4.10.3 Transmission and rate of selection for resistance in Kenya
The three areas under study in this thesis have varying transm ission intensities. 
Bondo is holoendemic and transm ission is perennial, Tiwi is hyperendemic and 
transm ission is perennial with seasonal variations, while Mwea is hypoendemic and the
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selective advantage of 0.26 (meaning theoretically resistant parasites can replace the 
entire population in only 4 years). The resistant parasite population in Bondo has only a 
0.10 selective advantage (theoretically it would take 10 years to replace the entire 
parasite population in Bondo) (Figure 28 and Figure 29). Selection in Mwea would 
appear to be the strongest, followed by that in Tiwi, while it would be slowest in Bondo 
(Figure 28, Figure 29 and Figure 30).
Taken together, these findings suggest that the high transm ission rates in Bondo, 
resulting into high recombination rates, break down the triple mutant haplotype thus 
taking a long time for it to introgress through the population; this explanation is 
supported by the higher variation seen in the loci flanking regions of triple mutant dhfr 
alleles.
An upshot of this finding is that during the initial stages of evolution and spread 
of drug resistance, the human population at highest risk would be that living in low 
transm ission areas. This is because even with their higher clinical cases with sensitive 
malaria parasites (due to their low immunity) they have the added risk of getting drug 
resistant parasites which would lead to epidemics and eventually higher morbidities and 
mortalities. This emphasizes the need for surveillance programs especially after the 
introduction of new antimalaria treatment regimens.
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transm ission is seasonal. From the arguments in section 4.10.1, drug resistance would 
be expected to evolve and spread fastest in Mwea while it would be slowest in Bondo. 
The mutant forms of dhfr associated with SP treatment failure were higher in Tiwi and 
Bondo compared to Mwea. For example, the triple mutant allele was found in 63% and 
70% of samples in Tiwi and Bondo respectively, but in only 33% of samples from 
Mwea (Table 22), and Mwea was the only site where wild-type dhfr alleles were 
detected. For dhps, wildtype alleles were seen in 13% and 27% of samples from Tiwi 
and Bondo respectively, and 39% of those from Mwea. Currently SP treatment failure 
rates in the three sites have been estimated to be between 20-60%. Data from previous 
studies reveal that SP treatment failure rate in Kilifi (an area including the Tiwi site) 
was 20% in 1998. Most of these persistent parasites carried the triple-mutant allele of 
dhfr with or without mutations in dhps (Nzila et a l, 2000). These failure rates were 
shown to have increased to about 30% in 1998 (Nzila et a l, 1998). This trend has now 
been confirmed by the results of this study, which reveal that in Tiwi SP failure rates 
were as high as 40% in 2000 when this study was carried out. This trend is expected to 
be the same in the other two sites with Mwea having lower rates and Bondo with higher 
rates consistent with the transm ission intensities.
Exam ination of the eight-locus haplotypes reveals that most of the variation in 
the triple mutant dhfr alleles was found in the isolates from Bondo (Figure 17 and Table
25), with only 15 out of 36 isolates bearing the triple dhfr allele having the same 
identical haplotype. This contrasts with Mwea, where 19 out of the twenty isolates 
bearing the triple dhfr mutant had a single eight-locus haplotype. In Tiwi, 25 out of the 
30 isolates bearing the triple dhfr allele had the same eight-locus haplotype.
Finally the estimated selection coefficients for SP resistant mutants (section 
3.5.9) suggest that the resistant parasite population in Mwea (lowest transm ission) has a
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4.11 SUMMARY
The work presented in this thesis has demonstrated that microsatellite markers 
perforai no better than antigenic markers in distinguishing genuine recrudescence of 
resistant parasites from reinfections during the follow-up period of in vivo drug efficacy 
trials.
Data have been presented showing that populations of parasites from three areas 
of Kenya, separated by more than 800 km, are genetically closely related such that there 
is apparent panm ixia. This has implications for the spread of drug resistance within the 
country; resistant parasites arising spontaneously, or moving into an area from outside 
of the country, have a high likelihood of spreading rapidly to all areas of Kenya.
The work presented also demonstrates that alleles of the dhfr gene, especially 
the triple mutant allele, isolated from the three different areas are closely related to one 
another and probably share a common and very recent ancestor. There is strong 
evidence for a selective sweep around dhfr in the Kenya P. falciparum  population. The 
same situation has occuiTed for dhps alleles (both the single and more especially the 
double mutant) in two of the sites studied. However at a third study site there was no 
evidence for selection at the dhps locus. Mai'kers flanking the gene showed high and 
similar diversity around wild-type and mutant alleles with multiple haplotypes present. 
This finding suggests that in this region, sulfadoxine is not driving selection of mutant 
dhps alleles, and, that factors such as diet or sulfa-antibiotic use may be affecting the 
efficacy of the sulfadoxine component of SP.
These findings have implications for the spread of antimalarial drug resistance in 
Kenya. SP resistant parasites appear to arise by immigration from other areas rather than 
by spontaneous emergence, as has been reported for other areas of Africa with lower
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intensities of transm ission. The strength of selection appears to be lower in areas of high 
transm ission, suggesting a more rapid increase in treatment failure in areas of lower 
transm ission. Since individuals living in regions of low transm ission develop paitial 
immunity more slowly, they are even more at risk because drug resistant levels will rise 
more quickly, and treatment failure rates will be higher due to higher parasite resistance 
as well as lower immunity. Malaria control programmes therefore should take great care 
to assess treatment failure rates/resistance in low transm ission areas, since there is the 
potential for epidemics with high morbidity and mortality.
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APPENDIX 1
Allele sizes (in base pairs) for all individuals studied across the five unlinked loci 
(0= nonamplification)
Sample ID C2M3 C3M85 TA40 TA17 TA48
BO ND O .l 265 292 222 276 288
B 0 N D 0 .2 300 336 308 256 279
B 0 N D 0 .3 306 289 233 254 275
B 0 N D 0 .4 325 350 233 289 288
B 0 N D 0 .5 319 296 239 327 275
B 0 N D 0 .6 313 336 265 313 288
B 0 N D 0 .7 299 353 289 302 296
B 0 N D 0 .8 325 309 300 274 283
B 0 N D 0 .9 313 335 323 252 283
BONDO.IO 275 329 221 244 292
BO ND O .l 1 280 332 308 294 318
B 0N D 0.12 260 306 229 323 335
B 0N D 0.13 295 269 221 228 271
B 0N D 0.14 290 215 207 300 335
B 0N D 0.15 275 290 243 250 276
B 0N D 0.16 252 254 207 211 252
B 0N D 0.17 274 233 207 167 281
B 0N D 0.18 260 296 196 331 295
B 0N D 0.19 279 243 226 256 262
BONDO.20 274 354 189 256 267
B 0N D 0.21 307 289 237 233 271
B 0N D 0.22 300 299 222 272 306
B 0N D 0.23 320 234 235 228 295
B 0N D 0.24 264 263 222 324 285
B 0N D 0.25 305 293 198 338 280
B 0N D 0.26 332 343 210 260 290
B 0N D 0.27 342 322 190 265 312
B 0N D 0.28 300 215 226 331 289
B 0N D 0.29 268 278 190 245 285
BONDO.30 276 332 214 300 225
B 0N D 0.31 305 363 204 313 265
B 0N D 0.32 256 222 215 183 322
B 0N D 0.33 0 273 0 200 0
B 0N D 0.34 288 298 242 228 301
B 0N D 0.35 311 269 188 217 272
B 0N D 0.36 260 231 227 244 268
B 0N D 0.37 279 289 212 233 312
B 0N D 0.38 232 299 220 336 332
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Sample ID C2M3 C3M85 TA40 TA17 TA48
B 0N D 0.39 248 342 206 244 265
BONDO.40 232 292 216 228 232
B 0N D 0.41 228 285 208 244 280
B 0N D 0.42 248 275 186 213 285
B 0N D 0.43 300 290 185 200 268
B 0N D 0.44 265 345 196 198 323
B 0N D 0.45 248 218 195 207 288
B 0N D 0.46 268 322 200 213 300
B 0N D 0.47 232 318 204 183 265
B 0N D 0.48 311 335 215 192 285
B 0N D 0.49 284 222 250 184 289
BONDO.50 256 299 235 192 295
B 0N D 0.51 305 318 213 210 322
B 0N D 0.52 260 314 225 220 272
B 0N D 0.53 264 298 190 194 232
B 0N D 0.54 244 325 185 207 290
B 0N D 0.55 264 275 210 213 300
B 0N D 0.56 279 0 225 213 322
B 0N D 0.57 288 311 234 227 265
B 0N D 0.58 248 243 213 227 290
B 0N D 0.59 232 265 189 200 306
BONDO.60 272 292 236 220 344
TIWI.l 321 335 206 217 293
TIWI.2 311 330 213 230 303
TIWL3 286 297 188 215 340
TIWL4 257 289 213 270 330
TIWL5 282 312 229 259 310
TIWL6 276 262 213 233 280
TIWL7 300 330 210 226 293
TIWL8 300 267 185 230 247
TIWI.9 286 287 178 225 310
TIWI.IO 306 344 226 189 290
TIWI. 11 313 290 200 200 323
TIWI.12 300 285 163 248 320
TIWI.13 258 293 173 256 0
TIWI.14 283 315 190 220 308
TIWI.15 296 285 200 252 331
TIWI.16 296 320 213 244 280
TIWI. 17 265 332 237 252 287
TIWI.18 293 266 216 199 310
TIWI. 19 252 267 220 197 340
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Sample ID C2M3 C3M8S TA40 TA17 TA48
TIWI.20 312 307 200 197 320
TIWI.21 296 258 211 212 287
TIWI.22 254 289 227 204 260
TIWL23 311 319 188 190 300
TIWI.24 306 296 230 193 267
TIWI.25 252 285 230 190 273
TIWI.26 248 357 170 211 304
TIWI.27 291 349 181 233 260
TIWI.28 252 321 236 207 280
TIWI.29 291 345 218 215 297
TIWL30 248 322 178 189 280
TIWI.31 287 298 202 195 287
TIWL32 289 324 191 230 293
TIWI.33 311 294 221 254 297
TIWI.34 305 255 214 190 280
TIWI.35 300 300 178 220 290
TIWL36 286 268 212 187 279
TIWI.37 294 306 233 199 267
TIWL38 312 292 190 195 293
TIWL39 333 288 239 239 280
TIWI.40 321 338 228 258 254
TIWL41 252 273 182 265 287
TIWI.42 265 332 258 235 260
TIWI.43 257 271 189 217 343
TIW1.44 265 252 240 256 290
TIWI.45 321 328 223 212 267
TIWI.46 326 277 203 248 300
TIWL47 289 299 217 239 289
TIWL48 312 305 234 223 290
TIWL49 325 289 211 202 254
TIWI.50 291 269 219 234 310
TIWI.51 316 327 225 226 293
TIWL52 353 270 231 230 340
TIWL53 296 290 226 218 293
TIWI.54 274 313 217 248 289
TIWL55 280 305 213 225 267
TIWI.56 300 311 209 220 290
TIWL57 235 288 224 199 254
TIWI.58 288 268 203 203 310
TIWL59 252 273 210 200 343
TIWI.60 296 275 192 241 287
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Sample ID C2M3 C3M85 TA40 T A Î7 TA48
MWEA.l 262 267 207 254 308
MWEA.2 296 311 186 195 293
MWEA.3 265 300 207 224 342
MWEA.4 305 267 194 198 325
MWEA.5 237 255 241 238 286
MWEA.6 296 324 230 215 293
MWEA.7 254 311 214 200 250
MWEA.8 260 290 207 272 286
MWEA.9 329 300 197 261 248
MWEA. 10 273 289 192 229 267
MWEA.l 1 265 353 175 214 273
MWEA. 12 262 324 200 187 267
MWEA. 13 327 295 216 187 273
MWEA.14 305 339 212 224 267
MWEA. 15 257 281 212 200 273
MWEA.16 318 300 208 203 270
MWEA. 18 323 329 224 207 325
MWEA. 19 282 318 190 188 286
MWEA.20 309 311 207 220 293
MWEA.21 308 282 216 210 252
MWEA.22 298 329 212 248 270
MWEA.23 330 277 207 271 320
MWEA.24 282 319 192 248 273
MWEA.25 254 284 197 187 286
MWEA.26 309 342 197 192 270
MWEA.27 264 294 223 187 262
MWEA.28 296 300 229 207 243
MWEA.29 309 364 163 230 293
MWEA.30 296 329 207 248 271
MWEA.31 265 290 212 212 300
MWEA.32 231 306 176 232 276
MWEA.33 309 355 187 188 286
MWEA.34 235 322 191 283 250
MWEA.35 303 266 172 219 284
MWEA.36 318 277 188 192 270
MWEA.37 327 256 190 212 349
MWEA.38 283 286 218 226 281
MWEA.39 234 281 207 191 340
MWEA.40 303 302 212 245 323
MWEA.41 300 286 228 212 278
MWEA.42 299 288 192 218 247
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Sample ID C2M3 C3M85 TA40 TA17 TA48
MWEA.43 266 265 176 248 287
MWEA.44 296 280 206 188 293
MWEA.45 279 311 189 215 296
MWEA.46 264 308 213 272 310
MWEA.47 285 306 209 225 350
MWEA.48 316 324 220 244 320
MWEA.49 320 356 200 230 254
MWEA.50 266 334 213 245 296
MWEA.51 274 289 254 262 286
MWEA.52 310 306 202 204 309
MWEA.53 282 323 229 256 250
MWEA.54 262 318 252 238 267
MWEA.55 242 342 176 197 276
MWEA.56 265 322 210 207 287
MWEA.57 242 271 198 238 343
MWEA.58 237 300 229 188 330
MWEA.59 260 290 193 220 310
MWEA.60 258 346 234 197 271
MWEA.61 332 295 193 215 343
MWEA.62 324 283 218 232 296
MWEA.63 262 319 213 257 270
MWEA.64 273 281 239 200 262
MWEA.65 318 342 183 212 276
MWEA.66 310 312 232 228 282
MWEA.67 265 290 175 254 308
MWEA. 6 8 309 282 194 232 250
190
APPENDIX 2
Dhfr-linked microsatellite haplotypes arranged hy sorting isolates according to 
their DhfrUl allele sizes (in hase pairs). Values in parentheses indicate whether the 
double mutant has the secondary mutation at either the 51 or 59 codons.
Sample ID DhftUl DhfrU2 DhffU3 DhfrU4 DhftDl DhfrD2 DhfrD3 DhffD4 Mutations HaplQtyi
B 0N D 0.54 107 158 174 200 120 235 180 263 1 1
TIWI.20 107 167 178 202 116 279 200 300 1 2
MWEA.61 110 181 210 219 92 276 218 294 0 3
B 0N D 0.49 111 162 178 235 122 240 185 266 1 4
B 0N D 0.17 111 174 188 212 100 244 183 283 3 5
MWEA.2 111 178 170 212 100 247 178 283 1 6
TIWI.38 111 180 191 238 108 251 200 298 1 7
BONDO.20 111 189 170 224 116 238 190 296 1 8 .
B 0N D 0.46 115 158 210 187 118 260 176 300 1 9
TIWI.l 115 169 183 206 97 269 205 288 2 # ^ 10
TIWI.17 115 169 183 206 97 269 205 288 2 ^ ^ 10
TIWI.60 115 169 183 206 97 269 205 288 2 ^ ^ 10
B 0N D 0.38 115 169 183 224 97 252 205 279 2(59) 11 '
B 0N D 0.53 115 169 183 224 97 269 192 275 2 ^ ^ 12
MWEA.29 115 169 183 224 97 269 192 294 2(51) 12
MWEA.34 115 169 183 224 97 269 192 294 2 ^ ^ 12
B 0N D 0.44 115 169 183 229 97 252 192 279 2 ^ ^ 13
B 0N D 0.47 115 169 183 229 97 252 192 279 2 ^ ^ 13
MWEA.22 115 169 183 229 97 252 192 279 2 ^ ^ 13
MWEA.l 1 115 169 183 229 97 252 192 279 2 ^ ^ 13
B 0N D 0.45 115 169 183 229 97 252 192 279 2 ^ ^ 13
MWEA.23 115 169 183 229 97 252 192 279 2 ^ ^ 13
MWEA.26 115 169 183 229 97 252 192 294 2 ^ ^ 14
TIWI.45 117 176 182 200 124 260 196 285 1 15
MWEA.47 117 176 182 200 124 260 196 285 0 15
TIWI.55 118 177 175 210 127 267 200 286 1 16
MWEA.24 118 192 167 171 109 266 211 289 1 17
MWEA.66 119 162 170 216 122 255 229 289 1 18
MWEA.33 119 190 199 212 122 245 178 283 0 19
MWEA.48 121 160 168 219 119 234 209 283 0 20
BONDO.40 122 192 183 187 115 256 179 290 1 21
MWEA.15 122 200 175 212 152 248 215 289 0 22
MWEA.35 125 166 211 198 119 252 202 278 1 23
B 0N D 0.35 126 160 174 218 90 231 176 275 1 24
B0N D 0.41 126 167 183 224 120 248 213 295 1 25
TIWI.43 126 169 183 206 97 252 192 288 2(59) 26
TIWI.9 126 169 183 206 97 252 192 288 2(59) 26
TIWI.8 126 169 183 206 97 252 192 288 2(59) 26
MWEA.62 126 169 183 229 97 252 192 288 2(59) 26
TIWI.49 126 184 183 229 97 252 218 296 2(59) 27
TIWI.35 126 184 183 229 97 252 218 296 2(59) 27
BONDO.50 126 184 183 229 97 252 218 296 2(59) 27
MWEA.6 126 184 183 229 97 252 218 296 2(59) 27
MWEA.28 126 184 183 229 97 252 218 296 2(59) 27
B 0N D 0.58 126 184 188 224 100 244 205 283 3 28
MWEA.l 126 184 195 224 97 252 205 279 2(59) 29
B 0N D 0.48 126 184 195 224 97 252 205 279 2(59) 29
BONDO.l 1 126 184 195 224 97 252 205 279 2(59) 29
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Sample ID DhftUl DhfrU2 DhftU3 DhftU4 DhftDl DhftD2 DhftD3 DhftD4 Mutations Haplotyj
B 0N D 0.51 126 184 195 224 97 252 205 279 2(59) 29
MWEA.14 126 184 195 224 97 252 205 279 2(59) 29
MWEA.49 126 184 195 224 97 252 205 279 2(59) 29
MWEA.50 126 184 195 224 97 252 205 279 2(59) 29
MWEA.51 126 184 195 224 97 252 205 279 2(59) 29
MWEA.55 126 184 195 224 97 252 205 279 2(59) 29
MWEA.57 126 184 195 224 97 252 205 279 2(59) 29
MWEA.68 126 184 195 229 97 252 205 279 2(59) 29
MWEA.40 127 181 170 180 96 272 216 294 0 30
MWEA.39 129 179 178 178 122 244 180 289 1 31
TIWI.24 133 174 183 212 100 244 183 291 3 35
BONDO.l 133 174 188 212 100 244 183 283 3 33
B 0N D 0.2 133 174 188 212 100 244 183 283 3 33
B 0N D 0.3 133 174 188 212 100 244 183 291 3 35
B 0N D 0.7 133 174 188 212 100 244 183 291 3 35
B 0N D 0.8 133 174 188 212 100 244 197 291 3 36
BONDO.IO 133 174 188 212 100 244 197 291 3 36
B 0N D 0.13 133 174 188 212 100 244 183 283 3 33
B 0N D 0.14 133 174 188 212 100 244 183 283 3 33
B 0N D 0.15 133 174 188 212 100 244 183 283 3 33
B 0N D 0.18 133 174 188 212 100 244 183 291 3 35
B 0N D 0.22 133 174 188 212 100 244 197 291 3 36
B 0N D 0.24 133 174 188 212 100 244 183 283 3 33
B 0N D 0.26 133 174 188 212 100 244 183 283 3 33
B 0N D 0.33 133 174 188 212 100 244 183 283 3 33
B 0N D 0.34 133 174 188 212 100 244 183 283 3 33 '
TIWI.3 133 174 188 212 100 244 183 291 3 35
TIWI.4 133 174 188 212 100 244 183 291 3 35
TIWI.7 133 174 188 212 100 244 183 291 3 35
TIWI.IO 133 174 188 212 100 244 183 291 3 35
TIWI.15 133 174 188 212 100 244 183 291 3 35
TIWI.18 133 174 188 212 100 244 183 291 3 35
TIWI.l 9 133 174 188 212 100 244 183 291 3 35 ,
TIWI.21 133 174 188 212 100 244 183 291 3 35
TIWI.22 133 174 188 212 100 244 183 291 3 35
TIWI.23 133 174 188 212 100 244 183 291 3 35
TIWI.25 133 174 188 212 100 244 183 291 3 35
TIWI.28 133 174 188 212 100 244 183 291 3 35
TIWI.30 133 174 188 212 100 244 183 291 3 35
TIWI.31 133 174 188 212 100 244 183 291 3 35
TIWI.34 133 174 188 212 100 244 183 291 3 35
TIWI.36 133 174 188 212 100 244 200 291 3 37
TIWI.41 133 174 188 212 100 244 183 291 3 35
TIWI.46 133 174 188 212 100 244 183 291 3 35
TIWI.47 133 174 188 212 100 244 183 291 3 35
TIWI.48 133 174 188 212 100 244 183 291 3 35
TIWI.52 133 174 188 212 100 244 183 291 3 35 ■
TIWI.53 133 174 188 212 100 244 183 291 3 35 ,
TIWI.58 133 174 188 212 100 244 183 291 3 35
TIWI.59 133 174 188 212 100 244 183 291 3 35
MWEA.8 133 174 188 212 100 244 183 278 3 33
MWEA.IO 133 174 188 212 100 244 183 289 3 33
MWEA.12 133 174 188 212 100 244 183 283 3 33
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Sample ID DhftUl DhftU2 DhftU3 DhftU4 DhftDl DhftD2 DhftD3 DhfrD4 Mutations Haplotyi
MWEA.27 133 174 188 212 100 244 183 283 3 33
MWEA.31 133 174 188 212 100 244 183 283 3 33
MWEA.37 133 174 188 212 100 244 183 283 3 33
MWEA.41 133 174 188 212 100 244 183 283 3 33
MWEA.42 133 174 188 212 100 244 183 283 3 33
MWEA.43 133 174 188 212 100 244 183 283 3 33
MWEA.44 133 174 188 212 100 244 183 283 3 33
MWEA.45 133 174 188 212 100 244 183 283 3 33
MWEA.54 133 174 188 212 100 244 183 283 3 33
MWEA.59 133 174 188 212 100 244 183 283 3 33
MWEA.60 133 174 188 212 100 244 183 283 3 33
MWEA.63 133 174 188 212 100 244 183 283 3 33
MWEA.64 133 174 188 212 100 244 183 283 3 33
MWEA.65 133 174 188 212 100 244 183 283 3 33
MWEA.67 133 174 188 212 100 244 183 283 3 33
TIWI.33 133 174 188 212 100 247 183 291 3 38
B 0N D 0.4 133 174 188 212 100 269 205 283 3 40
B 0N D 0.5 133 174 188 212 100 269 183 291 3 39
B 0N D 0.12 133 174 188 212 100 269 183 291 3 39
B 0N D 0.16 133 174 188 212 100 269 197 291 3 41
B 0N D 0.21 133 174 188 212 100 269 183 291 3 39
B 0N D 0.43 133 174 188 212 100 269 183 291 3 39
B 0N D 0.39 133 174 188 212 106 244 183 283 3 34
B 0N D 0.37 133 174 188 212 106 269 183 283 3 41
MWEA.5 133 174 188 212 113 244 183 283 3 42
TIWI.57 133 174 188 212 115 244 183 291 3 43
TIWI.27 133 174 188 212 121 244 183 291 3 44
TIWI.54 133 174 188 215 100 244 183 291 3 45
B 0N D 0.25 133 174 188 212 100 244 183 291 3 35
B 0N D 0.27 133 174 188 212 100 244 197 291 3 36
B 0N D 0.28 133 174 188 212 100 244 183 283 3 33
B 0N D 0.56 133 174 188 212 100 244 183 291 3 35
TIWI.56 133 174 188 212 100 244 183 291 3 35
B 0N D 0.29 133 174 188 212 100 244 183 283 3 33
BONDO.30 133 174 188 212 100 244 183 283 3 33
B 0N D 0.31 133 174 188 212 100 244 183 283 3 33
B 0N D 0.32 133 174 188 212 100 244 183 283 3 33
B 0N D 0.57 133 174 188 212 100 244 183 283 3 33
BONDO.60 133 174 188 212 100 244 183 283 3 33
B 0N D 0.59 133 174 188 212 106 244 183 283 3 34
MWEA.25 133 174 188 212 100 244 183 283 3 33
B 0N D 0.52 136 177 171 220 116 250 178 271 1 46
MWEA.36 137 158 198 187 126 245 218 283 1 47
MWEA.38 138 166 162 210 118 266 186 283 0 48
MWEA.56 139 189 176 237 117 248 189 294 0 49
B 0N D 0.19 141 169 183 224 111 269 192 275 2(59) 50
B 0N D 0.9 141 169 183 224 111 269 192 275 2(59) 50
B 0N D 0.36 141 164 183 224 111 269 192 275 2(59) 50
MWEA.46 141 188 182 175 88 230 223 289 1 51
MWEA.l 7 146 183 201 178 134 230 229 283 1 52
MWEA.53 147 166 174 243 109 249 187 289 0 53
MWEA.21 148 179 204 196 127 257 226 278 1 54
MWEA.13 151 189 190 212 113 250 209 294 0 55
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Sample ID DhfrUl DhftU2 DhftU3 DhftU4 DhftDl DhftD2 DhftD3 DhftD4 Mutations Haplotyj
B 0N D 0.55 152 162 170 220 90 238 175 271 1 56
MWEA.58 154 179 170 253 116 266 195 300 1 57
MWEA.52 158 181 170 216 111 233 198 278 0 58
MWEA.9 160 185 180 220 113 253 187 294 0 59 ■'
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APPENDIX 3
Dhps-linked microsatellite haplotypes arranged in their allele sizes based on the 
DhpsUl allele.
Sample ID DhpsUl DhpsU2 DhpsU3 DhpsU4 D hpsDl DhpsD2 DhpsD3 DhpsD4 Mutations Haplotype
B 0N D 0.46 120 232 154 193 106 271 236 205 0 1
B 0N D 0.49 122 196 136 199 109 280 246 200 0 2
B 0N D 0.39 124 221 150 194 112 253 218 229 1 3
TIWI.6 124 221 150 194 112 253 218 229 1 3
TIWI.46 124 222 154 189 114 279 226 208 0 4
B 0N D 0.42 127 196 154 197 119 279 227 204 0 5
MWEA.4 129 194 149 200 117 243 210 196 0 6
TIWI.56 129 194 149 200 106 243 210 196 0 6
B 0N D 0.12 130 205 136 189 106 268 231 208 0 7
B 0N D 0.41 130 205 136 189 106 268 231 208 0 7
BONDO.40 132 206 136 192 112 260 246 230 0 8
B 0N D 0.24 133 204 140 194 112 253 218 212 1 9
B 0N D 0.48 133 204 140 194 112 253 218 212 1 9
B 0N D 0.9 133 204 140 194 112 253 218 212 1 9
TIWI.24 133 212 163 188 112 265 218 225 1 10
TIWI.57 133 212 163 188 112 265 218 225 1 10
MWEA.46 136 198 125 218 119 268 218 208 2 11
MWEA.36 136 205 113 188 115 268 215 213 0 12
MWEA.32 136 210 125 213 111 246 210 208 2 13
MWEA.64 136 212 125 220 114 224 200 189 1 14
MWEA.9 139 200 130 233 108 219 210 200 2 15
B 0N D 0.21 139 200 160 188 112 253 235 208 1 16
TIWI.38 139 200 160 188 112 253 235 208 1 16
TIWI.21 139 210 141 196 114 271 220 218 0 17
MWEA.43 139 210 160 207 112 238 215 224 0 18
TIWI.35 139 212 163 188 112 253 218 208 1 19
TIWI.41 139 212 163 188 112 253 218 208 1 19
TIWI.55 139 212 163 188 112 253 218 208 1 19
TIWI.58 139 212 163 188 112 253 218 208 1 19
MWEA.54 139 224 125 213 117 238 210 218 1 20
TIWI.60 139 224 150 194 112 271 224 229 1 21
TIWI.9 139 224 163 188 112 253 235 213 1 21
B 0N D 0.37 140 196 133 195 110 250 226 225 0 22
B 0N D 0.56 140 200 154 198 116 266 210 210 0 23
MWEA.28 140 210 125 220 121 265 215 217 2 24
MWEA.48 140 210 125 220 121 265 215 217 2 24
MWEA.44 141 210 125 220 104 265 215 217 2 25
MWEA.52 143 192 147 220 111 253 190 229 0 26
MWEA.58 143 196 125 213 119 253 200 229 0 27
BONDO.l 143 204 130 194 112 265 218 212 1 28
BONDO.l 1 143 204 130 194 112 265 218 212 1 28
BONDO. 14 143 204 130 194 112 265 218 212 1 28
B 0N D 0.52 143 204 130 194 112 265 218 212 1 28
MWEA.40 143 208 141 227 109 246 238 217 2 29
BONDO.60 143 208 147 198 112 253 235 216 1 30
B 0N D 0.44 143 210 135 188 112 265 218 224 1 31
TIWI.1 143 212 140 194 112 265 218 204 1 32
195
TIWI.13 143 212 150 188 112 271 224 213 1 33
MWEA.66 143 216 146 207 115 257 215 200 2 34
BONDO.l 9 143 224 140 194 112 253 218 229 1 35
B 0N D 0.2 143 224 140 194 112 253 218 229 1 35
B 0N D 0.38 143 224 140 194 112 253 218 229 1 35
B 0N D 0.59 143 224 140 194 112 253 218 229 1 35
B 0N D 0.27 143 224 150 188 112 265 218 213 1 36
B 0N D 0.43 143 224 150 188 112 265 218 213 1 36
TIWI.52 143 224 150 188 112 265 218 213 1 36
MWEA.68 145 208 119 213 116 253 224 229 2 37
MWEA.33 148 200 125 213 124 224 210 217 2 38
MWEA.42 148 200 138 198 116 210 210 217 0 39
TIWI.54 148 200 138 200 119 276 212 213 2 40
B 0N D 0.26 148 200 140 200 119 276 212 224 2 41
TIWI.23 148 200 140 200 119 276 212 224 2 41
TIWI.27 148 200 140 200 119 276 212 224 2 41
B 0N D 0.22 148 200 160 200 119 276 212 213 2 42
B 0N D 0.28 148 200 160 200 119 276 212 208 2 43
BONDO.30 148 200 160 200 119 276 212 208 2 43
B 0N D 0.31 148 200 160 200 119 276 212 213 2 42
B 0N D 0.45 148 200 160 200 119 276 212 213 2 42
BONDO.50 148 200 160 200 119 276 212 213 2 42
B 0N D 0.57 148 200 160 200 119 276 212 213 2 42
TIWI.l 1 148 200 160 200 119 276 212 213 2 42
TIWI.18 148 200 160 200 119 276 212 213 2 42
TIWI. 19 148 200 160 200 119 276 212 213 2 42
TIWI.22 148 200 160 200 119 276 212 213 2 42
TIWI.25 148 200 160 200 119 276 212 213 2 42
TIWI.28 148 200 160 200 119 276 212 213 2 42
TIWI.29 148 200 160 200 119 276 212 213 2 42
TIWI.3 148 200 160 200 119 276 212 208 2 43
TIWI.30 148 200 160 200 119 276 212 213 2 42
TIWI.4 148 200 160 200 119 276 212 213 2 42
TIWI.40 148 200 160 200 119 276 212 213 2 42
TIWI.48 148 200 160 200 119 276 212 213 2 42
TIWI.5 148 200 160 200 119 276 212 213 2 42
TIWI.53 148 200 160 200 119 276 212 213 2 42
TIWI.59 148 200 160 200 119 276 212 213 2 42
MWEA.50 148 204 138 213 119 261 200 196 2 44
B 0N D 0.15 148 206 130 194 112 265 218 229 1 45
MWEA.2 148 210 130 213 119 219 210 197 0 46
MWEA.3 148 216 113 220 115 238 215 200 2 47
B 0N D 0.58 148 216 138 200 108 276 218 213 2 48
TIWI.34 148 216 138 200 108 276 218 213 2 48
B0N D 0.51 150 193 150 185 117 268 220 224 0 49
MWEA.55 150 196 125 198 104 229 210 200 0 50
MWEA.67 150 196 125 198 119 229 210 200 1 50
MWEA.ll 152 200 125 213 113 224 210 200 0 51
MWEA.29 152 200 125 213 105 224 210 200 2 51
MWEA.45 152 200 125 213 112 224 210 200 1 51
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Sample ID DhpsUl DhpsU2 DhpsU3 DhpsU4 D hpsDl DhpsD2 DhpsD3 DhpsD4 Mutations Haplotype
MWEA.65 152 200 125 213 118 224 210 200 2 51
MWEA.27 152 200 143 220 120 243 210 205 0 52
MWEA.56 152 204 119 233 113 238 224 196 0 53
MWEA.62 152 204 119 233 109 238 224 196 2 53
MWEA. 19 152 210 141 207 109 267 218 200 2 54
MWEA.47 152 216 125 224 112 229 210 229 0 55
MWEA.41 152 216 135 233 116 219 215 200 0 56
MWEA.22 152 232 125 207 114 253 215 200 2 57
MWEA.34 155 192 125 220 117 243 210 200 0 58
TIWI.15 155 196 156 194 117 272 224 225 0 59
MWEA.17 155 200 125 213 106 205 210 200 2 60
TIWI.IO 155 200 170 198 112 250 224 229 0 61
MWEA.l 155 210 133 213 108 229 210 197 1 62
MWEA.37 155 224 146 207 108 253 206 229 2 63
MWEA.31 157 206 125 240 116 253 190 229 1 64
MWEA.20 157 210 125 213 106 210 224 208 1 65
B 0N D 0.33 157 220 160 194 112 265 218 224 1 66
TIWI.49 157 220 160 194 112 265 218 224 1 66
MWEA.13 158 200 113 240 118 243 210 200 0 67
MWEA.23 158 200 119 227 114 229 190 196 2 68
MWEA.26 158 200 119 227 114 229 190 196 2 68
MWEA.8 158 200 130 220 107 243 215 197 2 69
MWEA.25 158 200 141 213 120 261 210 200 0 70
MWEA.14 158 210 133 213 120 210 210 205 0 71
MWEA.5 158 216 130 220 120 219 210 193 2 72
MWEA.51 158 216 160 207 122 246 210 218 0 73
MWEA.7 160 210 130 220 122 219 210 200 0 74
B 0N D 0.55 160 222 138 187 118 258 218 218 0 75
MWEA.57 160 224 141 220 118 205 215 217 1 76
MWEA.24 163 200 125 233 108 246 210 189 0 77
MWEA.60 163 210 125 207 106 246 200 224 0 78
MWEA.30 165 192 125 240 110 266 215 210 1 79
MWEA.12 165 210 125 213 113 219 215 197 1 80
MWEA.35 165 216 125 209 109 219 200 196 2 81
MWEA.38 165 220 113 220 117 205 200 217 0 82
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